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 ABSTRACT 
The role of the E4 protein in the human papillomavirus (HPV) life cycle is an enigma even 
though it has varied effects on cell behaviour and organisation in overexpression studies.  
Full-length E4 proteins are derived from E1^E4 spliced RNA transcripts and E1^E4 proteins 
from diverse HPV types interact with serine-arginine (SR)-specific protein kinase SRPK1, 
that regulates diverse cellular functions including RNA splicing.  This thesis has sought to 
address the hypothesis that E1^E4 alters SRPK1 activity and influences SRPK1 functions in 
the HPV life cycle.  This study has uncovered the novel finding that E1^E4 protein of HPV1, 
but not HPV5, 16 and 18, is a potent inhibitor of SRPK1 activity in vitro and in vivo and 
inhibition is dependent upon E1^E4 binding to SRPK1.  Whilst HPV1 E1^E4 inhibits SRPK1 
phosphorylation of cellular (ASF/SF2, SRp20, SC35, 9G8 and SRp75) and viral (HPV E2) 
SR protein substrates, it has only weak effects on SR protein cellular localisation and on 
cellular and viral RNA splicing in minigene systems.  Addition of the small molecule 
inhibitor of SRPK, SRPIN340 to organotypic raft cultures of HPV18 genome-containing 
keratinocytes enhances the morphological features of HPV viral replication suggesting that 
the HPV may modulate SRPK activity to facilitate the virus life cycle.   
  
 ACKNOWLEDGEMENTS 
I would like to thank my supervisor Sally Roberts, for her help and advice throughout my 
studies.  I would also like to thank my previous co-supervisor Ian Bell and past members of 
the HPV group, especially Craig Delury, for their advice and support.  I would like to thank 
Ben Willcox for his help with the Biacore experiments and all the other people in the School 
of Cancer Sciences who have given me help and support during the project.  Additionally I 
would like to thank all the good friends I have made during my time in Cancer Sciences, 
especially the 2007 intake of PhD students, for helping me have fun during my studies and 
supporting me through the hard times. 
 
I would like to thank the College of Medicine and Dentistry for their financial support during 
my studies and Cancer Research UK for funding the laboratory of Sally Roberts. 
 
Finally I thank my family for putting up with me during this stressful time and for believing 
that I could finish this thesis.  
 
Contents 
 
CHAPTER 1 GENERAL INTRODUCTION.................................................. 1 
1.1 Small DNA tumour viruses ...................................................................................................... 1 
1.2 Human papillomavirus ............................................................................................................. 2 
1.3 Classification of papillomaviruses ........................................................................................... 2 
1.4 Warts and verrucas .................................................................................................................. 5 
1.5 Human papillomavirus and cancer ......................................................................................... 6 
1.5.1 Non-genital ................................................................................................................................. 6 
1.5.2 Anogenital ................................................................................................................................... 9 
1.5.3 HPV screening and prophylactic vaccine ................................................................................. 11 
1.6 The HPV genome .................................................................................................................... 13 
1.7 HPV life cycle .......................................................................................................................... 14 
1.7.1 Early virus life cycle ................................................................................................................. 15 
1.7.2 Late virus life cycle ................................................................................................................... 17 
1.8 Transcriptional control in HPV ............................................................................................. 17 
1.8.1 Early promoter control .............................................................................................................. 17 
1.8.2 Late promoter control ............................................................................................................... 20 
1.9 Post-transcriptional modifications ........................................................................................ 20 
1.9.1 Genome splicing ....................................................................................................................... 20 
1.9.2 Control of genome splicing ....................................................................................................... 24 
1.9.3 Polyadenylation ........................................................................................................................ 25 
1.9.4 Translation ................................................................................................................................ 27 
1.10 HPV proteins ........................................................................................................................... 27 
1.10.1 HPV E1 ..................................................................................................................................... 28 
1.10.2 HPV E2 ..................................................................................................................................... 29 
1.10.3 HPV E6 protein ......................................................................................................................... 30 
1.10.4 HPV E7 ..................................................................................................................................... 33 
1.10.5 HPV E5 ..................................................................................................................................... 35 
1.10.6 Capsid proteins ......................................................................................................................... 37 
1.11 HPV E1^E4 ............................................................................................................................. 38 
1.11.1 Post-translational modifications of E4 ...................................................................................... 42 
1.11.2 Functions of E1^E4 ................................................................................................................... 43 
1.11.2.1 Interaction with structural proteins ........................................................................................... 43 
1.11.2.2 Regulation of the cell cycle and cellular DNA synthesis .......................................................... 45 
1.11.2.3 Disruption of ND10 bodies ....................................................................................................... 47 
1.11.2.4 Induction of apoptosis ............................................................................................................... 48 
1.11.2.5 Interaction with components of RNA metabolism .................................................................... 48 
1.12 Serine-arginine specific protein kinases ................................................................................ 49 
1.13 Serine arginine-rich proteins ................................................................................................. 53 
1.13.1 Localisation of SR proteins ....................................................................................................... 54 
1.14 Functions of SR proteins ........................................................................................................ 57 
1.14.1 pre-mRNA splicing ................................................................................................................... 57 
1.14.2 SR protein control of pre-mRNA splicing ................................................................................ 58 
Contents 
1.14.3 mRNA export, stability and translation .................................................................................... 61 
1.14.4 Other functions of SR proteins ................................................................................................. 62 
1.14.5 SRPKs, SR proteins and cancer ................................................................................................ 64 
1.15 Regulation of SR proteins ...................................................................................................... 67 
1.15.1 SRPK1 phosphorylation ........................................................................................................... 67 
1.15.2 Other kinases and regulatory systems ....................................................................................... 68 
1.16 HPV regulation of splicing factors ........................................................................................ 72 
1.17 Aims and objectives ................................................................................................................ 74 
 
CHAPTER 2 MATERIALS AND METHODS ............................................. 75 
2.1 Bacterial cell culture ............................................................................................................... 75 
2.1.1 Bacterial hosts growth and storage ........................................................................................... 75 
2.1.2 Preparation of chemically-competent bacteria .......................................................................... 75 
2.1.3 Transformation of competent bacteria with plasmid DNA ....................................................... 76 
2.1.4 Preparation of plasmid DNA .................................................................................................... 76 
2.1.4.1 Small scale preparation ............................................................................................................. 76 
2.1.4.2 Large scale preparation ............................................................................................................. 76 
2.1.5 Bacterial expression of recombinant GST and His-tagged fusion proteins .............................. 77 
2.1.5.1 Small scale expression .............................................................................................................. 77 
2.1.5.2 Large scale expression .............................................................................................................. 77 
2.1.5.3 Purification of recombinant GST or His-tagged fusion proteins .............................................. 78 
2.1.5.4 Thrombin cleavage of GST-tag ................................................................................................ 78 
2.2 Molecular Cloning .................................................................................................................. 79 
2.2.1 Polymerase chain reaction (PCR) ............................................................................................. 79 
2.2.2 Restriction enzyme digestion .................................................................................................... 80 
2.2.3 Calf Intestinal Phosphatase (CIP) treatment of plasmid DNA .................................................. 80 
2.2.4 Agarose gel electrophoresis ...................................................................................................... 80 
2.2.5 DNA ligation reactions ............................................................................................................. 81 
2.2.6 Cloning of DNA into a GST plasmid vector ............................................................................. 81 
2.2.7 Generation of HA-tagged pcDNAs ........................................................................................... 81 
2.2.8 PCR sequencing ........................................................................................................................ 82 
2.3 Protein Biochemistry .............................................................................................................. 84 
2.3.1 Bradford Assay for protein concentration determination .......................................................... 84 
2.3.2 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) .......................................................... 84 
2.3.3 Western blot analysis ................................................................................................................ 85 
2.3.4 Densitometry ............................................................................................................................. 87 
2.3.5 In vitro kinase assay .................................................................................................................. 87 
2.3.6 Trichloroacetic acid (TCA) protein precipitation ..................................................................... 87 
2.3.7 In vitro co-precipitations ........................................................................................................... 88 
2.3.7.1 GST “pull down” from lysates .................................................................................................. 88 
2.3.7.2 GST “pull-down” using purified proteins ................................................................................. 89 
2.3.8 Biacore® Surface Plasmon Resonance ...................................................................................... 89 
2.3.8.1 His-SRPK1 on a NTA chip ....................................................................................................... 89 
2.3.8.2 GST-chip................................................................................................................................... 89 
2.3.8.3 Amine-coupling of the proteins directly to the CM5 chip ........................................................ 90 
2.3.9 Statistical analysis ..................................................................................................................... 91 
2.4 Mammalian cell culture .......................................................................................................... 91 
2.4.1 Cell lines and growth media ..................................................................................................... 91 
2.4.2 Passaging of cells ...................................................................................................................... 92 
2.4.3 Freezing and thawing of cells ................................................................................................... 92 
Contents 
2.4.4 Transfection in 6 well plates ..................................................................................................... 92 
2.4.5 Harvesting of cells and protein extraction ................................................................................ 93 
2.4.6 Immunofluorescence ................................................................................................................. 93 
2.4.6.1 Transfection on slides ............................................................................................................... 93 
2.4.6.2 Fixation of cells ........................................................................................................................ 93 
2.4.6.3 Immune-labelling ...................................................................................................................... 94 
2.4.6.4 Microscopy ............................................................................................................................... 94 
2.4.7 Immunoprecipitation ................................................................................................................. 96 
2.4.8 In vivo kinase assay ................................................................................................................... 96 
2.5 In vitro splicing assay .............................................................................................................. 97 
2.5.1 Minigene constructs .................................................................................................................. 97 
2.5.2 Transfection, harvesting of DNA and reverse transcription...................................................... 97 
2.5.3 Radioactive PCR ....................................................................................................................... 98 
2.5.4 Native polyacrylamide electrophoresis (PAGE) ....................................................................... 98 
2.6 Human Foreskin Keratinocytes (HFKs) ............................................................................... 99 
2.6.1 Maintenance of untransfected HFKs ......................................................................................... 99 
2.6.2 Maintenance of HFKs containing HPV18 genomes ................................................................. 99 
2.6.2.1 E-medium ................................................................................................................................. 99 
2.6.2.2 Maintenance and irradiation of J2-3T3 mouse fibroblasts ...................................................... 100 
2.6.2.3 Maintenance of transfected HFKs containing HPV18 genomes ............................................. 100 
2.6.3 SRPIN340 toxicology study ................................................................................................... 101 
2.6.4 Southern blot analysis ............................................................................................................. 101 
2.6.4.1 Isolation of DNA .................................................................................................................... 101 
2.6.4.2 Digestion of DNA for Southern blot analysis ......................................................................... 102 
2.6.4.3 Transfer of DNA from agarose gel to nylon membrane ......................................................... 102 
2.6.4.4 Preparation of radiolabelled DNA probe ................................................................................ 103 
2.6.4.5 Hybridisation of radiolabelled probe to immobilised DNA .................................................... 104 
2.6.4.6 Stringency washes................................................................................................................... 104 
2.6.5 Organotypic raft cultures ........................................................................................................ 105 
 
CHAPTER 3 INVESTIGATING THE EFFECT OF THE INTERACTION 
BETWEEN HPV E1^E4 AND SRPK1 ON THE PROTOTYPICAL SR 
PROTEIN ASF/SF2 ........................................................................................ 106 
3.1 Introduction ........................................................................................................................... 106 
3.2 Results .................................................................................................................................... 109 
3.2.1 Expression of GST-ASF/SF2 .................................................................................................. 109 
3.2.2 GST-ASF/SF2 is a substrate for His-SRPK1 .......................................................................... 111 
3.3 HPV1 E1^E4 inhibits SRPK1 phosphorylation of ASF/SF2 ............................................. 114 
3.3.1 HPV1 E1^E4 interacts with SRPK1 ....................................................................................... 114 
3.3.2 Inhibition of SRPK1 phosphorylation of ASF/SF2 ................................................................ 117 
3.3.3 Inhibition is dependent on the interaction between SRPK1 and HPV1 E1^E4 ...................... 119 
3.3.4 Determination of the mode of inhibition of HPV1 E1^E4 ...................................................... 119 
3.3.5 HPV1 E1^E4 inhibits binding of SRPK1 to ASF/SF2............................................................ 124 
3.4 HPV16 and HPV18 E1^E4 do not inhibit SRPK1 kinase activity .................................... 130 
3.5 HPV5 E1^E4 ......................................................................................................................... 133 
3.5.1 HPV5 E1^E4 is a substrate for SRPK1 but does not affect kinase activity ............................ 136 
3.6 Discussion .............................................................................................................................. 138 
Contents 
 
CHAPTER 4 INTERACTION OF SRPK1 WITH CELLULAR AND 
VIRAL SR PROTEINS .................................................................................. 141 
4.1 Introduction ........................................................................................................................... 141 
4.2 Results .................................................................................................................................... 143 
4.2.1 Investigation of HPV E1^E4 action on SRPK1 phosphorylation of cellular SR proteins other 
than ASF/SF2 .......................................................................................................................... 143 
4.2.1.1 In vitro SRPK1 phosphorylation of cellular SR proteins ........................................................ 143 
4.2.1.2 Effect of HPV1, 5, 16 and 18 E1^E4 on SRPK1 phosphorylation of cellular SR proteins..... 145 
4.2.2 Effect of E1^E4 on SRPK1 phosphorylation of viral SR proteins .......................................... 150 
4.3 Discussion .............................................................................................................................. 154 
 
CHAPTER 5 BIOLOGICAL FUNCTIONS OF THE INTERACTION 
BETWEEN HPV1 E1^E4 AND SRPK1 ....................................................... 157 
5.1 Introduction ........................................................................................................................... 157 
5.2 Results .................................................................................................................................... 159 
5.2.1 In vivo inhibition of SRPK1 by HPV1 E1^E4 ........................................................................ 159 
5.3 SRPK1 colocalises with HPV1 and HPV5 E1^E4 in cells ................................................. 162 
5.4 HA tagged SR proteins ......................................................................................................... 169 
5.5 Overexpression of SRPK1 causes the relocalisation of SR proteins ................................. 171 
5.5.1 Phosphorylated SR proteins .................................................................................................... 176 
5.5.2 ASF/SF2 ................................................................................................................................. 176 
5.5.3 SC35 ....................................................................................................................................... 176 
5.5.4 HA-tagged SR proteins ........................................................................................................... 177 
5.6 Inhibition of SRPK1 kinase activity does not inhibit SRPK1-mediated relocalisation... 180 
5.6.1 HPV1 E1^E4 ........................................................................................................................... 180 
5.6.2 SRPIN340 ............................................................................................................................... 181 
5.7 The effect of HPV1 E1^E4 on SRPK1 function in alternative splicing ............................ 185 
5.7.1 The minigene system .............................................................................................................. 185 
5.7.2 The effect of SR proteins and SRPK1 on splice site selection ................................................ 187 
5.7.3 The effect of HPV1 E1^E4 on splice site selection ................................................................ 190 
5.8 Discussion .............................................................................................................................. 192 
 
 
 
 
 
Contents 
 
CHAPTER 6 ROLE OF SRPK1 IN EPITHELIAL DIFFERENTIATION .. 
  ................................................................................................... 195 
6.1 Introduction ........................................................................................................................... 195 
6.2 Distribution of SRPK1 upon epithelial differentiation ...................................................... 197 
6.2.1 Effect of HPV18 on SRPK1 distribution ................................................................................ 199 
6.3 The effect of SRPK inhibition on HPV18 genome containing HFKs ............................... 202 
6.3.1 In monolayer cell culture ........................................................................................................ 202 
6.3.2 In organotypic rafts ................................................................................................................. 204 
6.4 Discussion .............................................................................................................................. 206 
 
CHAPTER 7 DISCUSSION .......................................................................... 209 
7.1 Overview of findings ............................................................................................................. 209 
7.2 Inhibition of SRPK1 by HPV1 E1^E4 ................................................................................ 210 
7.3 Relocalisation of SRPK1....................................................................................................... 212 
7.4 Role of SRPK1 in the late virus life cycle ............................................................................ 213 
7.5 Substrates of SRPK1 ............................................................................................................ 214 
 
APPENDIX  ................................................................................................... 216 
Appendix 1A  pGex-2T-HPV5 E1^E4 against HPV5b complete genome ............................................... 216 
Appendix 1B GST-HPV5 E4 against HPV5b E4 protein sequence ......................................................... 217 
 
LIST OF REFERENCES ............................................................................... 218 
  
Contents 
 
LIST OF FIGURES 
Chapter 1 
 
Figure 1.1 Phylogenetic tree of HPV and HPV genome map. ........................................................................... 4 
Figure 1.2 Life cycle of HPV in dividing epithelia. ......................................................................................... 16 
Figure 1.3 Control of transcription in HPV. ..................................................................................................... 19 
Figure 1.4 Genome structure and transcript map of HPV1. ............................................................................. 22 
Figure 1.5 Genome structure and transcript map of HPV16. ........................................................................... 23 
Figure 1.6 Regulation of HPV16 alternative splicing. ..................................................................................... 26 
Figure 1.7 Cellular targets of E6 and E7 proteins. ........................................................................................... 32 
Figure 1.8 The HPV E1^E4 protein. ................................................................................................................ 41 
Figure 1.9 Sequence comparison of SRPK1 family members.......................................................................... 52 
Figure 1.10 SR protein domain structure. .......................................................................................................... 55 
Figure 1.11 SR protein control of splicing. ........................................................................................................ 60 
Figure 1.12 Mechanism of phosphorylation of ASF/SF2 by SRPK1. ................................................................ 66 
Figure 1.13 Regulation of SR proteins. .............................................................................................................. 71 
 
Chapter 3 
 
Figure 3.1  Expression of GST-ASF/SF2. ....................................................................................................... 110 
Figure 3.2  Phosphorylation of GST-ASF/SF2 by His-SRPK1. ...................................................................... 112 
Figure 3.3  SRPK1 kinase assay time course. ................................................................................................. 113 
Figure 3.4  Titration of GST-ASF/SF2 into an in vitro kinase assay. ............................................................. 115 
Figure 3.5  GST-HPV1 E1^E4 binds to His-SRPK1. ..................................................................................... 116 
Figure 3.6 GST-HPV1 E1^E4 inhibits GST-ASF/SF2 phosphorylation by His-SRPK1. .............................. 118 
Figure 3.7 HPV1 E1^E4 mediated inhibition of SRPK1 activity is dependent on an interaction with E1^E4.
 ...................................................................................................................................................... 120 
Figure 3.8 Inhibition of SRPK1 phosphorylation of ASF/SF2 by SRPIN340. .............................................. 121 
Figure 3.9 Determination of the mode of inhibition by HPV1 E1^E4 using Michaelis-Menten kinetics. ..... 123 
Figure 3.10 Biacore® interaction study using NTA and GST-antibody chips. ................................................. 125 
Figure 3.11 HPV1 E1^E4 inhibits the binding of His-SRPK1 to GST-ASF/SF2. ........................................... 127 
Figure 3.12 Biacore® interaction study using amine coupled proteins on a CM5 chip. ................................... 129 
Figure 3.13 His-SRPK1 interacts with HPV type 16 and 18 E1^E4. ............................................................... 131 
Figure 3.14 GST-HPV16 and GST-HPV18 E1^E4 proteins do not inhibit His-SRPK1 phosphorylation of 
GST-ASF/SF2. .............................................................................................................................. 132 
Figure 3.15 Expression of GST-HPV5 E1^E4. ................................................................................................ 134 
Figure 3.16 GST-HPV5 E1^E4 interacts with His-SRPK1. ............................................................................. 135 
Figure 3.17 HPV5 E1^E4 is a substrate but not an inhibitor for SRPK1. ........................................................ 137 
 
Chapter 4 
 
Figure 4.1 Expression of GST-tagged SR proteins. ....................................................................................... 144 
Figure 4.2 Phosphorylation of GST-SR proteins by His-SRPK1. .................................................................. 146 
Figure 4.3 Inhibition of SRPK1 kinase activity by HPV1 E1^E4. ................................................................. 147 
Figure 4.4 HPV16 and HPV18 E1^E4 do not inhibit SRPK1 phosphorylation of SC35. .............................. 149 
Figure 4.5 Expression of GST-tagged HPV1, HPV5 and HPV8 E2 and E2 Hinge. ...................................... 151 
Figure 4.6 In vitro kinase assay with viral E2 and E2H proteins. .................................................................. 153 
 
Contents 
Chapter 5 
 
Figure 5.1 In vivo inhibition of SRPK1 by HPV1 E1^E4. ............................................................................. 161 
Figure 5.2 Localisation of SRPK1 with HPV1 E1^E4 in H1299 and HeLa cells. ......................................... 163 
Figure 5.3 Localisation of Flag-SRPK1 with HPV1 E1^E4 in H1299 cells. ................................................. 164 
Figure 5.4 Localisation of HA-HPV5 E1^E4 in HeLa cells. .......................................................................... 166 
Figure 5.5 Localisation of HA-HPV5 E1^E4 and SRPK1 in HeLa, H1299 and SVJD cells. ........................ 167 
Figure 5.6 Localisation of Flag-SRPK1 with HA-HPV5 E1^E4 in HeLa cells. ............................................ 168 
Figure 5.7 Expression and localisation of HA-tagged SR proteins. ............................................................... 170 
Figure 5.8 Localisation of phosphorylated SR proteins upon Flag-SRPK1 expression. ................................ 172 
Figure 5.9 Localisation of ASF/SF2 upon expression of Flag-SRPK1. ......................................................... 173 
Figure 5.10 Localisation of SC35 upon expression of Flag-SRPK1. ............................................................... 174 
Figure 5.11 Localisation of SC35 upon expression of Flag-SRPK1. ............................................................... 175 
Figure 5.12 Localisation of SC35 upon expression of GFP and Flag-MCM7. ................................................ 178 
Figure 5.13 Localisation of HA-tagged SR proteins with expression of Flag-SRPK1. .................................... 179 
Figure 5.14 Localisation of SR proteins with HPV1 E1^E4 in H1299 cells. ................................................... 182 
Figure 5.15 Localisation of SC35 with Flag-SRPK1 and HPV1 E1^E4. ......................................................... 183 
Figure 5.16 Localisation of SC35 with Flag-SRPK1 expression and SRPIN340 treatment. ........................... 184 
Figure 5.17 X16 and E1A minigene constructs. ............................................................................................... 186 
Figure 5.18 X16 minigene with ASF/SF2, SRp20 and SRPK1. ...................................................................... 188 
Figure 5.19 E1A minigene with ASF/SF2, SRp20 and SRPK1. ...................................................................... 189 
Figure 5.20 X16 minigene with HPV1 E1^E4. ................................................................................................ 191 
 
Chapter 6 
 
Figure 6.1 Expression of SRPK1 in organotypic rafts of primary human foreskin keratinocyte. .................. 198 
Figure 6.2 SRPK1 expression in HPV18 genome containing organotypic rafts. ........................................... 200 
Figure 6.3 Localisation of SRPK1 and E1^E4 in HPV18 genome containing rafts. ...................................... 201 
Figure 6.4 The effect of SRPIN340 on HPV18 containing HFKs.................................................................. 203 
Figure 6.5 The effect of SRPIN340 on organotypic rafts. .............................................................................. 205 
  
Contents 
 
LIST OF TABLES 
Table 1 HPV types associated with different warts ....................................................................................... 5 
Table 2 Roles of SR proteins in post-transcriptional gene expression ......................................................... 62 
Table 3  Plasmid DNA vectors ..................................................................................................................... 79 
Table 4 Primers, template DNA and enzymes used for cloning .................................................................. 83 
Table 5 Sequencing primers ......................................................................................................................... 84 
Table 6 Antibody dilutions used in Western blotting................................................................................... 86 
Table 7 Cell lines used in this study............................................................................................................. 91 
Table 8 Dilutions for antibodies used in immunofluorescence .................................................................... 95 
Table 9 Minigene primers ............................................................................................................................ 97 
Abbreviations 
 
ABBREVIATIONS 
APS  Ammonium persulphate 
ASF/SF2 Alternative Splicing Factor/Splicing Factor 2 
ATP  Adenosine triphosphate 
BCC  Basal cell carcinoma 
CCE  Cornified cell envelope 
CDK  Cyclin-dependent kinase 
CIN  Cervical intraepithelial neoplasia  
CMV  Cytomegalovirus 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DAPI  4‟,6-diamidion-2-phenylindole 
DBD  DNA binding domain 
DNA  Deoxyribonucleic acid  
DTT  Dithiothreitol 
ESE  Exonic splicing enhancers 
ESS  Exonic splicing silencers 
EV  Epidermodysplasia verruciformis 
GFP  Green fluorescent protein 
GST  Glutathione-S-transferase 
H and E Haematoxylin and eosin 
HBV  Hepatitis B virus 
HCV  Hepatitis C virus 
HFK  Human foreskin keratinocyte 
HIV  Human immunodeficiency virus 
hnRNP Heterogeneous nuclear ribonucleoprotein 
HPV  Human papillomavirus 
HSV  Herpes simplex virus 
IGC  Interchromatin granule clusters 
IRES  Internal ribosome entry site 
LCR  Long control region 
MCM7 Minichromosome maintenance complex component 7 
mRNA  Messenger RNA 
mTOR  Mammalian target of rapamycin 
NES  Nuclear export signal 
NLS  Nuclear localisation signal 
Abbreviations 
NMD  Nonsense mediated decay 
NMSC  Non-melanoma skin cancer 
NRE  Negative regulatory element 
Nt  Nucleotide 
ORF  Open reading frame 
PBS  Phosphate buffered saline 
PIAS1  Protein inhibitor of activated STAT-1 
PKCI-r Protein kinase C-interacting protein 1 related 
PML  Promyelocytic leukaemia protein 
PMSF  Phenylmethanesulfonyl fluoride 
PP1  Protein phosphatase 1 
RNA  Ribonucleic acid 
RRM  RNA recognition motif 
RS  Arginine serine 
SCC  Squamous cell carcinoma 
snRNP  Small nuclear ribonucleoprotein 
SR  Serine arginine 
SRSF  Serine arginine splicing factor 
SRPK1 Serine arginine protein kinase 1 
Ss  Splice site 
SUMO  Small ubiquitin-related modifier 
TCA  Trichloro acetic acid 
UTR  Untranslated region 
VLP  Virus like particle 
VZV  Varicella-Zoster virus 
Introduction 
1 
 
CHAPTER 1 GENERAL INTRODUCTION 
1.1 Small DNA tumour viruses 
At the start of the twentieth century Rous (1911) identified that cells taken from a chicken 
tumour could cause a sarcoma to be induced when injected into another chicken and thus 
identified Rous sarcoma virus, a RNA virus capable of causing cancer in chickens.  Since this 
initial discovery many other viruses have been identified as cancer causing agents and now 
viruses and other infectious agents are predicted to be causal agents in around 17.8% of 
human cancers (Parkin, 2006).  Of the viruses which have been shown to cause cancer in vivo 
and/or in vitro, a number can be classified by genomic composition as DNA tumour viruses; 
these include papillomaviruses, polyomaviruses and adenoviruses.  Other viruses shown to 
cause cancer include hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus 
(EBV), human herpes virus 8 (HHV-8), human T-cell lymphotrophic virus, type-1 (HTLV-1) 
and Merkel cell polyomavirus (MCV) (Parkin, 2006).  Cancer is an unintended consequence 
of the virus infection and results in disruption of the productive life cycle, preventing the 
production of viral progeny.  Most DNA tumour viruses integrate into the host genome and 
only express part of the viral genome (Pagano et al., 2004).  Normally infection with the virus 
is only a prerequisite for cancer development, with additional factors required for the 
progression to carcinogenesis (Liao, 2006). 
Tumour viruses have become important tools in understanding not only the mechanisms of 
carcinogenesis but also general cellular biology.  Studying these viruses has led to the 
discovery of multiple cellular oncoproteins and tumour suppressors, such as p53, along with 
an increased understanding of cellular pathways (Carrillo-Infante et al., 2007).  Additionally, 
virally induced tumours can be treated with preventative therapeutics, such as the 
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prophylactic vaccines against HBV and HPV, giving new methods to help reduce the cancer 
burden. 
 
1.2 Human papillomavirus 
Papillomaviruses are a highly diverse group of small double-stranded DNA viruses, which 
can cause a range of lesions and diseases in a number of species.  The most commonly studied 
host of papillomaviruses are humans, which are infected with 120 different types of human 
papillomavirus (HPV) (Bernard et al., 2010).  HPV infects cutaneous and mucosal epithelia 
and causes a variety of lesions ranging from benign tumours (plantar, flat and common warts, 
genital condylomas and papillomas) to cervical neoplasia and cancer.  Cutaneous and genital 
warts have been known to be infectious and caused by a virus since the early twentieth 
century, and in 1949 the viral particles isolated from skin papillomas were visualised by 
electron microscopy (Strauss et al., 1949, zur Hausen, 2009).  The carcinogenic potential of 
papillomaviruses was initially demonstrated in rabbits, followed by investigations into the 
genital condylomata acuminata causing virus as a possible cause for cervical cancer (zur 
Hausen, 1976, 2009).  HPV has since been shown to be a causative agent for cancers of the 
anogenital tract (cervical, vaginal, vulval, anal and penile) non-melanoma skin cancer and 
oropharyngeal cancer (Parkin, 2006).   
 
1.3 Classification of papillomaviruses 
Of the 120 types of HPV identified approximately one-third have been shown to target 
epithelial cells in the genital tract and these types can be divided into two groups of high and 
low risk viruses.  The high risk HPV types include HPV16 and HPV18 and are found in 
99.7% of cervical cancers (Walboomers et al., 1999).  The low risk types, which include 
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HPV6 and HPV11, are more commonly associated with genital warts and are rarely present in 
cancers.  HPV is the most common sexually transmitted disease and there is an 80% chance 
of contracting a genital infection of HPV in the sexually active population (Bekkers et al., 
2004).  High risk HPV infections usually persist for 12-18 months (Bodily and Laimins, 
2011) and are cleared by the immune system, however about 10% to 20% of individuals do 
not clear the infection and develop a persistent infection (Stanley, 2008).  Persistent infection 
by high risk HPV is a risk factor for the development of cervical intraepithelial neoplasia 
(CIN) and cancer.   
The genomes of papillomaviruses are very static and mutations causing sequence changes are 
rare, occurring at a similar frequency as the genomes of the host (de Villiers et al., 2004).  
Within the genome the most conserved gene is the L1 ORF, this ORF is therefore used to 
classify different HPV types.  HPV types are classified as a new type if the sequence of L1 
differs by more than 10% to the closest known type; a subtype is therefore between 2% and 
10% difference in homology and a variant if there is less than 2% variance (de Villiers et al., 
2004).  The HPV types can be further classified into genera and species, genera share between 
60% and 70% nucleotide identity and species share between 71% and 89% (de Villiers et al., 
2004).  There are five HPV genera of which the main ones are alpha and beta which contain 
about 90% of known HPV types (Figure 1.1A).  The largest genus is the alpha 
papillomaviruses, which contains both the high and low risk mucosal HPV types, along with 
some cutaneous viruses.  The beta papillomaviruses are normally associated with insignificant 
cutaneous infections; however in individuals who are immunocompromised or have the 
genetic disease epidermodysplasia verruciformis (EV), the beta viruses can be associated with 
the development of non-melanoma skin cancer (Harwood and Proby, 2002).  EV is a rare 
genodermatosis associated with a high-risk of non-melanoma skin cancer resulting from a 
high susceptibility to beta papillomavirus infection (Harwood and Proby, 2002).    
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Figure 1.1 Phylogenetic tree of HPV and HPV genome map.  (A) There are five 
evolutionary genera of HPV types and species within the genera.  (B) HPV16 genome, 
early (p97) and late (p670) promoters are marked with arrows, polyadenylation sites AE 
and AL are marked, early proteins are in red and green, late proteins are in yellow. LCR: 
long control region.  Integration often occurs within the E2 ORF, around the region 
indicated. Taken from (Doorbar, 2006) 
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The remainder of the HPVs belong to the genera gamma, mu and nu and are generally 
associated with cutaneous warts and verrucas which do not progress to cancer (de Villiers et 
al., 2004).  
1.4 Warts and verrucas 
Infection of the cornified stratified squamous epithelium of skin with HPV can cause mostly 
benign warts and papillomas to form; warts can vary in appearance and are classified based 
upon their appearance and epithelial surface infected.  Different HPV types are more 
commonly found in the different wart types as shown in table 1.  Warts have multiple 
histological differences, but are often elevated (acanthosis), with areas of hyperkeratosis 
(thickening of the cornified layer) and parakeratosis (retention of nuclei in cornified layer).  
 Table 1 HPV types associated with different warts  
Clinical type Distinguishing features HPV type 
Common warts  
(Verruca vulgaris) 
Firm, rough keratotic papules and nodules 
on any skin surface 
1, 2, 4, 57 
Planar (flat) warts 
(Verruca plana) 
2-4 mm in diameter, slightly elevated 3, 10 
Intermediate warts 
(Butcher‟s warts) 
Features of common and planar warts 
2, 3, 7, 10, 
28 
Myrmecia 
(Palmoplantar warts) 
Deep burrowing wart 1 
Plantar warts  
(Verruca plantaris) 
Keratotic surface with collar of thickened 
keratin 
1, 2, 4, 57 
Mosaic warts 
Occur when palmar or plantar warts 
coalesce into large plaques 
2 
Anogenital warts 
(Condyloma acuminata or 
venereal warts) 
Epidermal and dermal nodules and papules 
in the perineum and on the genitalia 
6, 11 
Oral warts 
Small white of pink elevated papules on 
the oral mucosa 
6, 11, 32 
(Sterling et al., 2001)  
Warts are most common in children and adolescents with the prevalence of visible warts in 11 
and 16 year olds of between 3.9% and 4.9%, however most children clear warts easily and 
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spontaneously (Williams et al., 1993).  In the United Kingdom there are regional variations as 
well as ethnic and socio-economic factors in the prevalence of warts in children (Williams et 
al., 1993).  Warts can be painful, especially plantar warts and can be unsightly, leading to the 
need for treatment and removal, rather than wait for natural clearance.  Treatment of 
cutaneous warts is usually by destructive methods such as treatment with salicylic acid or 
cryotherapy, however no treatment is 100% successful and most treatments require an 
immune response to completely clear the infection (Sterling et al., 2001).  Generally there is 
not one therapy option that has been proven to be effective in all patients and thus multiple 
treatment options exist and are often used in combination. 
 
1.5 Human papillomavirus and cancer 
1.5.1 Non-genital  
HPV is commonly associated with cancers of the anogenital tract; however HPV has been 
linked with a diverse range of malignancies, including non-melanoma skin cancer (NMSC).  
NMSC includes basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) and is 
the most prevalent malignancy in the Caucasian population worldwide (Alam and Ratner, 
2001).  While BCCs are more common, accounting for around 80% of NMSC, and are locally 
aggressive they rarely metastasise, whereas SCCs can metastasise if not treated in a timely 
fashion, however still rarely cause death (Kiviat, 1999).  Solar ultraviolet (UV) irradiation has 
long been established as the major risk factor for developing NMSC; however molecular 
studies have identified a role for HPV, acting as a co-factor with UV to cause skin cancer 
(Akgul et al., 2006).  Skin cancers occur predominantly at sun-exposed sites and unlike 
anogenital cancers where at least one copy of the genome is present in each cell, only 1 in 20-
50,000 cells contain HPV DNA (Pfister, 2003).  The low copy numbers of viral DNA found 
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in NMSC suggests that cutaneous HPVs are involved in tumour initiation and progression, but 
are not required for the maintenance of the malignant phenotype (Pfister, 2003).   
The immune status of the host is an important factor in the development of NMSC, with 
immunosuppressed organ-transplant recipients having a 10-fold increased risk of BCC and an 
up to 100-fold increased risk of SCC (Pfister, 2003).  An increased risk of NMSC is also seen 
in individuals with the rare genodermatosis epidermodysplasia verruciformis (EV).  EV is an 
inherited disorder of cell mediated immunity, meaning that individuals with this disease are 
unable to adequately control infection with certain HPV types (Kiviat, 1999).  The mutations 
associated with EV are in the EVER genes, which negatively regulate zinc induced 
transcription factors and also regulate the zinc balance in keratinocytes (Lazarczyk et al., 
2009).  The knockdown of the EVER genes has been shown to correlate with increased 
activity of the AP-1 transcription factor, allowing the expression of transcription factors 
required for the expression and replication of the viral genome (Lazarczyk et al., 2009).  The 
HPV types associated with EV are the beta papillomaviruses, with HPV5 and HPV8 being 
most commonly associated with SCC (Pfister, 2003).  EV is characterised by widely spread, 
persistent, flat atypical warts and macular lesions which occur during childhood and can then 
metastasise later in life especially in sun-exposed areas of the skin (Pfister, 2003).  The 
precise mechanism by which beta HPV types cause NMSC is unknown, as in vitro the E6 and 
E7 proteins of cutaneous HPVs have been shown to have very weak or no transforming 
properties (Akgul et al., 2006).  The E6 protein of HPV38 is unable to induce p53 
degradation, but has been shown to interact with the histone acetyltransferase p300 to inhibit 
p53 acetylation and therefore the inhibition of p53 mediated growth arrest and apoptosis 
(Muench et al., 2010).  Additionally, several mechanisms by which HPV acts as a co-factor to 
UV have been proposed, these include the anti-apoptotic nature of E6 favouring the 
accumulation of somatic mutations, including p53 mutations which are common in NMSC 
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and abrogation of the p21 response to cellular stress by E6 (Alam and Ratner, 2001, Pfister, 
2003).  Also the immunomodulatory functions of E6 and E7 have been suggested to be 
involved in NMSC progression, as the secretion of anti-inflammatory cytokines by just a few 
HPV positive cells may impair the immunologic elimination of the cancer cells (Harwood and 
Proby, 2002, Pfister, 2003).  The E6 proteins of HPV5, 10 and 77 have been shown to inhibit 
UV-induced apoptosis in a p53 independent manner, by abrogating the anti-apoptotic 
functions of Bak, by promoting its proteolytic degradation (Jackson et al., 2000).  The E7 
protein of HPV types 5, 8, 20 and 38 has been shown to upregulate the expression of 
lipocalin-2 in both monolayer and differentiated cells, a strong induction of lipocalin-2 is 
characterised by dysregulated epithelial differentiation.  HPV-positive SCCs have increased 
levels of lipocalin-2 in the most differentiated layers and lipocalin-2 has been shown to have 
both pro- and anti-apoptotic functions.  Although the precise biological effect of lipocalin-2 is 
unknown, the upregulation of lipocalin-2 by E7 may contribute to the progression of SCCs 
(Akgul et al., 2011). 
The high-risk mucosal HPV types can infect the oral cavity and the oropharynx and have been 
etiologically linked with cancer at these sites.  There are 5949 new cases of head and neck 
cancer each year in the UK (WHO/ICO, 2010) and the main causes of head and neck cancers 
are smoking and alcohol, however HPV has been found in up to 24% of oral SCCs and up to 
60% of oropharyngeal SCCs in the USA, suggesting that HPV is a cause of these cancers 
(Kreimer et al., 2005, Marur et al., 2010).  The main HPV type found in HPV-positive 
oropharyngeal SCCs and oral SCCs is HPV16, accounting for 87% and 68% respectively.  
Strangely HPV18 is rare in HPV-positive oropharyngeal SCCs, accounting for only 2.8%, but 
is more common in oral SCCs, accounting for 34% of the HPV-positive cancers (Kreimer et 
al., 2005).  The incidence of oral HPV has been shown to increase with the number of sexual 
partners and is also more common in men, in HIV-infected individuals and in tobacco users 
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(Marur et al., 2010).  HPV has been shown to be an important cause of oral cancers in both 
smokers and non-smokers but while the incidence of HPV-negative head and neck cancers, 
frequently associated with smoking and drinking, are decreasing, the incidence of HPV-
positive head and neck cancers are increasing (Marur et al., 2010).  The role of HPV in 
causing head and neck cancers is unknown, but it is predicted that HPV may play a similar 
role to that played in the aetiology of anogenital cancers. 
1.5.2 Anogenital 
Cervical cancer is the second most common cancer in women worldwide; in 2010 there were 
529,828 cases of cervical cancer, which accounted for 275,128 deaths (WHO/ICO, 2010).  
The developing regions account for 76% of the cervical cancer cases worldwide and in 2010, 
17% of the cervical cancer cases were in sub-Saharan Africa (Forouzanfar et al., 2011).  In 
the United Kingdom the incidence of cervical cancer has more than halved since 1980, 
however in 2008 there were 2890 new cases of cervical cancer and 1111 deaths (Forouzanfar 
et al., 2011, WHO/ICO, 2010).  Over 99.7% of cervical carcinomas have been shown to be 
positive for HPV DNA, allowing the conclusion to be reached that HPV infection is a 
necessary cause of cervical cancer (Walboomers et al., 1999). 
Cervical cancer can be divided into two histological forms of cancer dependent upon the cell 
type which is infected.  Squamous cell carcinomas (SCCs) of the cervix account for 80-85% 
of cervical cancer cases and are predominantly caused by HPV16 (62% HPV16, 8% HPV18) 
(de Sanjose et al., 2010).  Adenocarcinomas, which are derived from adenomatous glandular 
cells, are less frequent, accounting for 15-20% of cases are commonly associated with HPV18 
(32% HPV18, 50% HPV16) (de Sanjose et al., 2010, Green et al., 2003).  However HPV 
types 31, 33, 35, 45, 52 and 58 have all been found in cervical cancers (de Sanjose et al., 
2010).  The prevalence of the different HPV types in cervical cancer varies with geography 
and age.  Women with cervical cancers which are positive for HPV45 or HPV18 are generally 
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much younger than women with HPV16 positive cancers and who in turn are younger than 
women with cancers related to any other HPV type (de Sanjose et al., 2010).  High risk HPV 
is also attributable to 40% of penile, vulvar and vaginal cancers and 90% of anal cancers 
(Parkin and Bray, 2006).  The cancers of other anogenital regions are rare, however like 
cervical cancer they are normally SCCs, more common in the developing world and are 
usually caused by HPV16 and HPV18 (Parkin and Bray, 2006). 
While infection with HPV is necessary for cervical cancer, HPV alone isn‟t sufficient to drive 
the progression to malignancy.  A number of cofactors have been reported to be important 
environmental risk factors; these include smoking, sexual promiscuity, parity and oral 
contraceptive use (Green et al., 2003, Kjellberg et al., 2000).  Sexual promiscuity increases 
the chances of contracting a HPV infection, whereas smoking has been shown to be the most 
significant non-HPV related environmental risk factor (Kjellberg et al., 2000).  The chemical 
carcinogens found in cigarette smoke may influence progression to carcinogenesis by causing 
DNA damage and impairing the immune system, or may increase the risk of getting an 
infection with HPV and/or prolong that infection.  Whatever the mechanism of action, 
smoking is an independent risk factor for cervical cancer and has been shown to be causal, 
with current smokers being twice as likely to be diagnosed with CIN as non-smokers (Collins 
et al., 2010, Kjellberg et al., 2000).  
Cervical cancer has a well-characterised pre-malignant phase which can be analysed by 
cytological examination of exfoliated cervical cells and confirmed by histological 
examination of cervical tissue.  The pre-malignant phases represent a range of histological 
abnormalities and are termed as cervical intraepithelial neoplasia (CIN) grades 1 to 3, with 
CIN1 representing mild dysplasia, CIN2, moderate dysplasia and CIN3, severe dysplasia or 
carcinoma in situ (Woodman et al., 2007).  In low grade CIN, a productive life cycle of the 
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virus is supported, with viral progeny produced.  However in high grade CIN, the HPV 
genome is often integrated into the host chromosomes, the site of integration is downstream 
of the E6 and E7 genes and often in the E1 or E2 region (Figure 1.1B).  Integration leads to 
the disruption of E2 regulation of E6 and E7 expression and the subsequent upregulation of 
these oncoproteins (Woodman et al., 2007).  When the genome is not integrated, the E2 
binding sites in the early promoter are often methylated, preventing E2 binding and the 
repression of expression.  
1.5.3 HPV screening and prophylactic vaccine 
The rates of cervical cancer have been falling over the last few decades in developed 
countries, due to the implementation of screening programmes, which allow early detection 
and early treatment of pre-cancerous cervical lesions.  In the UK the Papanicolaou (Pap) test 
of exfoliated cervical cells was introduced nationally in 1988 and since then the mortality 
rates of cervical cancer have decreased by about 80% (Peto et al., 2004).  Cervical cancer 
screening is based upon cytological and colposcopic analyses, looking for the presence of 
abnormal cells rather than the presence of HPV DNA (zur Hausen, 2002).  The screening 
programmes have reduced the incidence of cervical SCC since their introduction; however the 
rates of adenocarcinoma have been reported to have increased, this may be attributable to 
cervical screening being less efficient at the detection of adenocarcinoma (Parkin and Bray, 
2006).  The Pap test looks at the severity of cytological abnormalities; however 
adenocarcinoma, which is associated with HPV18, has only minor cytological abnormalities 
when compared to SCC.  Therefore the exfoliated cells are less likely to have severe 
cytological abnormalities and be referred for colposcopy.  This means that the screening 
programme is more likely to diagnose and interrupt disease progression with a HPV16 
infection than with HPV18 (Woodman et al., 2007).  The efficacy of cytological examinations 
has improved since the 1990s, with the introduction of liquid-based cytological screening and 
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new tests looking at viral load, viral genome integration and methylation of tumour 
suppressor genes are being developed, together these may aid in the detection of 
adenocarcinoma and reduce mortality rates further.  As the number of cases of cervical cancer 
in the developed world decreases due to better understanding of the causes of cervical cancer 
and more improved screening protocols, the number of cases and mortality in the developing 
world is increasing or remaining constant (Forouzanfar et al., 2011, Parkin and Bray, 2006), 
in areas where screening is absent due to costs and expertise, different approaches are 
required to combat this virus. 
Initial experiments with virus like particles (VLPs), which are the self-assembled 
papillomavirus structural proteins, in animals resulted in effective protection against primary 
papillomavirus infections (Breitburd et al., 1995, Suzich et al., 1995).  There are now two 
prophylactic vaccines against HPV infection which have been licensed to date, the 
quadrivalent vaccine Gardasil
®
 protects against HPV16, 18, 6 and 11 and is produced by 
Merck & Co., Inc.  The bivalent vaccine Cervarix
®
 is protective against HPV16 and 18 and is 
produced by GlaxoSmithKline plc.  Both vaccines also show some level of cross-protection 
against infection with other HPV types; including the closely related types HPV31 and 
HPV45 (Bonanni et al., 2009).  The vaccines are composed of HPV L1 proteins assembled 
into VLPs and are administered intramuscularly by injection in three doses at 0, 1 and 6 
months (Harper et al., 2004, Villa et al., 2006).  In the UK, both vaccines have been approved 
for use, but the bivalent vaccine Cervarix
®
 has NHS funding for administration to girls aged 
12-13, along with a catch up campaign for girls up to 18 years old, with the aim to vaccinate 
before sexual debut (Koulova et al., 2008).  The uptake rate in England is 87.4% for the first 
injection, but only 76.6% for the third, meaning some girls are not getting the full protection.  
In some areas of England the uptake rate is less than 70%, this is often in areas with a large 
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ethnic population and low income families (DoHealth, 2011).  In the UK males are not being 
vaccinated, as this is not considered to be cost-effective (Koulova et al., 2008).   
Cervical cancer screening programmes are the most expensive preventative health care 
measure in the world, costing the NHS around £157 million in England (including treatment), 
the vaccination programme may help to combat some of this cost, however screening will still 
be required against the HPV types not targeted by the vaccines (Villa, 2011).  The bivalent 
vaccine does not protect against HPV6 and 11 which cause genital warts and cost the NHS 
£22.4 million in 2003 (Brown et al., 2006), however this vaccine was chosen on purchase cost 
and not the potential savings.  The vaccines are expensive and are administered in three 
injections which need to be cold, factors which make implementation of the vaccination 
programmes in developing countries unfeasible, therefore other methods of delivery are 
required for the countries in which the disease burden is greatest.   
 
1.6 The HPV genome 
Papillomaviruses have a circular double stranded DNA genome of about 8 kb contained 
within an icosahedral capsid of around 55 nm in diameter (Z. M. Zheng and Baker, 2006).  
The genome can be split into three regions: the long control region (LCR), the early (E) 
region and the late (L) region; they are separated by two polyadenylation (poly(A)) sites: 
early poly(A) (AE) and late poly(A) (AL) (Figure 1.1B) (Z. M. Zheng and Baker, 2006).  The 
early region accounts for over 50% of the genome and commonly encodes for six early 
proteins: E1, E2, E4, E5, E6 and E7, which are responsible for transcription, viral genome 
replication and transformation of the host cell.  In the case of genital HPV types an E8^E2 
splice product is also coded for.  The late region occupies nearly 40% of the genome and lies 
downstream from the early region, the late region encodes for two late viral proteins: L1 and 
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L2, which encode the structural major (L1) and minor (L2) capsid proteins (Z. M. Zheng and 
Baker, 2006).  The LCR makes up the remaining 10% of the genome and has no-protein 
coding function, but has the origin of replication along with multiple transcription factor 
binding sites, which are involved in RNA polymerase II-initiated transcription regulation (Z. 
M. Zheng and Baker, 2006).   
 
1.7 HPV life cycle 
Papillomaviruses infect stratified squamous epithelia and link their productive life cycle to the 
differentiation of the host cell.  In normal epithelia only cells in the basal and parabasal layers 
are undergoing cell division, as the process of cell differentiation involves the exit of cell 
cycle along with a series of complex changes in gene expression (Bodily and Laimins, 2011).  
The virus infects the dividing cells of the basal layer, most likely gaining entry to this layer 
through micro-abrasions of the tissue.  Although the precise mechanism of viral uptake by the 
cells is unknown, it is believed that the heparin sulphate proteoglycans in the basement 
membrane are involved in the initial binding steps and/or virus uptake (Joyce et al., 1999).  
Following the initial binding steps, a conformational change of the capsid and furin cleavage 
of L2 occurs (Kines et al., 2009).  Binding then occurs with a secondary receptor on the 
leading edge of the epithelial cells, which move to heal the wound and form the basal layer 
(Schiller et al., 2010).  Entry into the cells is a relatively slow process and occurs via a 
keratinocyte specific receptor (Schiller et al., 2010).  The virus enters the cell through 
clathrin-mediated endocytosis and travels through the endocytotic pathway where uncoating 
occurs.  The uncoated genome remains bound to L2 and enters the nucleus where 
colocalisation with the ND10 body occurs and RNA transcription begins (Schiller et al., 
2010).   Following infection the life cycle of HPV can be divided into two stages, early and 
late (Figure 1.2).   
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1.7.1 Early virus life cycle 
Following infection the viral genome is established as a stable episome in cells in the basal 
layer.  Among the first viral proteins to be expressed are the replication factors E1 and E2, E2 
acts to recruit E1 to the viral origin of replication, E1 then in turn recruits cellular replication 
factors to mediate viral replication (Longworth and Laimins, 2004b).  In the basal layer the 
cells are undergoing cell cycle, therefore the viral genome can be replicated with the cellular 
DNA during S-phase.  The replicated viral genomes are equally divided between the daughter 
cells, due to the anchoring of viral episomes to mitotic chromosomes by E2.  In the basal 
layer the virus is maintained at approximately 20 to 100 episomal copies per cell (Longworth 
and Laimins, 2004b). 
Following cell division, one of the daughter cells migrates upwards into the parabasal layer, 
where the process of terminal differentiation starts, while the other continues to divide in the 
basal layer.  In uninfected epithelia, cells exit cell cycle once they leave the basal layer, 
however the virus requires the cellular replication machinery to replicate, therefore the early 
protein E7 drives the cells back into S-phase by binding to the retinoblastoma (Rb) family of 
tumour suppressors and other proteins involved in cell cycle regulation (Dyson et al., 1989).  
The re-entry into cell cycle induced by E7 activates pathways leading to growth arrest or 
apoptosis; however the early protein E6 has anti-apoptotic functions and associates with p53 
to allow the cell to enter a pseudo-S-phase where the virus can replicate.  During an infection 
caused by cutaneous viruses such as HPV1, only cells in the basal layer are proliferating, with 
the late phase of the life cycle occurring as soon as the cell leaves the basal layer (Peh et al., 
2002).  In infections with mucosal viruses, such as HPV6 and HPV16, a region of many 
layers of cells is retained in cell cycle prior to the onset of the late phase of viral genome 
amplification (Peh et al., 2002). 
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Figure 1.2 Life cycle of HPV in dividing epithelia.  In normal epithelia (right 
side) cells exit cell cycle once they migrate upwards from the basal layer.  In infected 
epithelia (left side), as the cells migrate from the basal layer they continue to undergo cell 
cycle.  Viral proteins are expressed with differentiation as shown, with mature virions 
only produced in the most superficial layers of the epithelium.  Adapted from (Frazer, 
2004). 
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1.7.2 Late virus life cycle 
The late stages of the virus life cycle are dependent upon cell differentiation and the up-
regulation of the differentiation-dependent promoter.  The trigger for the onset of the late 
events is not fully understood, however changes in cellular signalling are involved (Bernard, 
2002).  The activation of the late promoter leads to an increase in the levels of viral proteins 
required for replication, the proteins expressed are the E1, E2, E1^E4 and E5 early proteins 
and the L1 and L2 late proteins.  The viral genome is amplified to thousands of copies per 
cell, before being packaged into infectious virions formed by the capsid proteins L1 and L2.  
The infectious virions are then shed with the desquamated cells (Bodily and Laimins, 2011). 
 
1.8 Transcriptional control in HPV 
1.8.1 Early promoter control 
In high risk HPV types there are two major viral promoters, along with several other minor 
promoters, the main promoter which encodes early transcripts initiates upstream of the E6 
ORF and is expressed prior to productive replication, in HPV16 this promoter is p97 in 
HPV18 it is p105 (Longworth and Laimins, 2004b).  The cutaneous HPV types, such as 
HPV1 also contain a promoter upstream of the E6 ORF, which codes for the major early 
transcripts (Baker and Calef, 1997).  The early promoter is tightly controlled by upstream cis-
elements in the LCR, including four consensus E2-binding sites, (ACCGNNNNCGGT), 
which act to regulate transcription from the early promoter during differentiation (Bernard, 
2002) (Figure 1.3A).  In HPV1 and BPV1, E2 has been shown to activate the early promoter, 
however in mucosal HPVs, E2 acts primarily as a repressor (Bernard, 2002, Hirochika et al., 
1987).  In mucosal HPV types, the E2 binding sites overlap with a Sp1 binding site and the 
TATA box, the binding site for TFIID and general transcription factors, E2 binding to these 
sites displaces the transcription factors, first Sp1 and then TFIID as the concentration of E2 
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increases, this allows multiple levels of cell type specific repression of the promoter (Tan et 
al., 1994) (Figure 1.3B).  In cutaneous HPV types, the distance between the E2 binding sites 
and the TATA box is greater, so E2 binding does not displace the transcription factors 
(Garrido-Guerrero et al., 1996).  The repression of the early promoter by E2 allows feedback 
to control the level of transcription of the early genes and keep the episomal copy number of 
the genome stable.  In over half of HPV16- and most of HPV18-positive malignant lesions 
(Moody and Laimins, 2010), the HPV genome is integrated into the host chromosomes, this 
integration generally occurs downstream of the E7 gene, disrupting the expression of E2.  The 
loss of E2 regulation of transcription following integration leads to an increase in E6 and E7 
expression and may impart a selective growth advantage over cells harbouring only episomal 
copies of the genome (Francis et al., 2000, Jeon et al., 1995).   
The LCR contains an enhancer to stimulate the promoter; the enhancer is a 400 bp segment, 
100 bp upstream of the promoter, which contains clusters of binding sites for cellular 
transcription factors that can activate the promoter over a long distance (Bernard, 2002).  The 
HPV enhancer functions only in epithelial cells, restricting HPV exclusively to cells of 
epithelial origin.  The epithelial specificity of the enhancers originates from transcription 
factors which are ubiquitously expressed, but made up from different subunits in epithelial 
cells to other cell types; these include activator protein-1 (AP-1), nuclear factor 1 (NFI) and 
transcriptional enhancer factor 1 (TEF-1) (Bernard, 2002).   The 100 bp between the promoter 
and the enhancer contains binding sites for YY1 and CCAAT-displacement protein (CDP), 
which act as silencers for the promoter and repress transcription (Bernard, 2002).  The cellular 
factors involved in repression, alter in concentration during differentiation, allowing the 
coupling of transcription and replication to epithelial differentiation (Bernard, 2002).  The 
different activators and repressors which can bind to the enhancer and promoter are shown in 
Figure 1.3C. 
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Figure 1.3 Control of transcription in HPV.  (A) LCR of HPV16 showing the 
position of conserved E2 binding sites.  (B) Modulation of the E6 promoter by E2 with 
increasing amounts of E2.  (C) Summary of all currently known proteins bound to the 
HPV16 LCR and the E6 and E7 promoters.  Activator proteins are in blue, repressor 
proteins are in red.  Adapted from (Bernard, 2002) 
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1.8.2 Late promoter control 
The late promoter is activated with the induction of the productive phase and in genital HPV 
types directs expression for a series of heterogeneous start sites located within the E7 ORF, in 
HPV16 this promoter is p670 and in HPV18 p811 (Grassmann et al., 1996, Longworth and 
Laimins, 2004b, X. Wang et al., 2011).  However in non-genital HPV types such as HPV1 
and HPV8, the late promoter is in the LCR upstream from the early promoter (Bernard, 2002), 
the promoter in the E7 region of HPV1 can also transcribe late genes (Baker and Calef, 1997).  
The location of the late promoter, results in the late mRNA transcripts containing all or most 
of the early region and the late region.  The late mRNA can be processed into early region 
transcripts which are cleaved and polyadenylated at the early poly(A) site and late region 
transcripts which are polyadenylated at the late poly(A) site (Z. M. Zheng and Baker, 2006).  
The mechanisms of activation of the late promoter are unknown but several cellular 
transcription factors have been shown to repress the promoter, including CDP and YY1 
(Bernard, 2002) (Figure 1.3C).  The differentiation specific transcription factor Skn-1a can 
displace YY1 in a competitive manner and activate the late promoter (Kukimoto and Kanda, 
2001), indicating that the late promoter could be controlled in a similar differentiation 
dependent manner to the early promoter (Bernard, 2002).  Transcripts from the late promoter 
are only detectable in differentiated keratinocytes (Barksdale and Baker, 1995).  
 
1.9 Post-transcriptional modifications  
1.9.1 Genome splicing 
The transcripts produced from the HPV promoters undergo a large amount of post-
transcriptional modifications to produce multiple proteins from a single transcript.  
Alternative splicing allows the generation of multiple mRNAs from one single pre-mRNA 
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and is required for the differential expression of the HPV genes (Baker, 1997).  In HPV1 there 
are three putative promoters located in the E7 ORF, upstream of the E6 ORF and in the 
upstream regulatory region (URR), the major promoter is located within the E7 ORF 
(Palermo-Dilts et al., 1990) (Figure 1.4).  The early and late poly(A) sites have not been 
determined experimentally, but there are three poly(A) signals at 3985-3990, 7381-7386 and 
7427-7432 (Baker, 1997).  Within the genome there are four alternative 5‟ splice sites (ss), 
located at nt 827, 1231, 3592 and 7711 and three alternative 3‟ ss located at nt 2545, 3200 and 
5432 (Baker and Calef, 1997, Palermo-Dilts et al., 1990).  The most abundant mRNA in 
plantar warts is species A (Figure 1.4) which encodes the E1^E4 ORF and the most abundant 
L1 mRNA is species E (Figure 1.4), both transcripts are transcribed from the promoter in the 
E7 ORF, however species A is about 10 times more abundant than species E (Chow et al., 
1987). 
The early HPV16 pre-mRNAs produced from the p97 promoter have three exons and two 
introns, which undergo alternative RNA splicing and are polyadenylated at nt 4215 (Z. M. 
Zheng and Baker, 2006) (Figure 1.5).  There is one alternative 5‟ ss at nt 226 and three 
alternative 3‟ ss in intron 1 (nt 409, 526 and 742), this allows the truncated species of E6 
(E6*I, E6*II and E6*III) to be produced, when this intron is unspliced the full length 
oncogenic E6 is produced (Z. M. Zheng and Baker, 2006, Z. M. Zheng et al., 2004).  Intron 2 
contains three alternative 3‟ ss (nt 2582, 2709, 3358), which can lead to the production of 
another truncated E6 species, E6*IV, and E2, altogether the splices sites lead to the 
production of at least fourteen different mRNA transcripts with various coding potential (Z. 
M. Zheng and Baker, 2006).  Interestingly the E6 coding regions for HPV18 and HPV31 have 
only one 3‟ ss and the low-risk HPV types such as HPV6 and HPV11 have none (Z. M. Zheng 
et al., 2004).     
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Figure 1.4 Genome structure and transcript map of HPV1.  (Top) Open 
reading frames of HPV1 genes, numbers are positions of first nt of the start codon and 
last nt of stop codon.  (Middle) Linear form of the HPV1 genome showing position of 
promoters and polyadenylation sites.  (Bottom) Reported RNA species derived from 
alternative promoter usage and alternative splicing.  Exons (thick lines) are coloured 
according to the protein produced, numbers are the splice site positions.  Adapted from 
(Baker and Calef, 1997) 
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Figure 1.5 Genome structure and transcript map of HPV16.  (Top) Open 
reading frames of HPV16 genes, numbers are positions of first nt of the start codon and 
last nt of stop codon.  (Middle) Linear form of the HPV16 genome showing position of 
promoters and polyadenylation sites.  (Bottom) Reported RNA species derived from 
alternative promoter usage and alternative splicing.  Exons (thick lines) are coloured 
according to the protein produced, numbers are the splice site positions.  Adapted from 
(Baker and Calef, 1997, Milligan et al., 2007, Z. M. Zheng and Baker, 2006) 
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The transcripts containing E6 and E7 are only efficiently spliced when capped, with cellular 
cap-binding factors involved in the splicing.  The efficiency of the splicing of the capped 
RNA, depends on the distance of the cap-proximal intron from the RNA 5‟ cap (Z. M. Zheng 
et al., 2004).  Splicing of the E6E7 mRNA has been shown to promote E7 translation, 
suggesting that the small cap-proximal exon allows HPV16 to confer efficient splicing of the 
transcripts to get better E7 expression.  However splicing of the E6E7 transcript does not 
produce the full length E6 protein, so a balance in splicing needs to be maintained to produce 
the optimal ratio of E6 and E7 proteins throughout the virus life cycle (Z. M. Zheng et al., 
2004).  
1.9.2 Control of genome splicing 
The late mRNAs of HPV16 are initiated and spliced at splice sites in the early region and are 
processed upstream of the early poly(A) site, a site which is used by both early and late 
mRNAs (Rush et al., 2005).  Therefore the regulation of splicing of HPV16 late pre-mRNAs 
utilises exonic splicing enhancers (ESEs) and exonic splicing silencers (ESSs) to avoid 
premature late gene expression (Figure 1.6).  The 3‟ splice site at nt 3358, which allows the 
production of E1^E4, is a suboptimal splice site, which is promoted through a 65 nucleotide 
AC-rich ESE located approximately 100 nucleotides downstream in exon 2 (Rush et al., 
2005).  The 3358 ss may also be promoted by terminal exon recognition, due to this splice site 
being the most 3‟ splice site to the early poly(A) signal.  At the end of the E4 ORF is a 5‟ 
splice site, however, approximately 45 nucleotides upstream of the 3632 5‟ ss is an ESS, this 
may be present to counteract recognition of the late-specific 5‟ 3652 ss and enhance 
recognition of the early poly(A) site, to allow the production of early mRNAs terminating at 
the early poly(A) and block premature late mRNA expression (Rush et al., 2005).  The late 
pre-mRNAs contain three exons and two introns along with two potential poly(A) sites, the 
second intron is an alternative intron/exon, retention of which allows the production of L2 (Z. 
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M. Zheng and Baker, 2006).  The retention of the second intron may be enhanced by an ESS 
in the 3‟ terminal exon of the late transcripts, which binds hnRNP A1 (X. Zhao et al., 2004).  
Although the precise mechanisms of control of late gene expression are unknown, they are 
partly regulated by a family of splicing factors, serine arginine (SR) proteins, which will be 
covered in greater detail in a later section. 
1.9.3 Polyadenylation 
The maturation of the 3‟ end of most pre-mRNAs involves cleavage of the nascent transcript 
and addition of a poly(A) tail (polyadenylation), the polyadenylation of mRNA is another 
point where the expression of HPV proteins in controlled.  In HPV16 the early and late 
transcription units overlap each other and the two poly(A) sites are in competition with each 
other (Z. M. Zheng and Baker, 2006).  Cis-elements in the 3‟ untranslated regions (UTR) of 
late transcripts have been shown to be cryptic 5‟ splice sites which inhibit the usage of the late 
poly(A) site (Furth et al., 1994).  In HPV16 the negatively regulatory element (NRE) is 79 
nucleotides long and overlaps the 3‟ end of the L1 ORF and extends into the 3‟ UTR.  The 5‟ 
end of the HPV16 NRE is composed of four cryptic 5‟ splice sites, which contribute together 
to make the NRE function and interact with a U1 snRNP-like complex (Cumming et al., 
2003).  The 5‟ end also contains a predicted stem-loop structure, whereas the 3‟ end is very 
GU rich and is a less potent inhibitor than the 5‟ end (Cumming et al., 2003).  The NRE along 
with cis-acting elements which can up-regulate usage of the early poly(A) site means the early 
mRNAs are produced preferentially in undifferentiated cells, how the activation of the late 
poly(A) site occurs is unknown, but is probably due to changes in concentrations of the 
cellular proteins which interact with the cis-elements in the mRNA.  
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Figure 1.6 Regulation of HPV16 alternative splicing.  (Top) Alternative 3‟ 
splice site selection in early transcripts.  (Bottom) Production of L1 and L2 are regulated 
by multiple cis-acting elements.  Adapted from (Z. M. Zheng and Baker, 2006) 
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1.9.4 Translation 
The bicistronic and polycistronic transcripts produced by HPV which have tandemly arranged 
ORFs require specialised mechanisms for initiation of protein translation on a downstream 
ORF.  Ribosomes scan mRNA in a linear fashion starting at the 5‟ AUG, how they bypass an 
upstream ORF to translate the next one is unknown.  Several mechanisms have been proposed 
and have some experimental support in HPV, these include: translation re-initiation, leaky 
scanning and ribosome shunting (Remm et al., 1999, Stacey et al., 2000, Z. M. Zheng et al., 
2004).  In HPV16 the E6 and E7 ORFs are only separated by 2 nucleotides, in HPV18 this 
gap is 9 nucleotides, consequently the ribosome would not be able to efficiently re-initiate E7 
translation after translating E6 in an unspliced full-length E6E7 mRNA, therefore the 
unspliced E6E7 mRNAs mainly serve for the translation of E6 (Tang et al., 2006).  The 
splicing which produces E6*I mRNAs creates a premature stop codon after the splice junction 
and therefore increases the distance between the E6*I and the E7 ORFs to around 130 
nucleotides, allowing a scanning ribosome to re-initiate E7 translation (Tang et al., 2006).  
Leaky scanning ribosomes have been shown to scan over the E6 ORF to then start translation 
at the E7 AUG (Stacey et al., 2000) and ribosomes have also been shown to discontinuously 
scan over the polycistronic transcripts containing E6, E7 and E1 ORFs to translate E1 (Remm 
et al., 1999).  In practice the translation of the HPV genome may be down to a collection of 
several different mechanisms acting together to regulate the levels of the proteins throughout 
the virus life cycle. 
 
1.10 HPV proteins 
The early E1 and E2 proteins produced by HPV are the viral replication proteins, involved in 
initiation of replication, genome segregation and DNA replication.  E5, E6 and E7 are viral 
oncoproteins, involved in the regulation of cell cycle, cellular transformation and immune 
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modulation (Kim et al., 2010).  The main functions of the E1^E4 protein in the virus life cycle 
are largely unknown, however E1^E4 has been shown to be involved in the regulation of the 
late virus functions.   The late proteins L1 and L2 spontaneously form the icosahedral capsids, 
in which the viral DNA is packaged.  
1.10.1 HPV E1 
The E1 protein is a phosphoprotein which is approximately 650 amino acids long (68 kDa) 
and belongs to the helicase superfamily III (SF3).  E1 can be divided into three functional 
regions (Hickman and Dyda, 2005).  The C-terminal domain has ATPase and helicase activity 
and can self assemble into hexamers, this domain is also used by E2 to recruit E1 to the AT-
rich sequences at the viral origin of replication, which are located proximal to the start sites of 
early transcription (Hughes and Romanos, 1993, Longworth and Laimins, 2004b, Y. Sun et 
al., 1998, Titolo et al., 2000).  The central region of E1 contains the DNA-binding domain 
(DBD), which binds to the origin and dimerises (Titolo et al., 2003).  The N-terminal region 
of E1 contains a cyclin E/A-CDK2 binding motif, a nuclear localisation signal (NLS) and a 
CRM1-dependent nuclear export signal (NES), which act together to regulate the 
nucleocytoplasmic shuttling of the protein (Deng et al., 2004, Fradet-Turcotte et al., 2010).  
Alone, E1 only weakly binds origin sequences, but this binding is facilitated by the formation 
of a complex with E2 (Frattini and Laimins, 1994), once bound to the origin, the E1 proteins 
form hexamers with a high affinity for DNA (Sedman and Stenlund, 1998).  The E1 
complexes then efficiently unwind the supercoiled DNA with the help of chaperone proteins 
(Longworth and Laimins, 2004b).  E1 also binds to the p68 subunit of DNA polymerase α-
primase, to help recruit cellular replication complexes to the viral origin (Masterson et al., 
1998).  Phosphorylation of the N-terminal domain of E1 inhibits the NES, and results in E1 
accumulation in the nucleus; the nuclear export of E1 is not essential for viral DNA 
replication but is required for long-term maintenance of episomal genomes (Fradet-Turcotte 
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et al., 2010).  Continuous nuclear accumulation of E1 leads to reduced cellular proliferation, 
due to S phase progression being delayed (Fradet-Turcotte et al., 2010).  The E1 protein is 
expressed at low levels in HPV-infected cells and an increase in E1 expression has a negative 
effect on replication efficiency, the ratio of E1 to E2 also has been shown to be important in 
determining replication efficiency (Deng et al., 2003). 
1.10.2 HPV E2 
The E2 proteins are approximately 365 amino acids long (50 kDa) and function as dimers; 
they are required for both viral DNA replication and transcriptional regulation (Longworth 
and Laimins, 2004b).  The C-terminal region has a dimeric β-barrel structure and encodes a 
DNA-binding domain (Hegde et al., 1992); the DBD of E2 interacts with the DBD of E1 
(Chen and Stenlund, 2000).  The N-terminal region consists of a glutamine-rich α-helix 
packed against a β-sheet framework and contains a transactivation domain (Antson et al., 
2000).  The N- and C-terminal domains are linked by a variable length hinge region, which is 
unstructured (Gauthier et al., 1991).  The E2 proteins bind to the consensus palindromic 
sequences in the LCR as dimers, three of the four E2-binding sites flank the E1 recognition 
sequences in the origin of replication, allowing E2 to load E1 onto the origin (Longworth and 
Laimins, 2004b).  The transcription of early genes following infection is primarily activated 
by cellular transcription factors and at low concentrations E2 continues to activate early gene 
expression (Steger and Corbach, 1997).  However, when the concentration of E2 increases, 
the binding of transcription factors to their recognition sequences is inhibited, as there is an 
overlap in the binding sites (Demeret et al., 1997).  Upon differentiation, the late promoter, 
which is not repressed by E2, is activated, this leads to an increase in E1 and E2 expression 
and viral amplification occurs (Klumpp and Laimins, 1999).  The E2 protein has also been 
shown to improve the efficiency of genome encapsidation, as the E2 brings the viral DNA to 
ND10 bodies where capsid formation occurs (K. N. Zhao et al., 2000). 
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Another role for the E2 protein is in the long-term episomal maintenance of viral genomes 
and in partitioning the viral DNA into daughter cells following cell division (Bastien and 
McBride, 2000, Lehman and Botchan, 1998).  The E2 protein tethers the viral genome to the 
host chromosome during mitosis helping to maintain an equal division of nuclear located 
episomes between the cells (Bastien and McBride, 2000).  The tethering of E2 to 
chromosomes is conserved among many HPV types; however the mitotic binding pattern 
varies between different types with the majority appearing as small speckles over the arms of 
all mitotic chromosomes (Oliveira et al., 2006).  The E2 protein from the beta papillomavirus 
HPV8, bind as large foci to the pericentromeric regions of chromosomes (Oliveira et al., 
2006).  The E2 proteins from the beta papillomaviruses have longer hinge regions than those 
in the other genera, which are rich in RG and RS dipeptide motifs.  The E2 protein of HPV16 
has been shown to directly interact with the E7 protein and be involved in the recruitment of 
E7 to the mitotic chromosomes during the later stages of mitosis (Gammoh et al., 2006).  The 
interaction between E2 and E7 results in a reduction in the ability of E7 to induce centrosome 
duplication abnormalities, thus reducing the chances of aberrant mitosis (Gammoh et al., 
2009).   
1.10.3 HPV E6 protein 
The HPV E6 protein is approximately 150 amino acids long and has a high content of α-
helical and β-sheet secondary structure; the protein has two CXXC zinc fingers and a PDZ 
binding domain but lacks any enzymatic activity (Bodily and Laimins, 2011, Nomine et al., 
2006, Tungteakkhun and Duerksen-Hughes, 2008).  The C-terminal region of HPV16 
contains three NLSs, which lead to the E6 protein having a nuclear localisation, whereas the 
E6 proteins of low risk HPV types have a predominantly cytoplasmic localisation (Tao et al., 
2003).  The E6 gene is one of the earliest genes expressed following viral infection and is one 
of two principal oncogenes, along with E7.  E6 expression can lead to hyperproliferation of 
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cells, loss of epithelial cell differentiation and tumour formation (Tungteakkhun and 
Duerksen-Hughes, 2008).  Expression of high-risk E6 alone is sufficient to immortalise 
primary human mammary epithelial cells (Band et al., 1991) and together with E7 can 
transform primary human embryonic fibroblasts (Watanabe et al., 1989) and human foreskin 
keratinocytes in culture (Hawley-Nelson et al., 1989).  E6 has been shown to interact with a 
large number of cellular proteins, as shown in figure 1.7A, but the most studied interaction of 
E6 is with the cellular E3 ubiquitin ligase, E6 associated protein (AP).  E6 binding to E6AP 
recruits p53 to a trimeric complex, resulting in p53 ubiquitination and proteasomal 
degradation (Huibregtse et al., 1991, Scheffner et al., 1993).  p53 is not a natural substrate for 
E6AP and is only targeted in the presence of high-risk E6 (Huibregtse et al., 1991), low-risk 
E6 proteins are able to bind E6AP but unable to degrade p53 (Bodily and Laimins, 2011).  
Not only does E6 target p53 for degradation, both high and low-risk E6 proteins can directly 
interact with p53 to inhibit p53 binding to DNA and cause aberrant p53 localisation (Lechner 
and Laimins, 1994, L. Sun et al., 2008).  E6 also independently inactivates p53 through the 
binding of CBP/p300 and hADA3, which are histone acetyltransferases, leading to reduced 
acetylation of p53 (Bodily and Laimins, 2011, M. C. Thomas and Chiang, 2005).  The 
degradation or loss of function of p53 leads to ablation of its ability to negatively regulate cell 
cycle progression, the G1/S and G2/M checkpoints and therefore facilitates the survival of the 
cells during differentiation (Tungteakkhun and Duerksen-Hughes, 2008).  With many direct 
interactions and degradations via the E6AP (Bak, c-myc, E6TBP1, MCM7, NFX1-91), E6 is 
able to modulate G-protein signalling (E6TBP1), immune system recognition (IRF-3), 
chromosomal stability (MCM7) and induce telomerase activity (NFX1-91) (Howie et al., 
2009).  High-risk E6 upregulates hTERT transcription through a complex mechanism which 
involves the binding of SP1 and c-myc and the down-regulation of p300 (Pim and Banks, 
2010).   
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Figure 1.7 Cellular targets of E6 and E7 proteins.  (A) Cellular proteins and 
pathways targeted by the E6 protein.   High-risk E6 proteins inhibit p53 dependent 
growth arrest and apoptosis through several mechanisms.  E6 is able to modulate G-
protein signalling (E6TP), immune system recognition (IRF3), chromosomal stability 
(MCM7) and induce telomerase activity (NFX1-91).  (B) Cellular pathways and proteins 
targeted by the E7 protein.  High-risk E7 proteins subvert G1-S arrest and induce 
hyperproliferation by interacting with RB family members and causing the constitutive 
activation of E2F-responsive genes.  E7 also interacts with multiple proteins to cause 
genomic instability and inhibit apoptosis.  Adapted from (Moody and Laimins, 2010) 
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Although the exact mechanism by which E6 activates hTERT is unknown, the prevention of 
telomere shortening is an important function of high-risk E6 in the immortalisation of cells 
(Pim and Banks, 2010). 
At the C-terminus of high-risk E6 proteins there is a S/TXV motif, a PSD-95/Dlg/ZO-1 
(PDZ) binding motif, which allows E6 to bind to PDZ proteins, these include hDlg, hScrib, 
MAGI-1, -2 and -3, MUPP1 and PTPN3 (Howie et al., 2009).  Some of the PDZ proteins 
have been shown to be tumour suppressors and generally are involved in epithelial tight 
junctions, basal cell adhesion, cell:cell junctions and epithelial polarity (Howie et al., 2009).  
As negative regulators of cell proliferation the PDZ proteins are targeted for degradation by 
the E6 protein, although different HPV types have differing specificity for individual PDZ 
proteins (M. Thomas et al., 2001).   
Together the functions of E6 allow the cell to bypass DNA damage checkpoints, resulting in 
cell proliferation in the presence of DNA damage, this enables mutations to be passed on to 
progeny cells and allows possible cancerous mutations to form.  
1.10.4 HPV E7  
The HPV E7 oncoprotein is approximately 100 amino acids in size and shares some sequence 
homology with adenovirus E1A and SV40 large T antigen (Phelps et al., 1988, Vousden and 
Jat, 1989).  The C-terminus contains a CXXC zinc-binding domain, similar to that found in 
E6 (Barbosa et al., 1989) and like E6, E7 does not possess any intrinsic enzymatic activity 
and functions by binding to several cellular factors, as shown in figure 1.7B (Moody and 
Laimins, 2010).  The N-terminal region of HPV16 E7 contains a NLS, whereas the C-
terminal region codes for a second NLS and a NES, the subcellular localisation of E7 varies 
during the cell cycle (Knapp et al., 2009).  Expression of high-risk E7 proteins alone can 
immortalise human keratinocytes at a low frequency (Moody and Laimins, 2010), however 
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E7 is unable to immortalise human mammary epithelial cells, highlighting that cell-specific 
factors may play a role in viral oncogene functions (Band et al., 1991).  When expressed 
together with E6, E7 can efficiently immortalise most primary cells (Hawley-Nelson et al., 
1989).  The primary interaction of E7 is with members of the retinoblastoma (Rb) family, 
including p105 (pRB), p107 and p130; binding of E7 to these proteins targets them for 
degradation by a cullin 2 ubiquitin ligase complex (Dyson et al., 1989, Huh et al., 2007).  The 
Rb family members control the G1-S phase transition by regulating the activity of E2F 
transcription factors; pRB forms a complex with E2F, which recruits histone deacetylases 
(HDACs) and represses transcription from E2F-dependent promoters.  The binding of E7 to 
pRB disrupts these complexes and E2F is released allowing the constitutive expression of 
E2F-responsive genes, such as cyclin A and cyclin E, promoting premature S phase entry and 
DNA synthesis, thus uncoupling the processes of differentiation and proliferation (Chellappan 
et al., 1992, Cheng et al., 1995, Moody and Laimins, 2010).  E7 can also interact directly with 
the HDACs, independently of Rb, this interaction is required for stable maintenance of 
episomes (Longworth and Laimins, 2004a).  E7 interacts with Rb family members via a 
conserved LXCXE motif in the E7 N-terminal region (Munger et al., 1989).  The disruption 
of the pRB/E2F complex requires additional sequences found in the C-terminal region of E7 
(E. W. Wu et al., 1993), which is highlighted in the case of HPV1 E7, which can bind to pRB 
as efficiently as HPV16 E7, but can not activate E2F-responsive promoters and transform 
primary cells (Schmitt et al., 1994).  The binding of E7 to Rb family members targets them 
for proteasomal degradation through an ubiquitin dependent pathway, which abrogates other 
Rb activities such as DNA repair and maintenance of genomic integrity (Boyer et al., 1996).  
The HPV16 E2 protein can directly bind to E7 and inhibit the E7 induced degradation of 
pRB, demonstrating a viral mechanism by which the transforming activity of E7 can be 
modulated (Gammoh et al., 2009).  The abrogation of Rb functions by E7 sensitises the cells 
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to p53-dependent apoptosis and stabilises p53, which is why the E6 degradation of p53 is 
important in the transformation of cells.   
High-risk E7 proteins also bind to p21 and p27, which are CDK inhibitors, the binding of E7 
to the inhibitors activates CDK2 and promotes G1 to S phase entry and progression through 
cyclin A and cyclin E respectively (Moody and Laimins, 2010).  Genomic instability is 
necessary for malignant progression to occur and high-risk E7 can induce this by rapidly 
inducing centrosome amplification, which occurs due to high levels of CDK2 activity and E7 
binding directly to γ-tubulin, which results in the removal of γ-tubulin from the mitotic 
spindle (Moody and Laimins, 2010, Nguyen et al., 2007).  The E2 protein of HPV16 can 
inhibit the centrosome amplification caused by HPV16 E7, by directly binding E7 and 
recruiting it to the mitotic chromosomes (Gammoh et al., 2009).  High-risk E7 activates the 
ATM DNA damage pathway, this pathway is essential for differentiation-dependent viral 
genome amplification but not for stable episomal maintenance, however the DNA damage 
response could lead to chromosomal alterations and the induction of genomic instability 
(Moody and Laimins, 2009).  HPV E7 also binds to a number of factors which help regulate 
the subversion of the interferon antiviral response (IRF1 and p48) and the inhibition of 
anoikis (p600) (Moody and Laimins, 2010).   
Together the functions of E7 allow the deregulation of the link between cellular 
differentiation and proliferation in epithelia, allowing the virus to replicate in differentiating 
cells which would have normally withdrawn from the cell cycle.  
1.10.5 HPV E5  
Although E6 and E7 provide the primary transforming activities of high-risk HPV, the small 
oncoprotein E5 can augment their function and contribute to tumour progression.  The HPV 
E5 proteins are small membrane bound, hydrophobic proteins, which are around 83-93 amino 
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acids long and localise to the endoplasmic reticulum, the Golgi apparatus and perinuclear 
membrane (Conrad et al., 1993).  The bovine papillomavirus (BPV) E5 protein is smaller than 
HPV E5 and is the primary transforming protein, BPV E5 acts by associating with the 
platelet-derived growth factor (PDGF) receptor and constitutively activating it (Petti et al., 
1991).  The HPV E5 proteins have little homology with BPV E5 and do not associate with the 
PDGF receptor, however HPV16 E5 has been shown to transform rodent fibroblasts and 
human keratinocytes (Straight et al., 1993).  The proposed mechanism by which HPV E5 
transforms cells is via the epidermal growth factor receptor (EGFR) signalling pathway (Kim 
et al., 2010, Straight et al., 1993).  The over expression of EGFR signalling is linked to the 
majority of cancers and activation of EGFR regulates gene transcription and modulates cell 
proliferation, apoptosis, angiogenesis, tumour invasion and metastasis (Kim et al., 2010).  E5 
acts to increase the number of EGF receptors, by interacting with and inhibiting vacuolar 
ATPase, interfering with the degradation of EGFR (Conrad et al., 1993), HPV16 E5 also 
increases EGFR phosphorylation in the presence of EGF (Straight et al., 1993).  The E5 
protein of HPV16 can also activate MAP kinase p38 and ERK1/2 in an EGF independent 
manner (Crusius et al., 1997) and down-regulate the tumour suppressors p21 and p27 
(Pedroza-Saavedra et al., 2010, Tsao et al., 1996).  E5 has also been shown to down-regulate 
the expression of surface HLA class I, reducing the recognition of infected cells by CD8 T 
cells (Campo et al., 2010).  Although E5 has transforming properties, the protein is likely to 
be expressed primarily during the late phase of the life cycle in differentiated cells 
(Longworth and Laimins, 2004b).  Mutation of HPV16 E5 in differentiated cells did not 
prevent viral DNA amplification; however the amount of suprabasal cells undergoing DNA 
synthesis was reduced compared to wild type (Genther et al., 2003).   
These interactions suggest that the role played by E5 in the productive phase of the life cycle 
is subtle, but E5 helps modify the differentiation-dependent cell cycle exit of the cells to 
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support proliferative competence (Fehrmann et al., 2003).  HPV E5 contributes to malignant 
transformation through the augmentation and supplementation of the roles of E6 and E7, also 
the upregulation of EGFR signalling pathway allows E5 to induce the inflammatory cell 
signalling, COX-2-PGE2 pathway, which is involved in various oncogenic processes such as 
angiogenesis and anti-apoptosis (Kim et al., 2010).  However, due to integration of the HPV 
genome during malignant progression, the expression of E5 is lost, whereas E6 and E7 are 
continually expressed, suggesting that the role played by E5 as an oncoprotein is only small 
compared to E6 and E7. 
1.10.6 Capsid proteins 
The major capsid protein, L1, is approximately 500 to 530 amino acids long (57 kDa) and is 
the primary structural element in the infectious virion.  The virions contain 360 copies of the 
L1 protein organised into 72 pentavalent capsomeres, which make up an icosahedral shell 
using the C-terminal arms of the L1 proteins to link them together (Modis et al., 2002).  The 
minor capsid protein, L2, is around 470 to 520 amino acids long (78 kDa) and unlike L1, the 
L2 protein is not highly conserved among HPV types, except for 50 amino acids in the N-
terminal region (Doorbar and Gallimore, 1987).  Within a capsid, the precise number of L2 
proteins is unknown and the general consensus was 12 L2 molecules per capsid; however this 
can vary up to 72, with one L2 protein at the centre of every L1 pentavalent capsomere (Buck 
et al., 2008).  A hydrophobic region in the C-terminal region of L2 is responsible for the 
binding of L2 to the L1 pentamers and is thought to insert into the central hole in the 
capsomere (Finnen et al., 2003).  The L2 protein is expressed before the L1 protein upon 
differentiation of the epithelia (Florin et al., 2002).  The L1 and L2 ORFs are transcribed in 
the undifferentiated epithelia but are not translated; the reason for this is that these ORFs 
contain codons which are not frequently found in mammalian cells.  As the cells differentiate 
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the tRNAs for the rare codons may become more available, allowing translation of the late 
proteins (Zhou et al., 1999). 
The L2 protein contains nuclear localisation sequences in its N- and C-terminal regions and is 
transported to the nuclear domain 10 (ND10 or PML) bodies once in the nucleus (Florin et al., 
2002).  The L2 protein then displaces the ND10 component SP100 and the viral DNA is 
recruited to the ND10 bodies by E2 (Florin et al., 2002).  The L1 protein assembles into 
capsomeres in the cytoplasm, prior to nuclear relocation and then is recruited to ND10 bodies 
(Florin et al., 2002).  The capsid particles can assemble in the absence of L2; however L2 
contributes to efficient packaging (Stauffer et al., 1998) and enhances virus infectivity (Roden 
et al., 2001).  The L2 protein of HPV16 can be stabilised by sumoylation, however 
sumoylation of L2 inhibits the interaction with L1, demonstrating a control mechanism, which 
modulates the formation of virions in cells (Marusic et al., 2010).  The virion matures and 
stabilises as the infected cells approach the cell surface as a result of disulphide cross-linking 
(Modis et al., 2002).  The C-terminal „arm‟ which links the pentamers together is exposed on 
the surface of the virion and is a likely target of the immune system (Modis et al., 2002).  The 
neutralising antibodies produced against L1 are HPV type specific, whereas those produced 
against L2 are broadly cross-neutralising.  The production of a VLP with the N-terminal 
regions of eight different L2s displayed on the surface, delivers cross-protection against 
multiple HPV types from multiple genera, therefore it is a viable prophylactic alternative to 
the vaccines currently in production (Tumban et al., 2011). 
 
1.11 HPV E1^E4 
The E4 protein is the most highly expressed protein in HPV infections, representing up to 
30% of the total protein in HPV1 warts (Doorbar et al., 1986), the expression is mainly 
cytoplasmic although nuclear forms are detected.  However despite numerous studies of its 
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actions in overexpression studies the precise role of this protein in the HPV life-cycle is an 
enigma. 
The E4 ORF lies within the early region of the genome and is present in early transcripts as a 
spliced E1^E4 product.  HPV E4 is expressed as the fusion protein E1^E4 and is encoded for 
from spliced E1 and E4 ORFs, with the first five amino acids of E1 fused to E4 (Chow et al., 
1987, Palermo-Dilts et al., 1990).  The E4 ORF lies entirely within the E2 ORF and overlaps 
with the highly variable E2-hinge region, resulting in poor sequence homology in E4 between 
HPV types.  Although the E4 ORF is in the early region, E4 is the third ORF on the 
polycistronic mRNAs (Figures 1.4 and 1.5).  The precise mechanism of translation of HPV 
transcripts is unknown, however it is likely that little E1^E4 protein is expressed from these 
transcripts in the early stages of the virus life cycle (Longworth and Laimins, 2004b).  Upon 
epithelial cell differentiation and activation of the late viral promoter, E4 is the first ORF on 
the late transcripts, leading to high expression of E1^E4 (Longworth and Laimins, 2004b).  
This protein only becomes detectable once cells have entered the productive phase, coinciding 
with the onset of viral genome amplification and persists in cells as they migrate to the 
surface of the wart or papilloma (Figure 1.8A); in cutaneous lesions caused by HPV1 this 
occurs as soon as cells have moved up from the basal cell layer (Breitburd et al., 1987) whilst 
in anogenital infection of HPV16 and HPV18, this phase is restricted to the upper spinous 
layers (Doorbar et al., 1997, Peh et al., 2002).   
The size of the E1^E4 protein ranges from 73 (HPV34) to 304 (HPV47) amino acids long (the 
E1^E4 protein from HPV1 is 125 amino acids long and 17 kDa).  E1^E4 contains several 
conserved regions including a leucine rich motif, LLXLL, a proline rich region in the N-
terminus and a C-terminal domain which contains conserved hydrophobic residues (Figure 
1.8B), these domains have been shown to be important in the functions of E4 (Ashmole et al., 
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1998, C. E. Davy et al., 2002, Roberts et al., 1994, Roberts et al., 1993).  Overexpression 
studies of E4 have shown E4 to affect diverse biological functions in cells including the 
suppression of chromosomal DNA synthesis (Roberts et al., 2008), inhibition of progression 
of cells through the mitotic cycle (C. E. Davy et al., 2002, Knight et al., 2004) and promotion 
of apoptosis (Raj et al., 2004).  It also has a destabilising effect on structures associated with 
cellular integrity such as the keratin cytoskeleton (Doorbar et al., 1991, Roberts et al., 1993) 
and the corneocyte (Bryan and Brown, 2000) as well as sub-nuclear ND10 bodies (Roberts et 
al., 2003).  The interactions of E1^E4 and the timing of E1^E4 expression suggest roles in the 
facilitation and support of viral genome amplification, regulation of late gene expression, 
control of virus maturation and mediation of virus release (Roberts, 2006).   
Indeed studies knocking out expression of E1^E4 in which E2 expression is preserved in viral 
genome containing cells demonstrated that E4 is required for viral DNA amplification and 
late gene expression of HPV18 and HVP31 (Wilson et al., 2005, Wilson et al., 2007) and the 
cottontail rabbit papillomavirus (Peh et al., 2004), but not for the maintenance of viral 
episomes (Wilson et al., 2005, Wilson et al., 2007). Deletional analysis across the E4 ORF of 
HPV16 genomes indicated that only the C-terminus of E4 is required for activation of the late 
functions (Nakahara et al., 2005).  Somewhat surprising was the finding that E4 is not 
required for viral DNA amplification and late gene expression of HPV11 genomes, which 
may reflect differences in experimental systems or that there are type specific functions of E4 
(Fang et al., 2006). 
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Figure 1.8 The HPV E1^E4 protein.  (A) Schematic showing the position of E4 
expression and E4 functions in the life cycle of alpha HPVs.  (B) Schematic showing the 
regions involved in known biological functions and interactions with cellular proteins.  
Arrows indicate positions of proteolytic cleavage sites in HPV1.  Adapted from figure 
provided by Sally Roberts and (Roberts, 2006) 
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1.11.1 Post-translational modifications of E4 
The E4 proteins exist in natural infections as multiple species, arising from a combination of 
proteolysis, phosphorylation and oligomerisation and these post-translational modifications 
play a significant role in regulating E4 biological functions.  The most studied E4 protein with 
regards to posttranslational modifications is  the E4 protein of HPV1, the full-length E1^E4 
protein of 17 kDa undergoes progressive N-terminal proteolytic cleavage to produce 16, 11 
and 10 kDa forms (Doorbar et al., 1988).  The first 15 N-terminal residues are cleaved off to 
produce the 16 kDa species, followed by a further 43 residues to produce the 11 and 10 kDa 
peptides (Figure 1.8B) (Roberts et al., 1994).  In HPV1 warts the full-length 17 kDa species is 
expressed in the parabasal cell layers, with the other species accumulating in a progressive 
manner so that in the most superficial cells the major E4 species present are the most 
processed forms of 11/10 kDa (Breitburd et al., 1987).  The E1^E4 proteins of other HPV 
types are subject to cleavage as well with calpain being the protease responsible for the 
cleavage of HPV16 and HPV18 E1^E4 in differentiating keratinocytes (Khan et al., 2011).  
The proteolysed peptides of E4 do not contain sequences necessary for some of the 
interactions the full-length protein is capable of, suggesting that some of the E4 functions are 
not required throughout the productive phase of the HPV life-cycle (Roberts et al., 1994, 
Roberts et al., 2003).  Additionally the truncated E4 species have biological activities, not 
possessed by the full-length E1^E4 protein, indicating that E4 function is regulated by post-
translational modifications (Knight et al., 2004).  
The E1^E4 protein is subject to phosphorylation at multiple serine and threonine residues by 
several cellular kinases including cAMP dependent protein kinase (PKA), serine-arginine 
protein kinase 1 (SRPK1), cyclin dependent kinases (CDKs), extracellular signal-regulated 
kinase (ERK) and mitogen-activated protein kinase (MAPK) (Bell et al., 2007, Bryan et al., 
2000, Grand et al., 1989, Knight et al., 2011, Q. Wang et al., 2009b).  Interestingly, in vivo the 
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full length 17 kDa E4 protein of HPV1 is phosphorylated, but the 16 kDa proteolysed species 
is not, even though both proteins are substrates for PKA in vitro (Grand et al., 1989).  This 
data suggests that the functions of E1^E4 may be modulated by phosphorylation in the 
parabasal layers of the epithelium but not in the more differentiated layers where cell death 
and virion assembly are occurring (Grand et al., 1989).  Phosphorylation of the HPV16 E1^E4 
protein by ERK at the onset of viral amplification causes the stabilisation of E1^E4 and 
enhanced binding of E1^E4 to the keratin network (Q. Wang et al., 2009b).   
The E1^E4 protein has been shown to self-multimerise in vivo and exists as multiple stable 
oligomers (Doorbar et al., 1988).  Hydrophobic residues in the C-terminus are important for 
this self-oligomerisation (Ashmole et al., 1998, Roberts et al., 1997).  The deletion of the N-
terminal region of E1^E4 leads the assembly of E4 into amyloid like fibrils, which facilitates 
the accumulation of E4 in the upper layers of the epithelia (McIntosh et al., 2008).  The 
multimerisation of E4 proteins is important for inducing the collapse of the keratin network 
(Q. Wang et al., 2004).  
1.11.2 Functions of E1^E4 
Much of our understanding of the E4 functions and actions have been derived from 
overexpression studied in established epithelial cell lines and these are discussed in more 
detail below and summarised in Figure 1.8A.   
1.11.2.1 Interaction with structural proteins 
The intermediate filaments (IFs) in epithelial cells are composed of keratin and as the cells 
differentiate, the keratin network undergoes keratinisation, which is where the keratin 
filaments aggregate to form a tough impenetrable barrier to the cell.  The E1^E4 protein from 
cutaneous and mucosal HPV types can interact with the keratin network, but only the E1^E4 
proteins from some HPV types can cause the collapse of the keratin network into a 
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perinuclear fibrous clump (Doorbar et al., 1991, Roberts, 2006, Roberts et al., 1993).  It has 
been proposed that the disruption of the keratin network by HPV16 E1^E4 may facilitate the 
release of infectious viral particles later in the virus life cycle (Doorbar et al., 1991).  The 
highly conserved N-terminal leucine-rich motif (LLXLL) has been shown to be involved in 
the association between E1^E4 and the keratin filaments (Roberts et al., 1994), but in HPV16 
a hydrophobic C-terminal domain, which is conserved amongst mucosal HPV types, is 
required for the induction of cytokeratin collapse (Roberts et al., 1997).  The C-terminal 
region in HPV16 required for cytokeratin collapse is the same as the region required for 
oligomerisation, suggesting that the self-association of E1^E4 proteins may allow cross-
linking of the keratin filaments and the subsequent collapse of the network (Roberts et al., 
1997).  The cross-linking of the keratin filaments prevents the keratins from freely moving 
between the soluble and insoluble compartments, thus disturbing the normal keratin dynamic 
reorganisation during the cellular life cycle (Q. Wang et al., 2004).  Additionally the 
interaction between HPV16 E1^E4 and the keratin network, results in the keratin filaments 
being hyperphosphorylated and ubiquitinated, which targets them for proteosomal 
degradation (McIntosh et al., 2010).  Interestingly the LLXLL motif required for association 
with the keratin filaments is lost after proteolysis of the E1^E4 protein (Roberts et al., 1994), 
and this suggests that interactions with the keratin cytoskeleton are modified during the virus 
life cycle.  The mechanism of E4 induced keratin collapse is still controversial, as although 
E4 and keratin have been shown to colocalise in natural HPV16 infections, the number of 
cells with this colocalisation is very small (Q. Wang et al., 2004).  
The cornified cell envelope (CCE) is an insoluble matrix which forms in terminally 
differentiated keratinocytes to provide a barrier against external factors.  HPV11 E1^E4 has 
been shown to bind to the CCE and induce the degradation of two components of the CCE, 
loricrin and cytokeratin 10 (K10).  The binding of E1^E4 to these CCE components results in 
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a CCE which has a thinner wall and increased fragility, which may facilitate virion release 
(Bryan and Brown, 2000).   
1.11.2.2 Regulation of the cell cycle and cellular DNA synthesis 
The expression of E4 proteins from several different HPV types (1, 11, 16 and 18) has been 
shown to modulate the progression of the cell cycle and induce a G2 arrest (C. E. Davy et al., 
2002, Knight et al., 2004, Nakahara et al., 2002).  Studies of the different E4 proteins has 
however shown that these proteins induce G2/M arrest using different mechanisms and in the 
case of HPV1, E4 mediates two distinct mechanisms of cell cycle arrest that are dependent on 
the processing of the viral protein.   
The progression of the cell cycle past the G2/M checkpoint is driven by the cyclin B1-CDK1 
(cyclin-dependent kinase) complex, which is a core component of the mitosis-promoting 
factor.  The E1^E4 protein of HPV16 induces the cytoplasmic retention of active cyclin B1-
CDK1 complexes, preventing them from translocating to the nucleus and allowing the cells to 
proceed through G2 and into mitosis (C. E. Davy et al., 2002).  In contrast HPV1 E4 protein 
inactivates the complex by promoting the inhibitory phosphorylation of CDK1 or by reducing 
the levels of cyclin B1 (Knight et al., 2006).  
Intriguingly unlike HPV16 or HPV18, the full length E1^E4 protein of HPV1 is not able to 
cause G2 arrest; inhibition of cell division is mediated by the truncated 16 kDa form expressed 
either alone or together with the full-length polypeptide (Knight et al., 2004).  The expression 
of the truncated 16 kDa form of E4 alone leads to a reduction in the levels of cyclin B1, 
whereas coexpression of the full length E1^E4 with the 16 kDa form leads to inactivated 
CDK1 due to phosphorylation by the kinase Wee1 (Knight et al., 2006).   
Expression of full-length HPV18 E1^E4 and the 16 kDa form of HPV1 E4 was also 
associated with chromosomal rereplication suggesting that E4 promotes G2 arrest and an 
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environment that is conducive to viral genome amplification through the access to the host 
replication machinery.  However when the full length HPV1 E1^E4 and the 16 kDa E4 
species are coexpressed, chromosomal rereplication was suppressed as was entry into S phase 
(Knight et al., 2004).  Further investigations revealed that cellular DNA replication was 
suppressed by this E4 complex by E4 blocking replication initiation through the prevention of 
the loading of replication licensing factors, minichromosome maintenance proteins (MCMs) 
onto chromatin (Roberts et al., 2008).  This E4 function may enhance viral genome 
amplification in replication activated cells by reducing competition of cellular replication 
factors by suppressing host cell DNA synthesis.  Studies in organotypic raft cultures of 
HPV16 and HPV18 genome containing cells have shown that viral genome amplification is 
largely confined to cells which show little evidence of cellular DNA synthesis, demonstrating 
that viral and cellular DNA are not replicated concurrently (Nakahara et al., 2005, H. K. 
Wang et al., 2009a).  Also, other unrelated DNA viruses such as EBV and CMV also have 
strategies to selectively inhibit host cell DNA replication (Roberts et al., 2008). 
An important question is therefore what purpose this conserved function of cell cycle arrest 
serves within the HPV life cycle.  A recent study from Roberts and co-workers has 
investigated this in the context of the HPV18 virus.  Mutations within a CDK-bipartite 
consensus recognition motif that disrupt the G2/M arrest function of the type 18 protein were 
inserted in to the E4 ORF of HPV18 genomes.  Primary foreskin keratinocytes were 
transfected with the genomes and stable cell lines established.  Following differentiation of 
the cells, viral genomes were efficiently amplified in the cells carrying mutant genomes 
indicating that this E4 function is not necessary for this vegetative phase of replication, even 
though loss of full-length E1^E4 expression does correlate with inefficient DNA 
amplification (Knight et al., 2011, Wilson et al., 2007).  The G2 arrest function might also be 
necessary to favour capsid expression (J. Ding et al., 2010), but there was no evidence from 
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organotypic raft cultures of a defect in the production of the major capsid L1 in the absence of 
the E4 G2/M arrest function (Knight et al., 2011). 
The study does not rule out a role for E4 G2/M arrest in viral genome replication.  The HPV18 
E7 protein is able to maintain cells in an extended G2 phase after the induction of S phase re-
entry through the activation of CDC2 and cyclin B1 (Banerjee et al., 2011).  This study shows 
the induction of cyclin B1 activity occurs before the expression of E1^E4 is upregulated, 
demonstrating that E1^E4 may be assisting this E7 function in the upper layers of the 
epithelia, to maintain the G2 arrest for the maximum length of time.  The combined activities 
of E7 and E1^E4 could stimulate the cells to be maintained in a pseudo S phase state, where 
replication enzymes are present, but the viral DNA is not competing with cellular DNA for 
these enzymes (Knight et al., 2004, Knight et al., 2011). 
1.11.2.3 Disruption of ND10 bodies 
The HPV1 E1^E4 protein forms cytoplasmic and nuclear inclusions in productively infected 
keratinocytes; these electron dense structures often contain relocalised cellular proteins.  One 
protein which HPV1 E1^E4 induces the relocalisation of is promyelocytic leukaemia protein 
(PML) (Roberts et al., 2003).  PML is a component of ND10 bodies, which are discrete 
nuclear foci, which contain multiple cellular proteins.   The exact function of ND10 bodies is 
unknown, but they have been linked with ontogenesis, DNA damage repair, apoptosis, stress 
response, senescence, the ubiquitin pathway and regulation of gene expression (Tavalai and 
Stamminger, 2008).  ND10 bodies have also been shown to constitute an interferon-mediated 
defence mechanism (Tavalai and Stamminger, 2008).  Multiple viruses are known to target 
ND10 bodies, however the reasons for this are unclear; the targeting of these structures may 
be a viral strategy to evade a cellular regulatory process which would inhibit viral replication. 
Alternatively disruption of ND10 bodies may facilitate the formation of viral replication 
centres by sequestration of the cellular proteins required for replication (Tavalai and 
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Stamminger, 2008).  The redistribution of PML to E1^E4 nuclear inclusions occurs in 
naturally infected cells which have switched to vegetative genome replication, suggesting that 
reorganisation of the ND10 bodies is only necessary when the virus changes its replication 
strategy (Roberts et al., 2003), this is similar to what occurs with viruses which have lytic 
replication cycles (Tavalai and Stamminger, 2008). 
1.11.2.4 Induction of apoptosis 
The E1^E4 protein of HPV16 has been shown to induce the redistribution of mitochondria 
from the microtubule network to perinuclear E4 aggregates (Raj et al., 2004).  This 
redistribution of mitochondria is specific as the localisation of other organelles such as the 
Golgi body and lysosomes are unaffected.  The region of E1^E4 required for the 
redistribution of mitochondria is the leucine cluster in the N-terminus of the protein, this is the 
same region required for the association of E1^E4 to the keratin network (Raj et al., 2004).  
The detachment of the mitochondria from the microtubules causes a severe reduction in the 
mitochondrial membrane potential and an induction of apoptosis.  Together with the 
disturbance of the cytokeratin network, the relocalisation of mitochondria and subsequent 
apoptosis may aid with the exit of the infectious virus particles (Raj et al., 2004). 
1.11.2.5 Interaction with components of RNA metabolism 
The HPV16 E1^E4 protein has also been shown to associate with a novel member of the 
DEAD box protein family of RNA helicases, E4-DBP (Doorbar et al., 2000).   This 
interaction is not conserved with HPV1 or HPV6 E1^E4 and occurs via sequences in the C-
terminus of the protein (Doorbar et al., 2000).  The interaction between E1^E4 and E4-DBP 
inhibits both the ATP binding and the RNA-independent ATPase activity of E4-DBP in vitro.  
E4-DBP has homology with bacterial and yeast DEAD box proteins involved in the 
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regulation of mRNA stability and degradation suggesting that E1^E4 has roles in regulating 
the stability of late viral transcripts (Doorbar et al., 2000).  
The E1^E4 proteins from HPV types 1, 16 and 18 have been shown to directly interact with 
the mammalian kinase, serine-arginine (SR) specific protein kinase 1 (SRPK1).  The HPV1 
E1^E4 protein but not that of HPV16 or HPV18 is a substrate for this kinase in vitro (Bell et 
al., 2007).  The study also found that SRPK1 is sequestered to E4 inclusion bodies in 
terminally differentiated cells in HPV1 warts and in cells expressing HPV1 E1^E4 alone (Bell 
et al., 2007).  The function of this novel interaction in the HPV life cycle is unknown, but may 
be involved in the facilitation of late viral gene expression (Bell et al., 2007).  The association 
between HPV E1^E4 and SRPK1 forms the subject of this thesis and is discussed in more 
detail later. 
In conclusion, E4 has multiple effects upon cell behaviour, but little is understood about the 
physiological significance of these functions.  It is likely that the protein has multiple actions 
within the life cycle and these are regulated by protein modifications.  Therefore identifying 
the functions of E4 and understanding their significance is important since the protein may be 
a valuable target for the development of anti-viral therapies. 
 
1.12 Serine-arginine specific protein kinases 
Serine-arginine (SR) specific protein kinases (SRPKs) are a family of serine-threonine 
kinases which specifically phosphorylate serine residues in serine-arginine/arginine-serine 
(SR/RS) dipeptide motifs.  SRPK1 was the first of the SRPK family to be indentified and was 
isolated following a search for a kinase which phosphorylated serine-arginine (SR) proteins 
(Gui et al., 1994a, Gui et al., 1994b).  SRPK1 was shown to phosphorylate the serine residues 
in the arginine-serine (RS) domain of the SR proteins and release the SR proteins from 
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nuclear speckles (Gui et al., 1994a, Gui et al., 1994b).  SRPK1 was found to be structurally 
similar to a fission yeast kinase, Dsk1, and both kinases have been shown to have a spacer 
domain separating the catalytic domain into two structural entities (Takeuchi and Yanagida, 
1993).  All members of the SRPK family contain highly conserved kinase domains separated 
by spacer sequences and these spacer sequences are unique to the SRPK family member (J. H. 
Ding et al., 2006).  The spacer domains may confer specific functions and regulatory 
properties to individual SRPKs.   
The second human SRPK family member SRPK2, is highly homologous to SRPK1, however 
SRPK2 has a proline rich tract at the N-terminus and an acidic region in the spacer domain 
(Kuroyanagi et al., 1998, H. Y. Wang et al., 1998).  SRPK1 and SRPK2 are very similar with 
respect to their enzymatic activity and substrate specificity; however these kinases have levels 
of tissue specific expression, with SRPK1 being highly expressed in the pancreas and SRPK2 
being highly expressed in the brain (H. Y. Wang et al., 1998).  Both kinases are moderately 
expressed in other tissues including heart and skeletal muscle and expressed at low levels in 
lung, liver and kidney cells (H. Y. Wang et al., 1998).  SRPK1 has been shown to associate 
with the U1-snRNP, which is involved in 5‟ splice site selection (Kamachi et al., 2002), 
whereas SRPK2 has been shown to be required for the formation of the U4/U6-U5 tri-snRNP, 
which is involved in 3‟ splice site selection (Mathew et al., 2008). 
Another human member of the SRPK family is SRPK1a, which is a product of the SRPK1 
gene and is produced by alternative splicing causing the insertion of an additional 171 amino 
acids at the N-terminus (Nikolakaki et al., 2001).  The N-terminal insertion in SRPK1a is 
proline rich, which is reminiscent of SRPK2.  Both SRPK1 and SRPK1a have similar 
substrate specificity and subcellular localisation (Nikolakaki et al., 2001). 
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SRPK3 has been identified in mouse and pig and is postulated to exist in humans; however no 
studies have shown SRPK3 expression and function in humans.  SRPK3 has been shown to 
have very limited and tissue specific expression in both mouse and pig (Giannakouros et al., 
2011).  SRPK family members have also been identified in budding yeast (Saccharomyces 
cerevisiae, Sky1), nematodes (Caenorhabditis elegans, SPK-1), insects (Drosophila 
melanogaster, Srpk79D), protozoan parasites (Trypanosoma cruzi, TcSRPK) and slime 
moulds (Physarum polycephalum, PSRPK), showing that SRPKs occur in organisms with 
varying evolutionary scales (Giannakouros et al., 2011).  The sequence conservation of the 
kinase domains is shown in Figure 1.9. 
SRPKs have a predominantly cytoplasmic localisation, however they can be translocated into 
the nucleus following stress, or other signals and during the cell cycle (J. H. Ding et al., 2006, 
Giannakouros et al., 2011).  Multiple elements in the spacer sequence in SRPKs control the 
cytoplasmic localisation, with deletion of the spacer leading to nuclear translocation (J. H. 
Ding et al., 2006).  As SRPKs are constitutively active, they are likely to be regulated by 
cellular distribution as an increased amount of SRPK1 in the nucleus following osmotic shock 
leads to differential phosphorylation of SR proteins and altered splice site selection (Zhong et 
al., 2009a).  In contrast to this, the kinase translocates into the nucleus in response to a cell 
cycle signal before the initiation of the mitotic phase, indicating that the kinase may play a 
role in cell cycle progression (J. H. Ding et al., 2006).  SRPK1 has been shown to interact 
with two co-chaperones for the major heat shock proteins, Hsp70 and Hsp90, with the 
ATPase activity of Hsp90 acting to regulate the cellular distribution of SRPK1 (Zhong et al., 
2009a).  Stress signals induced by osmotic shock can cause the inhibition of Hsp90 ATPase 
activity and the subsequent dissociation of SRPK1 from the chaperone complexes and 
translocation of SRPK1 into the nucleus (Zhong et al., 2009a).   
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Figure 1.9 Sequence comparison of SRPK1 family members.  Schematic 
showing the conservation of kinase domains between SRPK family members.  Percentage 
shown is comparison to SRPK1.  Adapted from (Siebel et al., 1999) 
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The heat shock proteins are involved in numerous signal transduction pathways suggesting 
that the regulation of SRPKs is complex and varies in response to a range of developmental 
cues and cellular signalling (Zhong et al., 2009a). 
  
1.13 Serine arginine-rich proteins 
Serine arginine-rich (SR) proteins are a family of RNA-binding proteins which are present in 
all metazoan organisms and in plants (Manley and Krainer, 2010).  SR proteins contain an 
arginine serine-rich (RS) domain along with one or two RNA recognition motifs (RRM).  The 
RS domain is involved in protein-protein and is extensively phosphorylated by several 
different kinases.  There are currently twelve members of the human SR protein family, which 
have recently been given a new nomenclature based on the root SRSF (SR splicing factor).  
According to the new definitions, SR proteins contain one or two conserved RRMs followed 
by a C-terminal RS domain of at least 50 amino acids with >40% RS content (Manley and 
Krainer, 2010).  The new and old names for the SR proteins along with their domain 
structures are shown in Figure 1.10A.  However, for this thesis the original nomenclature will 
be used.   
The first SR protein to be identified was alternative splicing factor/splicing factor 2 
(ASF/SF2), which was discovered and characterised by two groups independently.  ASF was 
identified as a protein which could influence the selection of 5‟ splice sites in an SV40 early 
pre-mRNA (Ge and Manley, 1990) whereas SF2 was identified as a protein required for the 
splicing of a β-globin pre-mRNA (Krainer and Maniatis, 1985), later SF2 was shown to be 
essential for splicing (Krainer et al., 1990).  ASF/SF2 is considered the prototypical SR 
protein as it contains two RRMs and a classical RS domain, the sequence of the RS domain of 
ASF/SF2 is shown in Figure 1.10B.  
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The second human SR protein to be discovered was SC35, which was detected with a 
monoclonal antibody against purified spliceosomes, and was shown to be necessary for 
splicing and spliceosome assembly in vitro (Fu and Maniatis, 1990).  Following the 
production of the monoclonal antibody, mAb104, the SR proteins SRp20, SRp75, SRp40 and 
SRp55 were identified (Zahler et al., 1992).  The SR protein 9G8 was identified using a 
monoclonal antibody and unlike the other family members contains a zinc knuckle in-between 
the RRM and RS domain (Cavaloc et al., 1994).  Other SR proteins including SRp30c and 
SRp54 were identified by oligonucleotide probes against the RNA recognition motif and auto-
antiserum reactivity (Screaton et al., 1995, W. J. Zhang and Wu, 1996). 
Along with the SR proteins there are a large number of proteins which contain RS or RS-like 
domains; these include the U1 snRNP-specific protein U1 70K, both subunits of the U2AF 
splicing factor and the splicing co-activators SRm 160/300.  A study of RS domain containing 
proteins has revealed proteins with functions not only in pre-mRNA splicing but in chromatin 
remodelling, translation, transcription by RNA polymerase II and cell cycle progression 
(Boucher et al., 2001).    
1.13.1 Localisation of SR proteins 
Many proteins involved in pre-mRNA splicing, including SR proteins and small nuclear 
ribonucleoprotein (snRNPs) are found in nuclear speckles, which are distinct nuclear 
compartments which occur throughout the nucleus.  There are two distinct structural types of 
speckles at the electron microscopic level, these are interchromatin granule clusters (IGCs) 
and perichromatin fibrils (Spector, 1993).  Based on [
3
H]uridine incorporation studies, 
transcription is thought to occur at the perichromatin fibrils which are approximately 3-5 nm 
in diameter (Spector, 1993, 1996).  The IGCs are about 20-25 nm in diameter and are sites of 
storage and/or reassembly of splicing factors (Spector, 1993, 1996).   
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Figure 1.10 SR protein domain structure. (A) The old names along with the new 
nomenclature and the domain structure are shown for the 12 human SR proteins.  RRM: 
RNA recognition motif, RRMH: RRM homology, RS: arginine serine-rich domain, Zn: 
Zinc knuckle. (B) Sequence of the RS domain of ASF/SF2, the RS domain can be 
divided into two subdomains (RS1 and RS2), RS/SR residues are shown in red, single 
serines are blue, docking motif and initiation box which are important for SRPK1 
phosphorylation are identified. Adapted from (Manley and Krainer, 2010) and (Ghosh 
and Adams, 2011). 
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There are visible connections between the speckles and the SR proteins and snRNPs are 
recruited from the IGCs to the perichromatin fibrils which are the active sites of transcription 
and splicing.  Inhibition of RNA polymerase II or splicing leads to the IGCs becoming larger 
and more uniform in shape, loss of the perichromatin fibrils and loss of the connections 
between speckles, confirming that the IGCs are sites of storage of splicing factors (O'Keefe et 
al., 1994, Spector, 1996).  Both phosphorylation of the RS domain and the presence of the 
RRM are required for the recruitment of the SR proteins from the IGCs to the perichromatin 
fibrils (Misteli et al., 1998). 
The RS domains of the SR proteins are partly responsible for targeting the SR proteins to 
nuclear speckles.  In SR proteins which have a single RRM, such as SC35 and SRp20, the RS 
domain is both necessary and sufficient to target the SR protein to the speckles (Caceres et al., 
1997).  In contrast, in SR proteins which contain two RRMs, such as ASF/SF2, the RS 
domain is neither necessary nor sufficient to target the protein to nuclear speckles, with two of 
the three constituent domains of ASF/SF2 being required for subnuclear compartmentalisation 
(Caceres et al., 1997).  
A subset of the SR proteins such as ASF/SF2, SRp20 and 9G8 shuttle rapidly and 
continuously between the nucleus and the cytoplasm, whereas SC35 and SRp40 do not, due to 
the presence of a dominant nuclear retention signal in the RS domain (Cazalla et al., 2002).  
The SR proteins SRp75 and SRp55 can shuttle between the nucleus and cytoplasm but with 
slower kinetics (Sapra et al., 2009).  Most shuttling proteins are predominantly nuclear at 
steady state and present in the cytoplasm only transiently.  SR proteins are exported from the 
nucleus as part of an RNA-protein complex, so require their RRM for cytoplasmic 
translocation.  ASF/SF2 and SRp20 require active transcription for reimport (Caceres et al., 
1998).   
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The reimport of SR proteins into the nucleus is mediated by transportin SR (TRN-SR), a 
member of the importin-β/transportin family (Kataoka et al., 1999).  The interaction of the SR 
proteins with TRN-SR is via the RS domain and only occurs when the RS domain is 
phosphorylated (Lai et al., 2000).  
  
1.14 Functions of SR proteins 
1.14.1 pre-mRNA splicing 
Pre-mRNA splicing is an essential process required for the expression of most eukaryotic 
protein-encoding genes.  The primary transcripts of almost all protein-coding genes contain 
multiple non-coding intervening sequences (introns) in between the coding sequences 
(exons), which must be precisely removed to give translatable mRNAs.  Alternative splicing 
allows single genes to encode multiple proteins, via the process of alternative exon inclusion 
and expands the proteomic complexity encoded by the genome.  The process of intron 
excision is referred to as splicing and takes place in a large ribonucleoprotein complex known 
as the spliceosome.  The spliceosome consists of five small nuclear ribonucleoproteins 
(snRNPs), designated U1, U2, U4, U5 and U6 along with a large number of non-snRNPs, 
including the SR proteins (Graveley, 2000).  Spliceosome assembly is partly directed by the 
RNA sequence at the splice sites, with introns being bound by conserved sequences which 
define their 5‟ and 3‟ splice sites.  In mammals the 5‟ splice site consensus sequence is 
AG/GURAGU (/ denotes the exon/intron boundary).  The 3‟ splice site is defined by three 
distinct sequence elements, the branchpoint (YNYURAC), which is 20-40 nucleotides 
upstream of the splice site, a polypyrimidine tract and the 3‟ splice site (YAG/N) (Graveley, 
2000).  The spliceosome assembles de novo on each intron, in a sequential and coordinated 
pathway, although parts of the spliceosome may be pre-assembled (Stevens et al., 2002).  The 
formation of the early (E) complex is initiated by the binding of the U1 snRNP to the 5‟ splice 
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site, splicing factor 1 (SF1) to the branchpoint sequence and the heterodimeric splicing factor 
U2 auxiliary factor (U2AF) to the pyrimidine tract and 3‟ splice site (Graveley, 2000).  U2AF 
then recruits U2 snRNP in an ATP dependent manner to the branchpoint to form complex A, 
followed by the recruitment of the U4/U6•U5 tri-snRNP to form complex B.  Finally the 
complex rearranges and U1 and U4 snRNPs are released, leading to the formation of the 
catalytically active complex C (Graveley, 2000). 
1.14.2 SR protein control of pre-mRNA splicing 
SR proteins participate at multiple steps in the assembly of the spliceosome; the selection of 
splice sites relies on the interactions of SR proteins and other RNA binding proteins with cis-
acting elements within exonic or intronic sequences.  The roles of the SR proteins in splicing 
can be divided into two categories: exon dependent and exon independent.  The exon 
dependent functions of SR proteins are the best-characterised functions and involve the 
binding of SR proteins to exon sequences (Graveley, 2000).  SR proteins can bind to exonic 
splicing enhancers (ESEs), where they function to enhance the splicing of the adjacent intron 
by stabilising the binding of U1 snRNP and U2AF to the 5‟ and 3 splice sites respectively, 
this process is known as exon definition  (Figure 1.11A) (Boukis et al., 2004, Sanford et al., 
2005).  SR proteins are important in the regulation of alternative splicing and many 
alternative exons are designated by weak splicing signals.  SR protein binding to ESEs can 
promote alternative 3‟ splice site selection by recruiting U2AF to suboptimal 3‟ splice sites 
with weak polypyrimidine tracts (Figure 1.11B).  Exonic splicing silencers (ESSs) can recruit 
splicing repressor proteins such as hnRNP A1 and block 3‟ splice site selection, SR proteins 
can antagonise the effects of splicing repressors, thus promoting splice site selection (Figure 
1.911) (Sanford et al., 2005).  SR proteins can also promote alternative splice site usage by 
binding to intronic sequences close to the splice sites and inhibiting recruitment of 
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spliceosomal components through steric hindrance or non-productive spliceosomal assembly 
(Figure 1.11D) (Shepard and Hertel, 2009).   
The exon independent functions of SR proteins are considered to be exon independent 
because it is not known whether the SR proteins must bind to exons to perform these 
functions or not.  SR proteins facilitate splice site pairing by simultaneously interacting with 
U1-70K snRNP and U2AF
35
 across the intron (Figure 1.11E) (J. Y. Wu and Maniatis, 1993), 
the SR proteins are also required for trans-splicing, where the 5‟ and 3‟ splice sites are 
contained on separate RNA molecules (Bruzik and Maniatis, 1995).   SR proteins have been 
shown to play a role in the recruitment of the U4/U6•U5 tri-snRNP into the spliceosome 
(Figure 1.11E) (Roscigno and Garcia-Blanco, 1995), with the SR proteins interacting with 
either the U4/U6•U5-27K or the U5-100K (Graveley, 2000).   
Multiple SR proteins have been shown to participate in the removal of each intron, suggesting 
that each splicing event requires at least one SR protein to perform a regulated exon 
dependent function and another SR protein to perform the exon independent functions.  The 
regulated exon dependent functions of the SR proteins have phosphorylation requirements 
which are distinct from the other SR protein functions (Graveley, 2000).  The splicing of 
strong introns only requires the exon independent functions of SR proteins and the SR 
proteins are all able to perform this activity (Hertel and Maniatis, 1999).    
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Figure 1.11 SR protein control of splicing.  (A)  SR proteins bound to an ESE can 
interact with U1 snRNP bound to the 5‟ site and U2AF bound at the 3‟ site.  (B)  SR 
proteins bound to ESEs can promote alterative 3‟ splice site selection by recruiting U2AF 
to a suboptimal 3‟ splice site (weak polypyrimidine tract).  (C)  Splicing repressor 
proteins such as hnRNP A1 can bind to ESSs and block 3‟ splice site selection by U2AF, 
SR proteins can antagonise these effects.  (D)  SR proteins can associate with intronic 
sequences and inhibit U2AF recruitment sterically.  (E)  SR proteins facilitate splice site 
pairing and assist in U4/U6•U5 tri-snRNP recruitment.  (YYYYYY)n represents 
pyrimidine tract Adapted from (Shepard and Hertel, 2009). 
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1.14.3 mRNA export, stability and translation 
Splicing not only removes introns from the mRNA, but also rearranges the mRNP particle to 
promote export from the nucleus.  Some mRNAs however do not require splicing, but are still 
exported.  The shuttling SR proteins, SRp20 and 9G8, have been shown to promote the 
nuclear export of intronless histone H2A mRNAs, by specifically binding to a 22 nt sequence 
within the H2A mRNA (Huang and Steitz, 2001).  The same two SR proteins have been 
shown to be adapter proteins, which stimulate the export of mRNA by forming a ternary 
complex with Tip-associated protein (TAP), which is an essential nuclear export factor 
(Hautbergue et al., 2008).  The binding of TAP to the SR proteins increases the RNA binding 
affinity of TAP and results in more efficient mRNA handover (Hautbergue et al., 2008). 
SR proteins have been implicated in RNA stability and quality control.  ASF/SF2 actively 
promotes the degradation of PKCI-r (protein kinase C-interacting protein 1 related) mRNA 
through the binding of a purine-rich element within the PKCI-r 3‟ untranslated region 
(Lemaire et al., 2002).  The overexpression of various SR proteins strongly enhances 
nonsense-mediated decay (NMD) of mRNAs containing premature termination codons, 
suggesting that SR proteins can enhance the nuclear steps of NMD and target mRNAs to this 
pathway (Z. Zhang and Krainer, 2004).  
SR proteins have been shown to influence translation either indirectly or directly.  An indirect 
function of ASF/SF2 is by influencing the alternative splicing of the pre-mRNA for the 
protein kinase MNK2, a kinase which regulates translation initiation.  High levels of ASF/SF2 
promote the production of an MNK2 isoform which enhances cap-dependent translation, 
whereas low levels of ASF/SF2 promote the opposite (Karni et al., 2007).  ASF/SF2 can also 
regulate translation directly, as ASF/SF2 can interact with polyribosome fractions in 
cytoplasmic extracts and enhance the translation efficiency of an ESE-containing luciferase 
reporter (Sanford et al., 2004).  ASF/SF2 has been shown to affect translation through the 
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mediation of recruitment of components of the mTOR (mammalian target of rapamycin) 
signalling pathway.  ASF/SF2 interacts with the protein kinase mTOR and the phosphatase 
PP2A and potentiates hyperphosphorylation of 4E-BP (eIF4E binding protein), blocking the 
inhibitory activity of 4E-BP on cap-dependent translation (Michlewski et al., 2008).  SRp20 
has been shown to be required for the stimulation of internal ribosome entry site (IRES)-
mediated translation of poliovirus RNA (Bedard et al., 2007), while both SRp20 and 9G8 
have been shown to increase the translation efficiency of unspliced mRNA containing a 
constitutive transport element (Swartz et al., 2007).  The numerous roles of SR proteins in 
post-transcriptional gene expression are summarised in table 2. 
Table 2 Roles of SR proteins in post-transcriptional gene expression  
 
Constitutive
/alternative 
splicing 
Splicing 
repression 
Nucleo-
cytoplasmic 
shuttling 
mRNA 
export 
mRNA 
stability NMD 
mRNA 
translation 
ASF/SF2 + + + - + + + 
SC35 + + - - ND + - 
SRp20 + - + + ND - + 
SRp75 + - + ND ND ND ND 
SRp40 + - - ND ND + - 
SRp55 + - + ND ND + ND 
9G8 + - + + ND - + 
SRp46 + - ND ND ND ND ND 
SRp30c + - ND ND ND ND ND 
SRp38 - + ND ND ND ND ND 
SRp54 + - ND ND ND ND ND 
ND: not determined, +: experimentally determined, -: no demonstrated role (Sanford et al., 
2005) 
1.14.4 Other functions of SR proteins  
The functions of SR proteins are not limited to post-transcriptional activities and there is 
growing evidence that the SR proteins act to couple transcriptional elongation to splicing.  
Depletion of ASF/SF2 and SC35 has been shown to dramatically attenuate the production of 
nascent RNA in vivo and SC35 has been shown to have an active role in transcriptional 
elongation (Lin et al., 2008).  The SR proteins interact with the phosphorylated C-terminal 
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domain (CTD) of the largest subunit of PolII (Misteli and Spector, 1999) and in vivo depletion 
of SC35 diminishes the association of PolII with pTEFb, a kinase that phosphorylates CTD at 
Ser2 positions, which is critical for transcriptional elongation (Lin et al., 2008).  This suggests 
that SR protein recruitment to PolII may help stabilise critical transcriptional elongation 
factors such as pTEFb and SR proteins may play an integral part in transcriptional elongation 
as well as reverse coupling transcription to splicing (Zhong et al., 2009b).   The SR proteins 
SRp20 and ASF/SF2 can also bind directly to the histone H3 tail via the RS domain, the SR 
proteins may bind to the exposed H3 tail as a consequence of nucleosome rearrangement 
during transcriptional elongation (Loomis et al., 2009).  SRp20 and ASF/SF2 associate with 
chromatin at interphase and are released from the hyperphosphorylated mitotic chromosomes 
and then reassociated with chromatin in the late M-phase.  The phosphorylation of the H3 tail 
at serine 10 by Aurora kinase B causes the detachment of the SR proteins from the chromatin, 
also hyperphosphorylation of the SR proteins by SRPKs causes the interaction between SR 
proteins and the H3 tail to diminish.  SR proteins have been shown to become 
hyperphosphorylated when cells enter M-phase.  ASF/SF2 has also been shown to be required 
for the dismantling the heterochromatin mark HP1 from chromatin, suggesting that SR 
proteins may facilitate chromosome condensation and contribute to cell-cycle progression 
through M-phase (Loomis et al., 2009, Zhong et al., 2009b).  
The SR protein ASF/SF2 has been shown to negatively autoregulate its expression to 
maintain homeostatic levels.  ASF/SF2 can modulate alternative splicing to downregulate 
itself by decreasing the production of the protein-coding isoform and increasing the isoforms 
that are retained in the nucleus and are therefore not translated or are degraded by nonsense 
mediated decay (NMD) (S. Sun et al., 2010).  ASF/SF2 can also form a negative feedback 
loop with a microRNA (miR-7), with ASF/SF2 promoting miR-7 maturation and mature miR-
7 targeting the 3‟ UTR of ASF/SF2 to repress its translation (H. Wu et al., 2010).  The SR 
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protein SRp20 has also been shown to negatively regulate the alternative splicing of its own 
mRNA, with overexpression of SRp20 leading to a transcript which encodes a truncated 
protein lacking the RS domain.  Interestingly ASF/SF2 antagonises this auto-regulation and 
suppresses the formation of the truncated protein (Jumaa and Nielsen, 1997). 
Another function of ASF/SF2 is the regulation of the sumoylation pathway, overexpression of 
ASF/SF2 stimulates SUMO (small ubiquitin-related modifier) conjugation, with ASF/SF2 
knockdown inhibiting sumoylation.  ASF/SF2 interacts with the SUMO E2 conjugating 
enzyme, Ubc9 and with specific substrates facilitates the transfer of SUMO from the thioester 
intermediate to the substrate, similar to a SUMO E3 ligase.  In addition, ASF/SF2 interacts 
with the SUMO E3 ligase PIAS1 (protein inhibitor of activated STAT-1) and regulates 
PIAS1-induced protein sumoylation (Pelisch et al., 2010).  
SR proteins are described as splicing factors; however they have diverse roles that couple the 
processes of translation, splicing, mRNA export and translation, along with many other roles 
which are unrelated to mRNA splicing. 
 
1.14.5 SRPKs, SR proteins and cancer 
The gene encoding the SR protein ASF/SF2 (SFRS1) is a proto-oncogene with roles in the 
establishment and maintenance of transformation.  The SFRS1 gene is upregulated in tumours 
of the colon, thyroid, small intestine, kidney, lung and cervix (Fay et al., 2009, Karni et al., 
2007).  ASF/SF2 controls the alternative splicing of the putative tumour suppressor BIN1, the 
transcription factor TEF-1, the kinase MNK2 and the ribosomal-protein kinase SK61.  
Overexpression of ASF/SF2 affects the splicing of these proteins and hence affects their 
control of transformation and apoptosis (Karni et al., 2007).  Another regulatory protein 
which is differentially spliced by ASF/SF2 is vascular endothelial growth factor A (VEGFA), 
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which is a key regulator of physiological and pathological angiogenesis.  Alternative splicing 
of VEGFA leads to two different isoforms which are either pro-angiogenic or anti-angiogenic.  
Overexpression of ASF/SF2 leads to the production of the pro-angiogenic isoform, whereas 
overexpression of SRp55 favours the productions of the anti-angiogenic isoform (Nowak et 
al., 2008).  The phosphorylation of ASF/SF2 by SRPK1 has been shown to be involved in the 
production of the pro-angiogenic isoform of VEGFA (Nowak et al., 2010).  Further evidence 
of the oncogenic functions of ASF/SF2 come from overexpression studies in which the 
overexpression of ASF/SF2 can cause colony formation in NIH 3T3 and Rat1 fibroblasts 
grown in soft agar; however the effect is not seen to the same extent with SC35 and SRp55 
(Karni et al., 2007).  Furthermore injection of ASF/SF2 overexpressing NIH 3T3 cells into 
nude mice formed large tumours.  ASF/SF2 has also been shown cooperate with H-Ras to 
enhance cellular proliferation and appeared to protect cells from DNA damage and serum 
deprivation induced apoptosis (Karni et al., 2007). 
SRPK1 has been shown to upregulated in breast and colonic tumours, with the expression of 
SRPK1 increasing with tumour grade (Hayes et al., 2007).  The down-regulation of SRPK1 
using siRNA, sensitised tumour cells to chemotherapeutic intervention with cisplatin and 
gemcitabine.  Additionally alterations in the splice patterns of MAPK kinase 2 were observed 
upon SRPK1 inhibition, which resulted in a decrease in phosphorylation of MAPK2, MAPK3 
and AKT (Hayes et al., 2007).  SRPK2 can bind to and phosphorylate the SR-like protein 
acinus, causing its relocalisation from nuclear speckles to the nucleoplasm, resulting in the 
activation of cyclin A1.  The overexpression of SRPK2 or acinus increases leukaemia cell 
proliferation and both of these proteins have been shown to be overexpressed in human acute 
myelogenous leukaemia patients (Jang et al., 2008).  These studies demonstrate that SRPKs 
are involved in mediating the regulation of splicing of oncogenes. 
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Figure 1.12 Mechanism of phosphorylation of ASF/SF2 by SRPK1.  (A) Grab-
and-pull mechanism for the phosphorylation of ASF/SF2.  SRPK1 docks at the C-
terminal end of RS1 and loosely initiates phosphorylation at the RS1/RS2 boundary 
(regional initiation).  SRPK1 then pulls N-terminal serines into the active site for 
phosphorylation.  (B) The N-terminal portion of RS1 (N‟-RS1) binds in the docking 
groove while the initiation box occupies the active site.  In the presence of ATP, RS1 is 
phosphorylated until the docking motif (D) occupies the docking groove.  Basic side 
chains in the P+2 site stabilise the phosphates on RS1.  Pink hexagons: RS pairs, dotted 
line: other RS pairs in RS1, yellow circles: phosphate groups. Adapted from (Ma et al., 
2008) and (Ngo et al., 2008).  
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1.15 Regulation of SR proteins 
1.15.1 SRPK1 phosphorylation 
The RS domain of the SR proteins controls a large number of the SR protein interactions and 
functions; therefore one method of controlling these interactions is phosphorylation of this 
domain.  A dynamic cycle of phosphorylation and dephosphorylation is required for pre-
mRNA splicing, as upon recruitment of the SR proteins for splicing, the RS domain is 
hyperphosphorylated (Gui et al., 1994a); however the RS domain becomes partially 
dephosphorylated during splicing in a step which is necessary for SR protein nuclear export 
(Lai and Tarn, 2004).  Multiple studies have been performed to identify the kinases and 
phosphatases responsible for regulating the SR proteins in vivo. 
The first kinase to be identified which phosphorylated the RS domain was SRPK1, which 
specifically phosphorylates the serine residues in the RS dipeptides.  SRPK1 is known to 
preferentially phosphorylate up to twelve serines in the N-terminal region of the RS domain 
(RS1) (Figure 1.10B) (Hagopian et al., 2008).  A docking motif (RVKVDGPR) in ASF/SF2, 
located between the second RRM and the RS domain specifically interacts with a docking 
groove in SRPK1 (Lukasiewicz et al., 2007, Ngo et al., 2005).  Start-trap experiments have 
shown that once bound SRPK1 phosphorylates ASF/SF2 in a processive manner (Aubol et al., 
2003, Velazquez-Dones et al., 2005) in the direction of the N-terminus using a „grab-and-pull‟ 
mechanism to control the regiospecific phosphorylation of the protein (Figure 1.12A) (Ma et 
al., 2008).  SRPK1 initially binds to an initiation box (Ser221-Ser225) and rapidly 
phosphorylates the first eight serines, the remaining serines are then modified in a slower 
phase, suggesting a dual-track mechanism, incorporating both processive and distributive 
phosphorylation steps (Ghosh and Adams, 2011, Ma et al., 2008).  Although SRPK1 prefers 
to bind to the initiation box at the C-terminal end of RS1, mutations in this region do not stop 
phosphorylation of the RS1 domain, indicating that SRPK1 can bind to different sites (Ma et 
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al., 2008).  Different crystallisation studies have identified that both the initiation box and the 
docking motif of ASF/SF2 can bind to the docking groove in SRPK1, indicating that the 
structure of the SRPK1-ASF/SF2 complex changes as a function of phosphorylation.  
Therefore a proposed model of phosphorylation is that the RS repeat motif (residues 204-210) 
serves as a mobile docking element, placing the C-terminal serine from the initiation box in 
the active site.  As each serine is phosphorylated the docking motif moves by two residues at 
a time towards the N-terminus, as the whole RS1 motif is fed through the active site of the 
kinase the N-terminal docking motif enters the docking groove (Figure 1.12B) (Ngo et al., 
2008).  The basic pocket at the P+2 site (prime site) interacts with a phosphoserine and 
stabilises the active conformation of the kinase, thus facilitating phosphorylation, after each 
round of phosphorylation a new phosphoserine replaces the old one with enhanced catalytic 
efficiency.  The priming phosphorylation demonstrated by SRPK1 suggests that the rate-
limiting step in the processive phosphorylation of ASF/SF2 is the phosphorylation of the first 
serine due to the lack of binding to the prime site (Ngo et al., 2008).  However it has been 
shown that SRPK1 binds to unphosphorylated ASF/SF2 with high affinity, but this affinity 
weakens during subsequent phosphorylation steps, promoting dissociation over forward 
catalysis leading to a slower rate of phosphorylation (Ma et al., 2008).  The fully 
phosphorylated ASF/SF2 protein binds to SRPK1 with five fold less affinity than the 
unphosphorylated protein (Koizumi et al., 1999).   
1.15.2 Other kinases and regulatory systems 
The second family of kinases which can phosphorylate SR proteins are the CLK/STY 
(CDC28/cdc2
+
-like kinase/serine threonine tyrosine) family of dual specificity kinases, 
consisting of CLK1-4 (Colwill et al., 1996).  The CLK family can phosphorylate both 
serine/threonine and tyrosine residues and CLK is the prototypical member of the LAMMER 
family of protein kinases, which are conserved throughout evolution and share a conserved 
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sub-domain (EHLAMMERILGPLP) within the kinase domain (Colwill et al., 1996).  Unlike 
SRPK1, CLK can phosphorylate all of the serine residues in the RS domain of ASF/SF2 with 
the phosphorylation occurring by a processive mechanism (Velazquez-Dones et al., 2005).  In 
contrast to SRPK1, X-ray structures of CLK reveal no deep docking groove; instead a shallow 
area with both acidic and basic charge patches is present.  The charge distribution in CLK 
suggests that the hypophosphorylated RS domain could interact with CLK with higher 
efficiency than the unphosphorylated domain, leading to the suggestion that the product of 
SRPK1 phosphorylation is the substrate for CLK (Ghosh and Adams, 2011).   
In addition to the SRPKs and CLKs, DNA topoisomerase I has been shown to phosphorylate 
the RS domain, DNA topoisomerase I has no obvious kinase domain, but can bind ATP with 
high affinity and can phosphorylate the serine residues in the RS domain of several SR 
proteins (Rossi et al., 1996).  The phosphorylation of the RS domain by DNA topoisomerase I 
is dependent upon the number of RS repeats, with DNA topoisomerase I requiring at least five 
RS dipeptide repeats for efficient binding and phosphorylation of ASF/SF2 (Labourier et al., 
1998).  Another kinase shown to be able to phosphorylate the RS domain of SR proteins is 
mammalian PRP4 (pre-mRNA processing mutant 4).  PRP4 contains an RS domain and 
putative nuclear localisation signals in the N-terminal region and has been shown to interact 
with and phosphorylate ASF/SF2 (Kojima et al., 2001).  The protein kinases C and A (Colwill 
et al., 1996), along with CDC2 kinase (Okamoto et al., 1998) and AKT kinase (Blaustein et 
al., 2005) can also phosphorylate ASF/SF2 in vitro.   
The phosphorylation of the RS domain has been shown to influence the localisation of the SR 
proteins as overexpression of both SRPKs and CLKs can cause the disassembly of nuclear 
speckles and a redistribution of splicing factors (Colwill et al., 1996, Gui et al., 1994a).  
Additionally, the phosphorylation of the SR proteins by SRPKs in the cytoplasm is required 
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for the interaction with the transportin-SR complex and nuclear reimport (Lai et al., 2000).  
The phosphorylation state of the RS domain controls the protein-protein interactions and the 
protein-RNA interactions, with phosphorylation required for the interaction between ASF/SF2 
and U1-70K snRNP (Xiao and Manley, 1997), whereas dephosphorylation is required for the 
binding of ASF/SF2 to the RNA export factor Tap/NFX1 (Huang et al., 2004).  The current 
model of the role of kinases in the control of SR proteins is that CLKs is responsible for 
recruiting the SR proteins to sites of active transcription and the SRPKs are responsible for 
nuclear reimport (Figure 1.13).  However, as SRPKs can enter the nucleus and multiple 
phosphorylation states are required for different functions, the regulation of SR protein by 
kinases is likely to be a great deal more complex.  
As dephosphorylation is required for the SR protein control of splicing, specifically 
spliceosome maturation, the export of mRNA and the release of the SR proteins from mRNA, 
phosphatases are required to remove the phosphate groups from the RS domain.  Protein 
phosphatase 1 (PP1) has been identified as a phosphatase responsible for dephosphorylating 
SR proteins.  PP1 removes the phosphate groups from the RS1 domain in an N to C direction, 
opposite to the direction which SRPK1 acts (Ma et al., 2010).  The interaction of ASF/SF2 
with ESEs negatively regulates dephosphorylation of the RS1 domain as does 
phosphorylation of the RS2 domain by CLK/STY, suggesting that the control of 
dephosphorylation is regiospecific (Ma et al., 2010).  
In addition to phosphorylation the SR proteins are also controlled by methylation, with three 
residues in the linker region between the RRM and RRMH domain of ASF/SF2 being 
methylated by the human homolog of Hmt1p (PRMT1).  This methylation influences the 
nucleo-cytoplasmic distribution as an ASF/SF2 mutant which could not be methylated was 
localised in the cytoplasm (Sinha et al., 2010).  
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Figure 1.13 Regulation of SR proteins.  SR proteins are usually in nuclear 
speckles; phosphorylation releases the SR proteins to participate in spliceosome 
assembly.  Phosphorylation and dephosphorylation of the SR proteins is required during 
splicing.  PP1 dephosphorylation of the SR proteins releases some post-splicing and the 
remainder after export from the nucleus.  The SR proteins are phosphorylated by SRPK1 
to facilitate re-import into the nucleus.  Grey lines indicate involvement or movement of 
SRPK1; dashed lines indicate movement of SR proteins. 
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1.16 HPV regulation of splicing factors 
As the genome of HPV requires extensive constitutive and alternative splicing, interactions 
between HPV proteins and splicing factors are to be expected in order for the virus to be 
preferentially spliced.  In normal epithelium the expression of ASF/SF2 is typically restricted 
to the dividing cells in the basal layer; however infection of the epithelium with HPV16 
causes ASF/SF2 to be expressed in the upper layers of the epithelium (McPhillips et al., 
2004).  The induction of ASF/SF2 expression by the virus is via the HPV16 E2 protein 
binding and trans-activating the promoter of the SFRS1 gene, causing a 4-8 fold increase in 
ASF/SF2 levels in differentiated cells (McPhillips et al., 2004, Mole et al., 2009b).  HPV16 
E2 has also been shown to specifically up-regulate SRp20 and SC35 (Mole et al., 2009a) and 
HPV31 has also been shown to regulate ASF/SF2 (Mole et al., 2009b).  The virally induced 
upregulation of the SR proteins is essential for the expression of some virus proteins, as HPV-
infected HFKs expressing a mutant E2 which cannot stimulate the expression of SR proteins 
showed reduced levels of late virus RNAs, including the virus capsid proteins which are 
required for virion formation.  This indicates that SR proteins are required for the expression 
of virus proteins in the mid-to-upper layers of the epithelium (McFarlane and Graham, 2010).  
The levels of SR proteins are also increased with cervical disease progression, with increased 
SR protein expression throughout the epithelial layers in higher grades of premalignant 
lesions (Mole et al., 2009a).  The levels of ASF/SF2, SRp20 and SC35 increase in cells with 
integrated HPV genomes, therefore this increase cannot be due to E2 regulation as the 
expression of E2 is abrogated in integration (McFarlane and Graham, 2010).  The 
hypothesised model of SR protein upregulation is that chromosomal rearrangements or 
changes in methylation patterns result in the amplification or activation of the genes 
(McFarlane and Graham, 2010). 
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The most frequently used splice site in HPV16 is splice acceptor 3358 (SA3358), which is 
used to produce E6, E7 and E1^E4 transcripts.  SA3358 is followed by an ESE with 15 
potential binding sites for ASF/SF2; mutational inactivation of the 15 sites redirected splicing 
to the late splice site SA5639 demonstrating that the SA3358 splice site is dependent on 
ASF/SF2 binding (Somberg and Schwartz, 2010).  Therefore high levels of ASF/SF2 may be 
a requirement for the high expression of E6 and E7.  The SA3358 ESE can also bind to 
SRp20 and this binding suppresses use of the late splice site SA5639 (Jia et al., 2009).  High 
levels of SRp20 promote the expression of E6 and E7, whereas low levels promote the 
expression of L1, with L1 and SRp20 having an inverse expression in HPV infections (Jia et 
al., 2009). 
The E2 proteins of the beta-HPV types (HPV5 and 8) contain RS dipeptide repeats in the 
hinge between the N- and C-terminal domains.  The RS dipeptide repeats allow the E2 protein 
of HPV5 to interact with the SR proteins ASF/SF2, SRp20, SC35, SRp40, SRp55 and SRp75 
and also with U1-70K and U1-100K.  The E2 protein could not recruit the splicing factors and 
trans-activate splicing without activating gene transcription through binding to the promoter.  
This data indicates that the E2 proteins can play a dual role in gene expression with the RS-
rich hinge of HPV5 E2 functioning to recruit splicing factors to splice pre-mRNA made via 
transactivation by E2 itself (Lai et al., 1999).  
A number of different DNA viruses target splicing factors via various different mechanisms 
to control the balance between host and viral post-transcriptional gene regulation, 
demonstrating that the SR proteins are important targets for the viruses and as more functions 
for these proteins emerge they have become potential targets for anti viral therapy. 
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1.17 Aims and objectives 
The E1^E4 protein of HPV types 1, 16 and 18 interacts with SRPK1 (Bell et al., 2007).  In 
warts, SRPK1 is associated with E4 containing inclusion bodies in cells present in the upper 
cell layers of the lesion (Bell et al., 2007).  SRPK1 cellular substrates are known to be 
involved in the regulation of HPV gene expression (Jia et al., 2009, Somberg and Schwartz, 
2010).   I hypothesise that the interaction between E1^E4 and SRPK1 alters SRPK1 activity 
and that this association influences the functions of SRPK1 in the HPV life cycle.  This PhD 
study aims to investigate how E1^E4 affects SRPK1 functions and to understand the role of 
SRPK1 in the HPV life cycle and how the virus regulates SRPK1. 
The specific objectives of this thesis are: 
To investigate how E1^E4 proteins from alpha, beta and mu papillomaviruses influence 
SRPK1 kinase activity in vitro (Chapter 3). 
To investigate the cellular and viral substrate specificity of any effect on SRPK1 activity 
caused by the interaction between SRPK1 and HPV E1^E4 (Chapter 4). 
To determine the effect of the interaction between SRPK1 and HPV E1^E4 on the cellular 
localisation of SRPK1 cellular substrates and SRPK1 functions such as splicing regulation 
(Chapter 5).  
To investigate the role of SRPK1 in the HPV life cycle (Chapter 6). 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Bacterial cell culture  
2.1.1 Bacterial hosts growth and storage 
The Escherichia coli (E. coli) strain DH5α was used as a bacterial host for growth of plasmid 
vectors to prepare the plasmid DNA.  The E. coli strains BL21 (Stratagene), BL21 pLys and 
BL21 CodonPlus
®
 (Stratagene) were used for the expression of recombinant proteins.  
Bacteria were streaked onto agar plates and grown at 37 °C (1.5% w/v agar in Luria-Bertani 
(LB) medium with appropriate antibiotic).  Plates were stored at 4°C for short periods of time 
or the bacteria were stored as a glycerol stock (25% glycerol, 50% overnight bacterial culture) 
at -80°C for longer periods of time. 
Ampicillin was used at 50 μg/ml, kanomycin used at 20 μg/ml and chloramphenicol used at 
34 μg/ml final concentration.  Chloramphenicol was dissolved in ethanol at 34 mg/ml. 
2.1.2 Preparation of chemically-competent bacteria 
A streak plate was prepared from the bacterial stock on a LB agar plate with no selection 
antibiotic.  Four millilitres of LB media was inoculated with a single colony from the agar 
plate and grown overnight at 37°C with shaking at 200 rpm.  The following day 200 ml of LB 
media was inoculated with the starter culture and grown at 37°C with shaking until an 
OD600nm of 0.4-0.6.  The bacteria were pelleted by centrifugation at 3,834 x g for 15 min at 
4°C and re-suspended in 50 ml of cold TFB1 buffer (30 mM KOAc, 50 mM MnCl2, 100 mM 
KCl, 10 mM CaCl2, 15% v/v glycerol) and pelleted again by centrifugation at 3,834 x g.  The 
pellet was re-suspended in 8 ml of cold TFB2 buffer (10 mM Na-MOPS pH 7.0, 75 mM 
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CaCl2, 10 mM KCl, 15% v/v glycerol), aliquoted, snap frozen in liquid nitrogen and stored at 
-80°C. 
2.1.3 Transformation of competent bacteria with plasmid DNA 
Plasmid DNA (0.5-1 µg) was added to 50 µl of competent bacteria in a pre-chilled 
polypropylene tube and incubated on ice for 10 min.  The bacteria were heat shocked at 42°C 
for 90 s and returned to the ice for 2 min.  Five hundred µl of LB media was added and the 
sample shaken at 200 rpm at 37°C for 45 min.  Fifty µl of bacteria was spread onto an LB 
agar plate containing the relevant antibiotic and incubated overnight at 37°C.  
2.1.4 Preparation of plasmid DNA 
2.1.4.1 Small scale preparation  
Four ml of LB media containing the relevant antibiotic was inoculated with a single colony 
and grown overnight at 37°C with shaking at 200 rpm.  The following day 3 ml of the bacteria 
were pelleted by centrifugation at 16100 x g for 5 min at 4°C and the pellets processed using 
the QIAprep
®
 Spin Miniprep kit (Qiagen) according to the manufacturer‟s instructions.  DNA 
was eluted from the column into 50 μl of Tris-EDTA (TE) buffer and stored at 4°C.  
2.1.4.2 Large scale preparation  
A 4 ml starter culture of LB media with antibiotics was inoculated with a single colony and 
grown at 37°C with shaking at 200 rpm.  After 6-8 h 200 ml of LB media was inoculated with 
the starter culture and grown at 37°C overnight with shaking.  The bacteria were pelleted by 
centrifugation at 3,834 x g for 15 min at 4°C and the pellet processed using the Qiagen 
HiSpeed
®
 Plasmid Maxi kit (Qiagen) or PureLink HiPure
®
 Plasmid Filter Maxiprep kit 
(Invitrogen) according to the manufacturer‟s instructions.  The DNA was re-suspended in 0.5-
1 ml of TE buffer and stored at 4°C (short term) or at -20°C (long term).  The concentration 
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of the plasmid DNA solution was determined using the Nanodrop
TM
 spectrophotometer 
(Thermo Scientific).  
 
2.1.5 Bacterial expression of recombinant GST and His-tagged fusion 
proteins 
2.1.5.1 Small scale expression 
To determine the optimum condition for the expression of glutathione-S-transferase (GST) 
and His-fusion (polyhistidine, His6) proteins a 20 ml starter culture of LB media with 
antibiotics was inoculated with a single bacterial colony and grown overnight at 37°C with 
shaking at 200 rpm.  The following day 60 ml of LB media with antibiotics was inoculated 
with 6 ml of the starter culture and grown at 37°C with shaking.  After 2 h, isopropyl β-D-1-
thiogalactopyranoside (IPTG, Sigma) was added to a final concentration of 1 mM and a 6 ml 
aliquot was taken as a 0 h sample and the bacteria were pelleted by centrifugation at 16100 x 
g for 5 min.  Cultures were grown at 37°C or 30°C with shaking and 6 ml samples taken at 1 
h, 4 h and 24 h post IPTG-induction.  
2.1.5.2 Large scale expression 
A 20 ml starter culture of LB media was prepared as described in section 2.1.5.1 and used to 
inoculate 200 ml of LB media with antibiotics and 1% glucose and grown at 37°C with 
shaking.  After 2 h, IPTG was added to a final concentration of 1 mM and the culture grown 
at 37°C or 30°C with shaking for an appropriate time that ensured maximum expression of the 
tagged fusion protein.  The bacteria were pelleted by centrifugation at 3,834 x g for 15 min at 
4°C.  
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2.1.5.3 Purification of recombinant GST or His-tagged fusion proteins 
The bacterial pellet was re-suspended in 4-6 ml (400 μl for small scale) of E. coli lysis buffer 
(0.5% v/v Triton
®
 X-100 and Complete
TM
 protease inhibitors (Roche) in phosphate buffered 
saline (PBS, Dulbecco A)) and sonicated with three 30 s, 10 Watt pulses, using a microson 
ultrasonic cell disrupter (Misonix).  The samples were centrifuged at 16100 x g for 5 min at 
4°C and then 200 μl (40 μl for small scale) of a 50% slurry of glutathione (Sigma-Aldrich) or 
nickel-NTA (Qiagen) agarose beads, washed in E. coli lysis buffer, were added to the 
supernatant.  The proteins were bound to the beads with slow speed rotation with inversion at 
4°C for 1-2 h.  The beads were pelleted by centrifugation at 200 x g for 1 min and the 
supernatant removed.  The beads were then washed 6 times with 0.5 ml of E. coli lysis buffer 
and the proteins were eluted off the beads with 2 x 125 μl aliquots of reduced glutathione (50 
mM Tris-HCl pH 8.0, 0.1 M glutathione) in E. coli lysis buffer or nickel elution buffer (50 
mM NaH2PO4, 300 mM NaCl, 250 mM imidazole) for 30 min at RT.  The proteins were 
dialysed using GeBAflex-tubes (MWCO 6-8 kDa, Gene Bio-Application Ltd) into 25 mM 
Tris-HCl pH 7.5, 200 mM NaCl overnight at 4°C, glycerol added to 5 %, aliquoted and stored 
at -80°C.  Protein concentration was determined using the Bradford assay (Section 2.3.1). 
2.1.5.4 Thrombin cleavage of GST-tag 
The pGex-2T vector system (GE Healthcare) has a thrombin cleavage site to enable the 
removal of the GST tag.  To remove the GST-tag from GST-HPV1 E1^E4, the fusion protein 
was expressed on a large scale (section 2.1.5.2), but not eluted from the glutathione agarose 
beads.  The beads were incubated with 5 units of thrombin protease (GE Healthcare) in PBS 
per 100 μl bed volume of beads, overnight at 30°C.  The cleaved protein was loaded onto a 
pre-equilibrated Benzamidine FF Hitrap column (GE Healthcare) and washed with 50 mM 
Tris-HCl pH 7.5, 0.5 M NaCl followed by 50 mM Tris-HCl pH 7.5, 1 M NaCl.  The protein 
was collected in the high salt wash and the salt reduced to 200 mM by dialysis.   
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2.2 Molecular Cloning 
Table 3  Plasmid DNA vectors 
Plasmid Source 
pGex-2T GE Healthcare 
pcDNA 3 and 3.1 Invitrogen 
pEGFP-C1 Clontech 
pCMVFlag4-SRPK1 (codes for N-
terminal flag tag (Sigma) 
(Bell et al., 2007) 
pcDNA HPV1 E1^E4 (Roberts et al., 1993) 
pcDNA HPV E1^E4 Δ44-48 (Roberts et al., 1994) 
pGex-2T HPV1 E1^E4 (Bell et al., 2007) 
pGex-3X HPV16 E1^E4 (Bell et al., 2007) 
pGex-3X HPV18 E1^E4 (Bell et al., 2007) 
pGex-2T HPV1 E1^E4 Δ44-48 (Bell et al., 2007) 
pGex-2T HPV1 E1^E4 Δ49-53 (Bell et al., 2007) 
pEGFP-ASF/SF2 A gift from Bettina Heinrich, University of Erlangen,  
pSG1aE2 A gift from Saleem Khan, University of Pittsburgh 
HPV 5b complete genome 
A gift from Ethel-Michele de Villiers, Deutches 
Krebsforshungszentrum 
HPV 8 complete genome 
A gift from Ethel-Michele de Villiers, Deutches 
Krebsforshungszentrum 
pRSET B-SRPK1 A gift from Bai-Gong Yue, University of Leicester 
 
2.2.1 Polymerase chain reaction (PCR) 
DNA for cloning was prepared by PCR amplification with specific primers (Table 4) using 
the Expand High Fidelity PCR system (Roche) or Taq polymerase (Roche).  The forward and 
reverse primers (25 pmol) (generated by AltaBiosciences) were mixed with 2 mM dNTPs 
(Roche), buffer (10 mM Tris-HCl pH 8.3, 1.5 mM MgCl2, 50 mM KCl), 1 µg of DNA 
template, 1 µl DMSO and 3.5 units of Expand or 5 units of Taq polymerase in a total volume 
of 100 µl.  Amplification was performed on a thermal cycler (2720 or 2700, Applied 
Materials and methods 
80 
Biosciences) using a 2 min 94°C hot start followed by 25 repeats of 94°C for 1 min, 55°C for 
30 s and 72°C for 3 min, followed by 7 min at 72°C before cooling to 4°C.  The PCR 
products were cleaned with High Pure PCR product Purification Kit (Roche) according to the 
manufacturer‟s instructions.  DNA was eluted from the column in 50 μl dH2O and stored at -
20°C.  
2.2.2 Restriction enzyme digestion 
PCR product (20 µl) or plasmid DNA (2-4 µg) was digested with 10 units of relevant 
restriction enzyme (Roche), in the provided appropriate buffers in a total volume of 40 µl.  
After 1 h at 37°C another 10 units of enzyme was added and the reaction continued at 37°C 
for a further hour.  Samples were purified using agarose gel electrophoresis and gel 
extraction. 
2.2.3 Calf Intestinal Phosphatase (CIP) treatment of plasmid DNA  
If necessary, the terminal 5‟ phosphate groups were removed from the digested products using 
CIP.  Digested products were mixed with 1 unit of alkaline phosphatase (Roche) and the 
dephosphorylation buffer (0.5 M Tris-HCl pH 8.5, 1 mM EDTA) in a total volume of 100 µl 
and incubated at 37°C for 15 min.  Samples were purified using agarose gel electrophoresis 
and gel extraction. 
2.2.4 Agarose gel electrophoresis  
For resolution of DNA samples, horizontal 1% (w/v) agarose gel (containing 0.25 mg/ml 
ethidium bromide) in TBE buffer (45 mM Tris, 45 mM Boric Acid, 1 mM EDTA).  The 
agarose solution was dissolved by boiling and cast in a Mini Sub-Cell GT electrophoresis tank 
(Bio-Rad) or a Fisherbrand HU13 horizontal electrophoresis tank (Fisher Scientific).  DNA 
samples were mixed with 6x Orange G Loading Buffer (4.4 mM Orange G, 10% v/v glycerol) 
prior to loading.  Small gels were run at 80V and larger gels run at 120V for 1 h in TBE 
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buffer and DNA bands visualised with a Gene Flash UV light box (Syngene Bio Imaging).  A 
1 kb plus DNA ladder
TM
 (Invitrogen) was run on each gel for size determination.   
To purify the DNA from the gel, bands of the expected sizes were excised using a clean 
scalpel upon UV illumination and purified from the gel using QIAquick Gel Extraction kit 
(Qiagen) according to the manufacturer‟s instructions.  The DNA was eluted from the column 
into 30 μl dH2O and stored at -20°C.  
2.2.5 DNA ligation reactions 
The prepared vector DNA and PCR product were mixed together in a ratio of 1:3, estimated 
via band intensity on an agarose gel, with 1 unit of T4 DNA ligase (Roche) and ligase buffer 
(660 mM Tris-HCl pH 7.5, 50 mM MgCl2, 10 mM dithioerythritol, 10 mM ATP) in a total 
volume of 10 μl, and the reaction was carried out at 16°C overnight.  
2.2.6 Cloning of DNA into a GST plasmid vector 
The coding sequence of the protein shown in table 4 was amplified by PCR using the shown 
primers and following PCR purification digested using the shown restriction enzymes and 
ligated into the pGex-2T vector which had been digested with the same enzymes.  
2.2.7 Generation of HA-tagged pcDNAs 
To allow expression and identification of proteins in mammalian cells a HA-tagged pcDNA 
vector was created.  A cassette containing the multiple cloning region and the sequence of the 
HA tag was created using the following primers: 5‟ primer 5‟-AG CTT ATG TAC CCA TAC 
GAT GTT CCA GAT TAC GCT GGA TCC CCG GGA ATT CC-3‟ and 3‟ primer 5‟-TCG 
AGG AAT TCC CGG GGA TCC AGC GTA ATC TGG AAC ATC GTA TGG GTA CAT 
A-3‟.  The primers were re-suspended to 100 μM and 10 μl of each primer was mixed 
together with 2 μl of Roche buffer M and heated to 95°C for 2 min then cooled very slowly to 
Materials and methods 
82 
room temperature.  The cassette was diluted to 50 nM and then 5 μl of the mix was ligated 
into 100 ng of pcDNA3 vector digested with HindIII and XhoI.  
The various cDNAs were removed from the pGex-2T constructs following digestion with the 
same enzymes used to clone.  The inserts were then ligated into the pcDNA3-HA vector 
digested with the same restriction enzymes.   
2.2.8 PCR sequencing 
Plasmid DNA (1 μg) was mixed with 2.5 pmol primer, 1 μl BigDye® terminator v.3.1 ready 
reaction mix (Applied Biosystems) and relevant buffer in a total volume of 20 μl.  Reaction 
was carried out with 25 cycles of 96°C for 10 s, 50°C for 5 s and 60°C for 4 min on a thermal 
cycler.  The sequencing primers used are listed in Table 5, and were generated by 
AltaBiosciences.  The DNA was precipitated with 5 μl 125 mM EDTA and 60 μl 100% 
ethanol at room temperature for 15 min, and the sample centrifuged at 16100 x g for 45 min at 
4°C.  The supernatant was removed and the pellet washed in 70 μl 70% ethanol, the sample 
was then centrifuged at 16100 x g for 15 min at 4°C.  The supernatant was removed and the 
pellet air dried and re-suspended in 10 μl HiDi Formamide (Applied Biosystems).  The DNA 
was run in a 3130xl ABI Prism
TM
 DNA capillary sequencer (Applied Biosystems).  
Sequencing data was collected using the 3130 data collection software version 3.0 and was 
analysed using FinchTV Version 1.4.0 (Geospiza) 
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Table 4 Primers, template DNA and enzymes used for cloning 
Protein  Primer Template 
Restriction 
enzyme 
ASF/SF2  
5‟ 
5‟ GCG CGG ATC CAT GTC GGG AGG TGG 
TGT GAT TCG TG 3‟ pEGFP-
ASF/SF2 
BamHI 
3‟ 
5‟ GCG CGG ATC CTT ATG TAC GAG AGC 
GAG ATC TGC T 3‟ 
9G8  
5‟ 
5‟ GCG CGG ATC CAT GTC GCG TTA CGG 
GCG GTA C 3‟ IMAGE: 
2967417 
BamHI 
3‟ 
5‟ GCG CGG ATC CTC AGT CCA TTC TTT 
CAG GAC T 3‟ 
SRp20  
5‟ 
5‟ GCG CGG ATC CAT GCA TCG TGA TTC 
CTG TCC 3‟ IMAGE: 
3049167 
BamHI and 
EcoRI 
3‟ 
5‟ GCG CGA ATT CCT ATT TCC TTT CAT TTG 
ACC TAG 3‟ 
SRp75  
5‟ 
5‟ GCG CGG ATC CAT GCC GCG GGT GTA 
CAT CGG C 3‟ IMAGE: 
3619538 
BamHI and 
EcoRI 
3‟ 
5‟ GCG CGA ATT CTT AGG ACC TTG AGT 
GGG ACC 3‟ 
SC35  
5‟ 
5‟ GCG CGG ATC CAT GAG CTA CGG CCG 
CCC CCC TC 3‟ IMAGE: 
5926371 
BamHI and 
EcoRI 
3‟ 
5‟ GCG CGA ATT CTT AAG AGG ACA CCG 
CTC CTT C 3‟ 
HPV1 E2  
5‟ 
5‟ GCG CGA ATT CAT ATG GAA AAC CTC 
AGC AGT CGC 3‟ 
pSG1aE2 EcoRI 
3‟ 
5‟ GCG CGA ATT CTT AAG ACC CAT TAA 
ACT GTC C 3‟ 
HPV1  
E2 H  
5‟ 
5‟ GCG CGA ATT CAT GTT ATG TCT TCC 
ACT AGC TCC 3‟ 
pSG1aE2 EcoRI 
3‟ 
5‟ GCG CGA ATT CTT ATA CAC AGA CCA 
CGG GTG G 3‟ 
HPV5 E2  
5‟ 
5‟ GCG CGG ATC CAT GGA GAA TCT CAG 
CGA GCG 3‟ 
HPV5b 
complete 
genome 
BamHI and 
EcoRI 
3‟ 
5‟ GCG CGA ATT CTT AAA GAC TGT CCA 
GGT TGC C 3‟ 
HPV5  
E2 H 
5‟ 
5‟ GCG CGG ATC CGT CAC CAG CTC CAC 
GCC TCC 3‟ 
HPV5b 
complete  
genome 
BamHI and 
EcoRI 
3‟ 
5‟ GCG CGA ATT CTT ATT TGA CAA TGA 
TTA CTG G 3‟ 
HPV8 E2  
5‟ 
5‟ GCG CGG ATC CAT GGA GAA TCT CAG 
CGA GCG TTT C 3‟ 
HPV8 
complete 
genome 
BamHI and 
EcoRI 
3‟ 
5‟ GCG CGA ATT CTT ATA GAC TGT CCA 
GGT TAC C 3‟ 
HPV8  
E2 H  
5‟ 
5‟ GCG CGG ATC CAC TGT GTT TGC TCC 
TGT TAC C 3‟ 
HPV8 
complete 
genome 
BamHI and 
EcoRI 
3‟ 
5‟ GCG CGA ATT CTT ATC GAA CCA ATA 
TTA CTG G 3‟ 
HPV5 
E1^E4  
5‟ 
5‟ GCG CGA ATT CAT ACG GAT CCT AAT 
CCT AAA GCT CCA CGC CTC CAG GGT C 3‟ pGex-2T  
HPV5 E2 
EcoRI 
3‟ 
5‟ GCG CGA ATT CTT ACT GGG GGG TCG 
CGA GCT TCT TCC 3‟ 
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Table 5 Sequencing primers 
Primer Direction Primer Sequence 
pGex-2T 
F 5‟ TTG AAG CTA TCC CAC AAA TTG 3‟ 
R 5‟ CAC CCG CCA ACA CCC GCT GAC 3‟ 
T7 F 5‟ TAA TAC GAC TCA CTA TAG GG 3‟ 
BGH R 5‟ CTG TGA ATG CTG TGG CAG GGG 3‟ 
ASF 261F 5‟ CTT CGT TGA GTT CGA GGA CC 3‟ 
SRp75 
371F 5‟ GGC CGA GAT AAA TAT GGC CC 3‟ 
1222R 5‟ CTC ACT CTT GCT GCG GCT GC 3‟ 
 
2.3 Protein Biochemistry 
2.3.1 Bradford Assay for protein concentration determination  
Protein concentration was determined using the Bradford method using a Bio Photometer 
(Eppendorf).  A calibration curve was made using 0, 4, 8, 16 and 20 μg of 1 mg/ml BSA in 1 
ml of 1:4 diluted protein assay reagent (Bio-Rad).  A known amount (1-5 μl) of the protein 
samples were then added to the reagent and the concentration determined. 
2.3.2 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Protein samples were resolved on 10-12.5% polyacrylamide separating gels (375 mM Tris-
HCl pH 8.8, 10-12.5% (w/v) acrylamide (Protogel, National diagnostics), 0.1% (w/v) SDS, 
polymerised with 0.04% (w/v) ammonium persulphate (APS) and 0.08% (v/v) TEMED) 
according to method published (Laemmli, 1970).  To ensure a flat surface in order for the 
samples to enter the gel uniformly, a layer of isopropanol was added to the surface of the gel 
before it set.  A stacking gel (125 mM Tris-HCl pH 6.8, 4.5% (w/v) acrylamide, 0.1% (w/v) 
SDS, polymerised with 0.05% (w/v) APS and 0.125% (v/v) TEMED) was then poured on top 
of the resolving gel and the comb inserted.  The gels were run in running buffer (25 mM Tris-
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HCl, 192 mM glycine, 0.1% (w/v) SDS).  With small gels (Mini Protean
®
 3 cell, Bio-Rad) 
run at 150 V for 1-2 h and large gels (the Sturdier system, Amersham Biosciences) run at 53 
V overnight.   
Protein samples were mixed 1:1 with 2X Laemmli sample loading buffer (Bio-Rad or 125 
mM Tris-HCl pH 6.8, 2% (w/v) SDS, 9% (v/v) glycerol, 0.01% (w/v) bromophenol blue)  
supplemented with 5% (v/v) β-mercaptoethanol, and heated at 100°C for 5 min before loading 
onto the gel along with a protein marker ladder (Bio-Rad Precision Plus Protein Dual Colour 
or NEB Prestained protein marker, Broad range (7-175 kDa)).  Protein bands were stained 
using Bio-Safe Coomassie (Bio-Rad). 
2.3.3 Western blot analysis 
Resolved proteins were transferred to Biotrace
®
 NT nitrocellulose membrane (Pall Life 
Sciences) using a Trans-Blot
®
 Cell transfer tank (Bio-Rad) in transfer buffer (25 mM Tris-
HCl, 192 mM glycine, 20% (v/v) methanol) at 350 mA for 3.5 h or 15 V overnight.  The total 
protein transfer was visualised using ponceau stain (1% (w/v) Ponceau Red, 3% (w/v) 
trichloroacetic acid), which was removed with repeated washing with 0.2% (v/v) Tween-20 in 
PBS.  The membrane was blocked in 2% (w/v) dried skimmed milk in PBS for 1 h at room 
temperature or overnight at 4°C, for phospho-specific antibodies the membrane was blocked 
in 5% BSA in Tris-buffered saline (20 mM Tris-HCl pH 7.6, 138 mM NaCl) (TBS) for 1 h at 
room temperature.  Antibodies were diluted in 2% (w/v) dried skimmed milk in PBS or 1% 
BSA in TBS (dilutions shown in table 6).  The primary antibody was incubated for 1 h at 
room temperature or overnight at 4°C and the secondary antibody for 1 h at room 
temperature.  The membranes were washed with 0.2% Tween (v/v) in PBS for 1 h with 4 
changes of buffer after incubation with the primary and secondary antibodies.  Membranes 
were developed by enhanced chemiluminescence (Amersham
TM
 ECL
TM
 Western blotting 
detection reagents, GE Healthcare) and signal detected using autoradiography film. 
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Table 6 Antibody dilutions used in Western blotting 
Antibody Name Manufacturer Species Dilution 
Human anti SRPK1 (Clone 12) BD Transduction Labs Mouse 1:1000 
Anti-Splicing Factor 2 
(SF2/ASF) (Clone 103) 
Zymed Labs Mouse 1:1000 
HA.II Monoclonal Antibody 
(Anti-HA) (Clone 16B12) 
Covance Mouse 1:1000 
Anti-FLAG M2 Monoclonal 
Antibody 
Sigma Mouse 1:5000 
Anti-FLAG Polyclonal Sigma Rabbit 1:1000 
Monoclonal anti-polyHistidine Sigma Mouse 1:1000 
Anti-SR Proteins (1H4) (Clone 
1H4G7) 
Zymed Labs Mouse 1:1000 
Anti-SRPK2 (Clone 23) BD Transduction Labs Mouse 1:1000 
Anti-SFRS4 (SRp75) Sigma Rabbit 1:1000 
Anti-SFRS3 (SRp20) Sigma Rabbit 1:1000 
Splicing Factor SC-35 Sigma Mouse 1:1000 
Anti-GST Pharmacia Biotech Goat 1:1000 
4.37 (Anti-HPV1 E4) 
In house (Doorbar et al., 
1988) 
Mouse 1:150 
GAPDH Santa Cruz Mouse 1:1000 
Lamin A/C Santa Cruz Mouse 1:1000 
mAb104 (Anti-phospho RS 
domain) 
A gift from Sheila Graham, 
University of Glasgow 
Mouse Neat 
Anti-mouse IgG (whole 
molecule)-Peroxidase 
Sigma Goat 1:3000 
Polyclonal Swine Anti-Rabbit 
Immunoglobulins/HRP 
DAKO Swine 1:3000 
Anti-goat IgG (whole 
molecule)-Peroxidase 
Sigma Rabbit 1:3000 
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2.3.4 Densitometry 
Protein levels from Western blot films were analysed using a Scanning Densitometer GS-800 
(Bio-Rad) and quantified using the Quantity One 4.6.7 software (Bio-Rad) 
2.3.5 In vitro kinase assay 
In vitro kinase assays were carried out following the previously described method of 
Papoutsopoulou et al. (1999).  The reactions were performed in a buffer containing 25 mM 
Tris-HCl pH 7.5, 200 mM NaCl, 10 mM MgCl2 and 20 µM ATP.  Between 1 and 2 μg of 
recombinant His-SRPK1 along with 5 μCi [γ-32P] ATP (Perkin Elmer) was added to 1-25 μg 
of substrate protein (GST-SR, -E2 and -E1^E4 proteins).  For inhibition studies 1-10 μg of the 
inhibitory protein (GST and GST-E1^E4 proteins) or 10 or 50 μM of SRPIN340 (N4-[2-
Piperidino-5-(trifluoromethyl)phenyl]isonicotinamide, Maybridge) in DMSO was added to 
the reaction.  The reaction was incubated for 10-30 min at 30°C and the reactions stopped by 
the addition of 2X Laemmli loading buffer.  The samples were resolved by SDS-PAGE gel 
electrophoresis on gels containing 12.5% acrylamide and stained using Bio-Safe Coomassie 
(Bio-Rad).  The stained gels were dried down and exposed to autoradiography film.  Band 
intensities were quantified using a phosphorimager; gels were exposed to a Molecular 
Dynamics storage phosphor screen, then analysed using a Typhoon 8600 Variable mode 
imager and Molecular Dynamics ImageQuant Version 5.1.   
The amount of substrate protein and the length of incubation were optimised experimentally.  
2.3.6 Trichloroacetic acid (TCA) protein precipitation 
To quantify the amount of phosphate incorporated into the substrate proteins, trichloroacetic 
acid (TCA) protein precipitation was used to remove the unincorporated [γ-32P] ATP from the 
sample.  The kinase assay was carried out as described in section 2.3.4, but at the end of the 
reaction the sample was split into two aliquots.  One aliquot was prepared as described for 
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analysis by SDS-PAGE (section 2.3.4).  To the other aliquot, 20% (w/v) TCA and 0.2 mg 
bovine serum albumin (BSA) were added; the sample was vortexed and spun at 16100 x g for 
5 min.  The pellet was washed with 10% (w/v) TCA three times and then re-suspended in 
acetone and centrifuged at 16100 x g for 5 min.  The pellet was allowed to air dry and re-
suspended in scintillation cocktail (OptiPhase „HiSafe‟ 3, Perkin Elmer).  The amount of 
phosphate incorporated was determined using a scintillation counter (Packard Tri-Carb liquid 
scintillation counter) and calculated using the following equations  
pmol incorporated =        Scintillation count 
               Count 1 pmol gives 
 
Count 1 pmol gives =              1 μCi count            
                [
32
P] / specific activity 
 
1 μCi count determined by measuring the scintillation count of 1 μCi of radioisotope 
[
32
P] is concentration of radioisotope determined using Perkin Elmer decay calculator  
Specific activity of batch of radioisotope determined using Perkin Elmer decay calculator 
http://www.perkinelmer.co.uk/tools/RadCalculator 
2.3.7 In vitro co-precipitations 
2.3.7.1 GST “pull down” from lysates 
Co-precipitations were carried out using recombinantly expressed GST-proteins and His-
SRPK1, in E. coli lysis buffer (0.5% v/v Triton
®
 X-100 and Complete
TM
 protease inhibitors 
(Roche) in PBS).  The proteins were recombinantly expressed as section 2.1.5, and the GST-
tagged proteins were bound to glutathione agarose (Sigma) (washed in E. coli lysis buffer) for 
1 h at 4°C.  After washing in E. coli lysis buffer the glutathione agarose bound proteins were 
mixed with the His-SRPK1 lysate for 1 h at 4°C.  Following washing, the beads were re-
suspended in 2X Laemmli loading buffer, resolved by SDS-PAGE and analysed by Western 
blotting.  
Materials and methods 
89 
2.3.7.2 GST “pull-down” using purified proteins 
Co-precipitations were carried out using recombinantly expressed GST proteins and His-
SRPK1, in a buffer containing 25 mM Tris-HCl pH 7.5, 200 mM NaCl, 10 mM MgCl2 and 20 
μM ATP.  The GST-tagged proteins (10-50 μg) were purified as described in section 2.1.5.3 
and then bound to glutathione agarose beads, washed and incubated with His-tagged SRPK1 
for 2 h at 4°C.  To “pull-downs” containing GST-ASF/SF2; HPV1 E1^E4 (10 μg), SRPIN340 
(5 μM) and Staurosporine (5 μM) were added.  Following washing the beads were re-
suspended in 2X Laemmli loading buffer, resolved by SDS-PAGE and analysed by Western 
blotting. 
2.3.8 Biacore® Surface Plasmon Resonance 
Surface Plasmon resonance was performed on a Biacore
®
 3000 and analysed using 
BIAevaluation version 3.1.   
2.3.8.1 His-SRPK1 on a NTA chip 
Two micrograms of purified His-tagged SRPK1 was bound to a nickel primer nitrilotriacetic 
acid (NTA) chip (GE Healthcare) by nickel chelation in HBS-EP (10 mM HEPES pH 7.4, 
150 mM NaCl, 3 mM EDTA, 0.005% Surfactant P20) using a flow rate of 5 μl/min.  A His-
tagged control protein was obtained from Ben Wilcox (School of Cancer Sciences), and 2 μg 
was bound.  The quick-inject programme was used to flow 1 μg of GST-ASF/SF2 and 1 μg of 
GST-HPV1 E1^E4 over the relevant chambers.  The NTA surface was regenerated using 
EDTA regeneration solution (GE Healthcare). 
2.3.8.2 GST-chip 
A goat anti-GST antibody (GE Healthcare) was diluted to 30 μg/ml in immobilisation buffer 
(10 mM sodium acetate pH 5.0), and then following EDC/NHS (1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride/N-hydroxysulfosuccinimide) activation of 
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the CM5 chip, the goat anti-GST antibody was amine-coupled onto the activated surface.  The 
surface was then deactivated with 1 M ethanolamine HCl pH 8.5 and regenerated with 10 mM 
glycine-HCl pH 2.2.  Once the anti-GST surface was ready, 3.5 μg of GST, 1.2 μg of GST-
ASF/SF2 or 1.4 μg of GST-HPV1 E1^E4 were bound to the surface in 25 mM Tris-HCl pH 
7.5, 200 mM NaCl with a flow rate of 5 μl/min.  His-SRPK1 was then flowed over the 
chambers in 25 mM Tris-HCl pH 7.5, 200 mM NaCl, or in 25 mM Tris-HCl pH 7.5, 200 mM 
NaCl, 2 mM MgCl2 and 1 mM ATP, for 5 min and 15 min at 5 μl/min.   
2.3.8.3 Amine-coupling of the proteins directly to the CM5 chip 
To determine the binding conditions, the proteins were flowed over the chamber until a 
characteristic binding pattern was observed and this was performed at a pH lower than the pI 
of the protein.  GST-ASF/SF2 was diluted to 50 μg/ml in 10 mM sodium borate pH 7.9, 10 
mM sodium acetate pH 5.5 or 10 mM sodium acetate pH 5.0 and passed through the chamber 
until binding was observed at pH 5.0.  His-SRPK1 was diluted to 10 μg/ml in 10 mM sodium 
acetate pH 5.0, 10 mM sodium acetate pH 4.5 or 10 mM sodium acetate pH 4.0 and passed 
through a different chamber until binding was observed at pH 4.0.  His-SRPK1 was also 
diluted in the presence of 1 mM ATP and 2 mM MgCl2 in 10 mM sodium acetate pH 5.0 or 
10 mM sodium acetate pH 5.5 and passed through a chamber until binding was observed at 
pH 5.0.  The chip was then regenerated with 10 mM glycine-HCl pH 2.2 before further use. 
The CM5 chip was activated by EDC/NHS and 50 μg/ml GST-ASF/SF2 in 10 mM sodium 
acetate pH 5.0 was amine coupled onto the chip, followed by 1 M ethanolamine deactivation.  
For His-SRPK1, the protein was diluted to 10 μg/ml in 10 mM sodium acetate pH 4.0, or 10 
mM sodium acetate pH 5.0, 2 mM MgCl2, 1 mM ATP for the amine coupling step.   
GST-ASF/SF2 (1 μg) was passed through the chambers in 10 mM HEPES pH 7.5, 150 mM 
NaCl, followed by 1 μg of His-SRPK1, and then by 1, 2 and 5 μg of GST-HPV1 E1^E4.  For 
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the His-SRPK1 bound in the presence of MgCl2 and ATP, 5 μg of GST-ASF/SF2 was used, 
and 5 and 20 μg of GST-HPV1 E1^E4 were passed through the chamber.  The flow rate was 5 
μl/min and the binding interactions carried out at 4°C.   
2.3.9 Statistical analysis 
The significance of the results was calculated using a two-tailed Student‟s t-test, when the raw 
data was compared or a two-tailed Welch‟s t-test when the data was normalised.  A result was 
considered significant when p was less than 0.05. 
 
2.4 Mammalian cell culture 
2.4.1 Cell lines and growth media 
Table 7 Cell lines used in this study 
Cell line Cell type 
HeLa Cervical adenocarcinoma derived cell line, contains integrated HPV18 genomes  
COS-1 Simian virus 40 (SV40)-immortalised African green monkey epithelial cell line  
SVJD SV40-immortalised human epidermal keratinocytes (Roberts et al., 1993) 
HEK 293 Adenovirus 5 transformed human embryonic kidney cell line 
H1299 Non-small lung carcinoma derived cell line 
 
The cell lines COS-1, HeLa, HEK 293 and H1299 were all cultured in Dulbecco‟s modified 
Eagle medium (DMEM) HEPES modification (Sigma-Aldrich) supplemented with 4 mM 
glutamine and 10% (v/v) foetal calf serum.  SV40-immortalized human epidermal 
keratinocytes (SVJD) were grown in Minimum Essential Medium Jocklik modification 
(Sigma-Aldrich), supplemented with 4 mM glutamine and 10% (v/v) foetal calf serum.  Cells 
were kept at 37°C, 5.0% CO2 in an incubator and were routinely grown in 75 cm
3
 flasks 
(Iwaki) or 10 cm tissue culture dishes (Iwaki).   
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2.4.2 Passaging of cells 
The cells were harvested once they reached about 80% confluency, the media was removed 
and the cells washed with PBS.  The cells were removed from the dish using 0.05% trypsin 
EDTA (Gibco-Invitrogen) with gentle tapping over a 5 min incubation at 37°C, the adhesion 
of the cells was monitored frequently under a microscope.  The trypsin was neutralised by 
addition of the appropriate growth media.  The cells were counted in a haemocytometer and 
seeded out at the required density for experimentation.  
2.4.3 Freezing and thawing of cells 
Cells were grown to 70-80% confluency before freezing and were harvested as described in 
section 2.3.2.  Following counting the cells were re-suspended to a concentration of 2 x 10
6
 
cells/ml in 85% (v/v) FBS, 15% DMSO.  Cells were transferred in 1 ml aliquots to Nunc 
cryovials (Nalgene-Nunc) and stored at -80°C in Nalgene
®
 Mr Frosty, a slow-cool freezing 
chamber with isopropanol (Nalgene Nunc) for 16 h before being transferred to liquid nitrogen 
for long term storage. 
To defrost the cells, the cryovials were removed from liquid nitrogen and thawed at 37°C for 
1 min.  The cells were transferred using a transfer pipette into a 22.5 ml universal tube and 10 
ml of growth media added drop-wise, before centrifugation at 538 x g for 5 min.  The cells 
were then re-suspended in 10 ml of the appropriate media and grown in the appropriate tissue 
culture vessel. 
2.4.4 Transfection in 6 well plates 
Cells were seeded out at 3 x 10
5
 cells per well of a 6-well plate (Iwaki) and grown to 80% 
confluence.  The cells were transfected with 3 μg DNA and LipofectamineTM 2000 (2 μl/μg 
DNA transfected) (Invitrogen) reagent or Lipofectamine
TM
 LTX (1.5 μl/μg DNA) 
(Invitrogen) with PLUS reagent (1 μl/μg DNA) in 500 μl Opti-mem® (Invitrogen) according 
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to the manufacturer‟s instructions.  The cells were flooded after 4 h with the appropriate 
growth media and harvested after 48 h with various methods.   
2.4.5 Harvesting of cells and protein extraction 
Cells were harvested from dishes using trypsin treatment.  Following neutralisation of the 
trypsin, the cells were pelleted by centrifugation at 538 x g for 5 min before being washed in 
PBS and re-pelleted twice.  The pellet was then re-suspended in UTB (8 M Urea, 25 mM 
Tris-HCl pH 8.0, 0.15 M β-mercaptoethanol) and incubated on ice for 20 min.  The lysate was 
sonicated for 20 s at 2 watts using a microson ultrasonic cell disrupter (Misonix) and the 
insoluble material removed by high speed centrifugation at 16100 x g for 10 min.  The 
proteins were analysed using a Bradford assay (2.3.1) before resolution by SDS PAGE 
(2.3.2).  
2.4.6 Immunofluorescence 
2.4.6.1 Transfection on slides 
Cells were seeded out at 3-5 x 10
4
 cells per spot on frosted multispot glass slides (Hendley-
Essex) and grown to 80% confluence.  The cells were transfected with 0.5-1 μg DNA per spot 
and Lipofectamine
TM
 2000 (2 μl/μg DNA) (Invitrogen) or LipofectamineTM LTX (1.5 μl/μg 
DNA) (Invitrogen) with PLUS reagent (1 μl/μg DNA) in 100 μl Opti-mem®, according to the 
manufacturer‟s instructions.  After 4 h the slides were flooded with 15 ml of the appropriate 
growth media. 
2.4.6.2 Fixation of cells 
 Cells were fixed 48 h after transfection; various fixation methods were used following a wash 
in ice-cold saline.  (a) Fixation with 4% paraformaldehyde in PBS for 5 min followed by two 
washes in PBS and permeabilisation in acetone at -20°C for 10 min. (b) A 30 s pre-wash in 
0.1% Triton
®
 X-100 (Sigma) in PBS followed by fixation with 4% paraformaldehyde for 5 
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min and permeabilisation in acetone (-20°C) for 10 min.  For both fixation methods, slides 
were then air-dried and stored wrapped in aluminium foil at -20 C.  
2.4.6.3 Immune-labelling 
Slides were immersed in blocking buffer (20% (v/v) HINGS, 0.1% (w/v) BSA in PBS) at 
room temperature for 30 min, the primary antibody, diluted in blocking buffer (dilutions 
shown in table 8) was applied and incubated at 37°C in a humidity chamber for 90 min.  After 
washing twice in PBS for 15 min, the secondary AlexaFluor
®
 dye conjugate (Molecular 
Probes) were diluted 1:500 in blocking buffer and incubated for 45 min at 37°C.  The slides 
were washed twice in PBS for 15 min and then for a further 10 min with 4‟,6-diamidion-2-
phenylindole (DAPI, a nuclear stain) (Sigma-Aldrich) added to the wash buffer.  Slides were 
mounted on coverslips using a mounting media containing 2.5 % (w/v) 1,4-
Diazabicyclo[2.2.2]octane (DABCO, an anti-fade reagent) (Sigma-Aldrich) in 90% (v/v) 
glycerol and PBS, pH 6.8.  
2.4.6.4 Microscopy 
Epiflourescence microscopy was performed on a Nikon Eclipse E600 microscope and images 
were captured using Nikon DXM1200F digital camera.  Confocal microscopy was performed 
on a LSM 510 META confocal microscope (Zeiss) using multi-track imaging.  Images were 
assembled in Adobe Photoshop
®
 CS2. 
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Table 8 Dilutions for antibodies used in immunofluorescence 
Antibody Name Manufacturer Species Dilution 
Human anti-SRPK1 (Clone 
12) 
BD Transduction Labs Mouse IgG1 1:500 
Anti-Splicing Factor 2 
(SF2/ASF) (Clone 103) 
Zymed Labs Mouse IgG1 1:100 
HA.II Monoclonal Antibody 
anti-HA tag (Clone 16B12) 
Covance Mouse IgG1 1:1000 
Anti-FLAG M2 Monoclonal 
Antibody 
Sigma-Aldrich Mouse IgG1 1:200 
Anti-FLAG Polyclonal  Sigma-Aldrich Rabbit 1:200 
Anti-SR Proteins (1H4) 
(Clone 1H4G7) 
Zymed Labs Mouse IgG1 1:100 
Anti-β-Galactosidase, 
purified monoclonal 
Promega Mouse IgG2a 1:2000 
Splicing Factor SC-35 Sigma-Aldrich Mouse IgG1 1:2000 
4.37 (Anti-HPV1 E4) 
In house (Doorbar et al., 
1988) 
Mouse IgG2a 1:200 
R424 (Anti-HPV18 E4) 
In house (Wilson et al., 
2007) 
Rabbit 1:1000 
mAb104 (Anti-phospho RS 
domain) 
A gift from Sheila 
Graham, University of 
Glasgow 
Mouse IgM Neat 
AlexaFluor
®
 488 Goat anti-
mouse IgG 
Molecular Probes 
(Invitrogen) 
 1:500 
AlexaFluor
®
 488 Goat anti-
mouse IgG1 
Molecular Probes 
(Invitrogen) 
 1:500 
AlexaFluor
®
 594 Goat anti-
mouse IgG2a 
Molecular Probes 
(Invitrogen) 
 1:500 
AlexaFluor
®
 594 Goat anti-
rabbit IgG 
Molecular Probes 
(Invitrogen) 
 1:500 
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2.4.7 Immunoprecipitation 
Cells grown in six-well plates, transfected with the appropriate plasmids were washed with 
ice cold PBS and lysed in NP-40 buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% (v/v) 
NP40, Complete
TM
 protease inhibitors (Roche)) or RIPA buffer (50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton
®
 X-100, 
Complete
TM
 protease inhibitors) cells were harvested using a cell scraper.  Following 
incubation on ice for 10 min the lysate was cleared by centrifugation at 16100 x g for 10 min 
and an aliquot taken as a control sample.  The lysate was mixed with 0.5 - 2 µg of the relevant 
antibody for 1 h at 4°C and then 30 μl of a 50% slurry of protein G/A Sepharose was added 
and rotated at 4°C for 1 h.  The beads were washed 5 times with lysis buffer and re-suspended 
in 30 μl Laemmli buffer and boiled for 5 min. 
2.4.8 In vivo kinase assay 
Cells grown in six-well plates, transfected with the appropriate plasmids were washed with 
ice cold PBS and lysed in kinase lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% 
(v/v) Triton
®
 X-100, 1 mM PMSF, 5 mM DTT) cells were harvested using a cell scraper.  
Following incubation on ice for 30 min the lysate was cleared by centrifugation at 16100 x g 
for 30 min.  The supernatant was analysed by Bradford assay (2.3.1) and 1 mg of lysate was 
mixed with 1 µg of M2 (mouse anti-Flag) antibody or 200 µl of 4.37 (mouse anti-HPV1 E4) 
for 30 min at 4°C, then 50 µl of 50% slurry protein G Sepharose was added and rotated at 4°C 
for 1 h.  Beads were washed 2 times with kinase lysis buffer, then 2 times with 50 mM Tris-
HCl pH 7.5, 150 mM NaCl.  The beads were resuspended in 50 µl of 50 mM Tris-HCl pH 
7.5, 150 mM NaCl and had 1 µg GST-ASF/SF2 added, followed by 5 μCi [γ-32P] ATP 
(Perkin Elmer) in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM MgCl2 and 20 µM ATP.  
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Following 30 min at 30°C, the reaction was stopped by the addition of 50 µl 2 X Laemmli 
loading buffer and resolved by SDS PAGE.  Analysis was carried out as with 2.3.5. 
2.5 In vitro splicing assay 
2.5.1 Minigene constructs 
The minigene constructs were generously donated from other laboratories: The pCRXH 
construct which contains the 3‟ region of exon 3, exon 4 and 5‟ region of exon 5 of X16 
(Mouse SRp20) was donated by Peter Nielsen, Max Planck Institute for Immunobiology, 
Germany.  The pMTE1A construct which contains the Adenovirus E1A coding sequence was 
donated by Adrian Krainer, Cold Spring Harbor Laboratory, USA.  The primers used to 
amplify the minigenes are shown in table 9. 
Table 9 Minigene primers 
Minigene Primer Name Sequence 
pCRXH (X16) 
X16 Exon 3 F GAG ATG ATT ACC GCA GGA GGA GTC 
X16 Exon 5 R CTT CTC CTT CTT GGG GAT 
pMTE1A (E1A) 
E1A Exon 1 F GTT TTC TCC TCC GAG CCG CTC CGA 
E1A Exon 2 R CTC AGG CTC AGG TTC AGA CAC AGG 
 
2.5.2 Transfection, harvesting of DNA and reverse transcription 
Cells were transfected with 2 μg of the minigene plasmid and 1 μg of each of the possible 
effector plasmids, with 1.5 μl LipofectamineTM LTX per μg of DNA, and 1 μl PLUS reagent 
per μg of DNA.  After 48 h the cells were washed with PBS and harvested using the Qiagen 
RNeasy
®
 mini kit (Qiagen) according to the manufacturer‟s instructions.  Total RNA was 
eluted into 50 μl of RNase-free water (Qiagen) and the RNA concentration measured using a 
Nanodrop
TM
 2000 spectrophotometer (Thermo Scientific).  One microgram of RNA was 
Materials and methods 
98 
reverse transcribed using the Qiagen QuantiTect
®
 Reverse Transcription kit (Qiagen) 
according to the manufacturer‟s instructions (genomic DNA elimination: 2 min at 42°C, 
reverse transcription: 15 min at 42°C, then 3 min at 95°C) using a Thermal cycler (2720 or 
2700, Applied Biosystems).   
2.5.3 Radioactive PCR 
Two microlitres of the transcribed DNA was used as a template, using the primers in table 9, 
Taq polymerase, and 1 μCi of [α-32P] dCTP (Perkin Elmer) to amplify the minigene construct 
in a total volume of 50 μl.  The X16 minigene was amplified with an initial degradation at 
94°C for 2 min then 30 cycles of 94°C for 30 s, 55°C for 1 min and 72°C for 1 min followed 
by 72°C for 20 min, before cooling to 4°C.  The E1A minigene was amplified with an initial 
degradation at 94°C for 2 min, then 20 cycles of 94°C for 30 s, 65°C for 1 min, decreasing by 
0.5°C each cycle, and 72°C for 2 min, then 10 cycles of 94°C for 30 s, 55°C for 1 min and 
72°C for 2 min, followed by 72°C for 20 min before cooling to 4°C.   
2.5.4 Native polyacrylamide electrophoresis (PAGE) 
Ten microlitres of the PCR reaction was mixed with 5 μl FICOLL buffer (15% (w/v) 
FICOLL, 0.25% Bromophenol blue, 0.25% Orange G) and run on a native PAGE gel (10% 
(v/v) Protogel, 90 mM Tris, 90 mM boric Acid, 2 mM EDTA, 0.07% (w/v) APS, 0.08% 
TEMED) in TBE (90 mM Tris, 90 mM boric Acid, 2 mM EDTA) for 1 h at 125 V, a 1 kb 
plus DNA ladder (Invitrogen) was run on each gel for size determination.  The gels were 
washed in ethidium bromide solution (0.25 mg/ml) for 15 min and visualised on Gene Flash 
UV light box (Syngene Bio Imaging).  The gel was then dried down and exposed to 
autoradiography film.  Band intensities were quantified using a phosphorimager as described 
in section 2.3.5.  
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2.6 Human Foreskin Keratinocytes (HFKs) 
2.6.1 Maintenance of untransfected HFKs 
Primary human foreskin keratinocytes (HFKs) isolated “in house” from neonatal foreskin by 
Sally Roberts were grown in serum-free keratinocyte growth medium (Gibco-Invitrogen), 
with fresh media every 2 days.  Cells were grown in an incubator at 37°C and 5.0% CO2 and 
grown to no more than 80% confluency.  Cells were passaged by removing the media and 
washing with PBS, 2 ml of 0.05% trypsin-EDTA was then added and after 5 min at 37°C the 
trypsin was inactivated by 4 ml of trypsin neutralising solution (TNS, 0.25 mg/ml soybean 
trypsin inhibitor (Invitrogen) in PBS (magnesium and calcium free) pH 7.2).  The cells were 
transferred to a tube and the plate washed with 6 ml serum-free media, then centrifuged at 538 
x g for 5 min.  The cells were re-suspended in 10 ml serum-free media and counted before 
being seeded out at 2 x 10
5
 cells in a 10 cm tissue culture dish. 
2.6.2 Maintenance of HFKs containing HPV18 genomes 
HFKs containing HPV18 genomes were grown on irradiated J2-3T3 mouse fibroblasts in E-
medium. 
2.6.2.1 E-medium 
To make 2 litres of E-medium the following components were mixed: 1200 ml DMEM 
HEPES modification, 640 ml Ham‟s F-12, 20 ml of 100 X cocktail (described below), 10 ml 
of 100 X Penicillin/Streptomycin (PAA Laboratories), 100 ml Foetal Bovine Serum (FBS, 5% 
(v/v)), 2 ml 1000 X Cholera toxin (ICN Biomedical) and 2 ml 1000 X Hydrocortisone 
(Sigma-Aldrich). 
To make 200 ml of 100 X cocktail the following components were mixed: 20 ml 0.18 M 
Adenine (Sigma-Aldrich, 0.486 g in 15 ml H2O with addition of 10 M HCl until dissolved, 
then addition of 5 ml H2O), 20 ml 5 mg/ml Insulin (Sigma-Aldrich, 0.1 g added to 20 ml 0.1 
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M HCl), 20 ml 5 mg/ml transferin (Sigma-Aldrich, 0.1 g added to 20 ml PBS), 20 ml 2 x 10
-8
 
M 3,3‟,5-Triiodo-L-thyronine (T3) in PBS (Sigma-Aldrich, 13.6 g added to 100 ml 0.02 M 
NaOH to make 2 x 10
-4
 M T3 further diluted in PBS to make 2 x 10
-8
 M).  The 100 X cocktail 
mix was filter sterilised and frozen prior to use. 
Following mixing, E-medium was filter sterilised and stored at 4°C in the dark.  Immediately 
prior to use the media was supplemented with 4 mM L-glutamine and 5 ng/ml epidermal 
growth factor (EGF, BD Biosciences).  E-medium was prepared by Craig Delury. 
2.6.2.2 Maintenance and irradiation of J2-3T3 mouse fibroblasts 
J2-3T3 mouse fibroblasts were routinely grown in Dulbecco‟s Modified Eagle Medium 
(DMEM) HEPES modification (Sigma-Aldrich) supplemented with 10% (v/v) new born 
bovine serum and 4 mM L-glutamine, in 10 cm tissue culture dishes (Iwaki).  When the J2-
3T3 cells were required as feeder cells, they were harvested and re-suspended in E-medium at 
2 x 10
6
 cells/ml in a 50 ml tube.  Cells were irradiated using 50 Gray of a caesium-137 source.  
Irradiated J2-3T3s were plated out at 2 x 10
6
 cells per 10 cm dish in E-medium and allowed to 
settle for at least 2 h before addition of HFKs.  If not required within 24 h of irradiation, J2-
3T3 cells were stored in E-medium at 4°C for up to 3 days. 
2.6.2.3 Maintenance of transfected HFKs containing HPV18 genomes 
Cell lines established from HFKs transfected with HPV18 genomes were generated by Sally 
Roberts and Gillian Knight.  The cells were routinely grown on a feeder layer of irradiated J2-
3T3 fibroblasts in E-medium at 37°C and 5.0% CO2.  The media was replaced every 2 days 
and cells not allowed to reach more than 80% confluency.  The HPV18 genome containing 
cells were passaged by first removing the J2-3T3 feeder layer with 2 ml of warm 0.5 mM 
EDTA in PBS.  Once the feeder layers began to detach, a transfer pipette was used to aspirate 
the EDTA and remove the J2-3T3 cells.  The cells were washed with PBS and then removed 
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using 2 ml 0.05% Trypsin EDTA and incubation at 37°C for 5-10 min.  The trypsin was 
neutralised with 8 ml E-medium and a further 5 ml used to wash the dish.  The cells were 
centrifuged at 538 x g for 5 min and re-suspended in 10 ml E-medium.  The cells were plated 
out at 2 x 10
5
 cells on top of the irradiated J2-3T3 cells. 
2.6.3 SRPIN340 toxicology study 
Keratinocytes containing HPV18 genomes were grown on J2-3T3s seeded out in 6 well 
plates.  Once cells reached 50% confluency SRPIN340 (in DMSO) was added to the cells, 
using SRPIN340 concentrations of 0, 1, 5, 10, 25 and 40 μM.  Equivalent volumes of DMSO 
were added to the control wells.  After 48 h cells were harvested as described in 2.6.2.3 
except the original media was kept and added back to the trypsinised cells.  After 
centrifugation at 538 x g for 5 min, the cells were re-suspended in 1 ml of fresh media and a 
250 μl aliquot taken.  To the aliquot of cells, 0.4% trypan blue stain (Sigma-Aldrich) was 
added and incubated at room temperature for 5 min.  The total cells and the non-viable cells 
were counted using a haemocytometer.  The remaining cells were used for DNA analysis.  
2.6.4 Southern blot analysis 
2.6.4.1 Isolation of DNA 
The pelleted cells were washed in PBS and then re-suspended in 3 ml lysis buffer (400 mM 
NaCl, 10 mM Tris pH 7.4, 10 mM EDTA).  RNase A was added to a final concentration of 
400 μg/ml, the cell lysates were vortexed and put at 37°C for 30 min.  Proteinase K (Roche) 
was then added to a final concentration of 50 μg/ml, and SDS to 0.2% (w/v), before vortexing 
and incubation at 37°C overnight.  The cellular DNA was sheared by passing the lysate 
through a 20-gauge needle 10 times.  Phenol-chloroform extraction was performed by the 
addition of 6 ml phenol/chloroform/isoamyl alcohol (25:24:1) (Sigma-Aldrich) before 
inversion of the tube 8 times and centrifugation at 537 x g for 5 min.  The upper aqueous layer 
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was retained and the extraction repeated, before extraction with 6 ml chloroform/isoamyl 
alcohol (24:1).  The DNA was then precipitated by the addition of 2 volumes of ethanol and 
1/10
th
 volume of 3 M sodium acetate, followed by incubation at -80°C for 1 h, or -20°C 
overnight.  Following precipitation the samples were centrifuged at 537 x g for 30 min and 
the DNA pellet was washed twice with 70% ethanol.  The DNA was allowed to air dry for a 
few minutes before re-suspension in 20-100 μl TE buffer and incubated at 37°C for 5 min.  
The DNA yield was determined using the Nanodrop
TM
 spectrophotometer (Thermo Scientific) 
and samples stored at 4°C. 
2.6.4.2  Digestion of DNA for Southern blot analysis 
The extracted DNA was subjected to digestion with BglII (Biolabs) and DpnI (Roche), with 5 
μg of DNA being digested overnight at 37°C; this digests the expression plasmid and digests 
host genetic material without cutting the HPV18 genome.  The DNA was resolved on a 0.8% 
(w/v) agarose gel in TBE (90 mM Tris-HCl, 90 mM boric Acid, 2 mM EDTA) buffer 
overnight at 50 V in a Fisherbrand HU20 Horizontal electrophoresis tank.  To enable 
quantification of genome copy numbers, copy number standards were generated by digestion 
of pGEMII-HPV18 with EcoRI to release the HPV18 genome from the vector.  The 
equivalent of 5 and 50 genome copies per cell were used as copy number standards on the gel. 
2.6.4.3 Transfer of DNA from agarose gel to nylon membrane 
Once the agarose gel had run, the loading and digestion of the DNA was checked using a 
Gene Flash UV light box (Syngene Bio Imaging).  The gel was washed twice in 250 mM HCl 
for 30 min at room temperature with gentle agitation, before washing twice in 400 mM NaOH 
for 30 min.  To transfer the DNA to the nylon membrane, a tray was set up with 1 L of 400 
mM NaOH with a glass plate resting across the tray.  A 24 x 33 cm single sheet of 
Whatman
TM
 3 mm paper was soaked in 400 mM NaOH and laid across the glass plate with 
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both ends submerged in the NaOH.  The bubbles were removed by rolling a pipette across and 
3 more layers of 24 x 33 cm Whatman
TM
 paper were placed on top in the same manner.  The 
agarose gel was placed on top of the paper layers with the loading wells facing downwards 
and the bubbles removed with a pipette.  A 20 x 22.5 cm sheet of Gene Screen Plus nylon 
membrane (Perkin Elmer) was soaked in 400 mM NaOH and placed on top of the gel, 
followed by 4 layers of 21 x 23.5 cm Whatman
TM
 paper, placed on top one at a time with 
care.  Two stacks of absorbent paper towels were placed on top, covering the paper, ensuring 
there were no gaps between the stacks.  Another glass plate was placed on top of the towels 
and a weight centred on top.  Saran wrap was then placed between the top and bottom layers 
of Whatman
TM
 paper to ensure they were not in contact and the transfer was left overnight.  
The following day the position of the wells was marked onto the membrane and the DNA 
crosslinked to the membrane using a UV crosslinker (Stratalinker, Stratagene) on auto-
crosslink mode.  The membrane was soaked in SSC (600 mM sodium citrate, 300 mM NaCl 
pH 7.0) and stored at -20°C wrapped in saran wrap.   
2.6.4.4 Preparation of radiolabelled DNA probe 
To make the DNA probe the pGEMII-HPV18 plasmid was linearised by digestion with EcoRI 
and resolved on a 1% agarose gel.  The ~ 8 kb fragment HPV18 genome fragment was 
excised and purified by using the QIAquick Gel Extraction kit (Qiagen).  Fifty ng of the 
purified HPV18 linearised genome was diluted into 45 μl TE buffer and denatured by boiling 
at 95°C for 5 min followed by incubation on ice for 5 min.  The denatured DNA was then 
bound to Amersham
TM
 Ready-To-Go
TM
 DNA labelling beads (GE Healthcare) and 50 μCi [α-
32
P] dCTP (Perkin Elmer) added.  Following incubation at 37°C for 30 min, the radiolabelled 
probe was loaded onto a pre-prepared Illustra Probe Quant G-50 microcolumn (Amersham) 
and centrifuged at 801 x g for 2 min to remove unincorporated nucleotide.   
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2.6.4.5 Hybridisation of radiolabelled probe to immobilised DNA 
To make the hybridisation buffer: A 2 X hybridisation solution (20% (w/v) Dextran sulphate 
(USB), 10 X Denhardts (0.2% (w/v) Ficoll 400, 0.2% (w/v) Polyvinypyrolilone, 0.2% (w/v) 
BSA fraction V (Sigma-Aldrich)) and 5 X SSC (1.5 M sodium citrate, 750 mM NaCl pH 7.0)) 
was diluted 1:1 with deionised formamide and SDS (1% final concentration (w/v)) added.  
Salmon sperm DNA (200 μl of 10 mg/ml, Invitrogen) was denatured by boiling at 100°C for 
10 min followed by cooling in an ice/water slurry for 5 min and subsequently added to 10 ml 
of the hybridisation buffer to make the pre-hybridisation buffer.  The nylon membrane on 
which the DNA was immobilised was rolled with a sheet of mesh and placed into a 
hybridisation canister with the DNA side facing inwards.  The pre-hybridisation buffer was 
added to the canister and put in the hybridisation oven with rotation at 42°C for 1 h.  
Following the pre-hybridisation, hybridisation buffer containing the radiolabelled DNA probe 
was prepared by addition of the probe to 200 μl of 10 mg/ml salmon sperm DNA, followed by 
boiling at 100°C for 10 min, cooling in ice/water for 5 min and subsequent addition to 10 ml 
of hybridisation buffer.  The pre-hybridisation buffer was poured out of the canister and the 
hybridisation buffer containing the probe added the canister was incubated at 42°C with 
rotation overnight.   
2.6.4.6 Stringency washes 
Following removal from the hybridisation canister, the membrane was rinsed in buffer 1 (600 
mM sodium citrate, 300 mM NaCl, pH 7.0, 0.1% (w/v) SDS), using a sponge to wipe the 
surface of the membrane, before 2 x 15 min washes with agitation in the same buffer.  Further 
washes were 2 x 15 min with buffer 2 (150 mM sodium citrate, 75 mM NaCl, pH 7.0, 0.1% 
(w/v) SDS), then 2 x 15 min with buffer 3 (30 mM sodium citrate, 15 mM NaCl, pH 7.0, 
0.1% (w/v) SDS) and finally 15 min at 55°C with buffer 4 (30 mM sodium citrate, 15 mM 
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NaCl, pH 7.0, 1% (w/v) SDS).  The membrane was then wrapped in saran wrap and exposed 
to autoradiography film or a phosphorimager screen. 
2.6.5 Organotypic raft cultures 
Organotypic raft cultures were prepared on my behalf by Sally Roberts as described in Wilson 
and Laimins (2005)  Briefly 2 x 10
6
 keratinocytes (HFK or HPV18 genome containing 
keratinocytes) were grown on a collagen plug containing 2 x 10
6
 J2-3T3 fibroblasts.  After 
24-48 h the collagen plug was placed on top of a wire mesh to create an air/liquid interface 
with E-media –EGF.  The media was changed every 2 days and the rafts grown for 13 days.  
SRPIN340 (10 µM or 25 μM), or an equivalent amount of DMSO was added for the final 7 
days and added fresh when the media was changed.  The nucleotide analogue BrdU was 
added 12-15 h before harvest to identify nuclei containing synthesizing cellular DNA.  Rafts 
were harvested by flooding the dish with 10% (v/v) formaldehyde (36.5- 38%, Sigma) in 
DMEM and the rafts were embedded in paraffin prior to sectioning (Propath UK Ltd). 
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CHAPTER 3 INVESTIGATING THE EFFECT OF THE 
INTERACTION BETWEEN HPV E1^E4 AND SRPK1 ON 
THE PROTOTYPICAL SR PROTEIN ASF/SF2 
3.1 Introduction 
The phosphorylation of ASF/SF2 by SRPK1 controls protein-protein and protein-RNA 
interactions along with the localisation of ASF/SF2 and its functions in splicing.  This cellular 
kinase is a target of several unrelated viruses, including herpes simplex virus and Varicella-
Zoster virus (Ote et al., 2009, Sciabica et al., 2003), indicating that the modulation of SRPK1 
is beneficial for the life cycle of these viruses.   
GST-HPV1 E1^E4 was used to coprecipitate cellular proteins from lysates prepared from 
human keratinocytes and mass spectroscopical analysis identified SRPK1 as an interacting 
partner, further analysis confirmed that there is a direct interaction between the two proteins 
(Bell et al., 2007).  In keratinocytes SRPK1 colocalises to the cytoplasmic inclusion bodies 
formed by HPV1 E4.  This novel association has physiological significance since in natural 
HPV1 infections, SRPK1 is found to be present in the E4 inclusions formed in cells of the 
more superficial layers where the virus is amplifying the viral DNA and producing viral 
capsids.  The SRPK1 interaction is not confined to HPV1; the E1^E4 proteins of the mucosa-
tropic HPV types 16 and 18 interacted with the cellular kinase as well.  Two regions within 
HPV1 E1^E4 were identified as critical determinants in the interaction, the C-terminal E4 
oligomerisation domain and an arginine-rich sequence (GRPRR) that bears resemblance to 
the arginine-rich sequences present within SRPK1 substrates (R-X-R/K-X-X-X-R) and indeed 
HPV1 E1^E4 was a substrate for SRPK1 in vitro, although the phosphorylated sequences 
were not confirmed (Bell et al., 2007).  Of interest was the observation that in in vitro kinase 
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assays the interaction between HPV1 E1^E4 and SRPK1 also modulates SRPK1 
autophosphorylation and this was dependent upon SRPK1 binding by E1^E4 (Bell et al., 
2007).   
The inhibition, modulation or sequestration of SRPK1 by E1^E4 may affect the functions of 
some of the substrates of SRPK1.  SRPK1 has been shown to phosphorylate the lamin-B 
receptor (LBR) which interacts with B-type lamins and chromatin, the interaction with 
chromatin is dependent upon phosphorylation of RS repeats at the N-terminus (Takano et al., 
2002).  Inhibition of the phosphorylation of LBR may inhibit the attachment of LBR to 
chromatin and result in the loss of nuclear envelope integrity.  The sequestration of SRPK1 to 
E4 inclusion bodies is restricted to the upper layers of the warts, where virion assembly 
occurs; therefore destabilisation of the nuclear envelope in these cells may facilitate the egress 
of virions (Bell et al., 2007).  The regulation of HPV late gene expression is controlled by 
multiple cis-acting elements, including the major substrates of SRPK1, the SR proteins 
(McPhillips et al., 2004).  The modulation of SRPK1 by E1^E4 may impact on SR protein 
regulation of host and/or virus gene expression and splicing (Bell et al., 2007).  Additionally, 
there are viral proteins which are substrates for SRPK1, such as the HPV5 E2 protein which 
has multiple RS repeats in the hinge region (Lai et al., 1999).  SRPK1 may influence the 
functions of HPV5 E2 by modulating E2s ability to activate transcription and/or replication.  
Interestingly the E1^E4 protein of HPV16 has been shown to stabilise HPV16 E2 and also to 
promote E2s translocation to the nucleus, this demonstrates that E1^E4 may be acting to 
regulate the functions of E2 by controlling how much active E2 there is present in the nucleus 
(C. Davy et al., 2009).  
Besides HPV, other viruses interfere with SRPK1 and SR proteins, the ICP27 protein of 
herpes simplex virus (HSV)-1 plays multiple roles in post-transcriptional regulation and has 
been shown to interact with SR proteins, such as SRp20, this interaction occurs via the RRM 
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and not the RS domain (Sciabica et al., 2003).  Additionally, ICP27 can interact with SRPK1 
and cause its relocalisation to the nucleus.  In vitro, ICP27 is a substrate for SRPK1 and the 
interaction between ICP27 and the kinase causes the hypophosphorylation of SR proteins and 
consequently the downregulation of cellular pre-mRNA splicing (Sciabica et al., 2003).  
ICP27 has been shown to inhibit splicing before the conversion of the intermediate B complex 
into the catalytically active C complex (Bryant et al., 2001).  The result of ICP27 interacting 
with SRPK1 is to shut-off the splicing machinery and facilitate the export of the HSV-1 
intronless RNAs, along with host-protein synthesis shut-off.   
The Varicella-Zoster virus (VZV) immediate-early (IE) 4 protein acts as an important 
regulator of VZV and cellular gene expression and can directly interact with the SR proteins 
ASF/SF2, 9G8 and SRp20.  The VZV IE4 protein can also interact with and is a substrate for 
SRPK1 in vitro, however this interaction does not seem to cause any relocalisation of SRPK1 
nor alteration of the kinase activity (Ote et al., 2009).  Additionally, the IE4 protein has been 
shown to interact with the TAP/NXF1 export receptor and bind to RNA, together this data 
suggests that IE4 acts with the SR proteins to export intronless mRNA via TAP/NXF1 and the 
reimport of IE4 into the nucleus is dependent upon phosphorylation by SRPK1 in a similar 
manner to the shuttling SR proteins (Ote et al., 2009).   
The early region 4 (E4)-ORF4 protein of Adenovirus 5 can activate the dephosphorylation of 
SR proteins by interacting with the phosphatase PP2A, leading to the depression of IIIa 
splicing (Estmer Nilsson et al., 2001).  E4-ORF4 also interacts with the SR proteins ASF/SF2 
and SRp30c, which can bind to an intronic element of IIIa pre-mRNA and inhibit exon IIIa 
inclusion (Estmer Nilsson et al., 2001).  Interestingly, the interaction between E4-ORF4 and 
PP2A can induce HPV16 late gene expression and the production of L1 mRNA, this switch in 
splice site selection is dependent upon the phosphorylation state of ASF/SF2 (Somberg et al., 
2009).   
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The utilisation of host SR protein kinases during viral replication has led to the search for 
specific inhibitors of these kinases, the isonicotinamide compound SRPIN340 has been 
developed by Fukuhara et al. (2006), which specifically inhibits SRPK1 and SRPK2.  
Treatment of cells with this inhibitor has been shown to suppress the propagation of Sindbis 
virus, cytomegalovirus (CMV) and hepatitis C virus (HCV) (Fukuhara et al., 2006, Karakama 
et al., 2010).  SRPIN340 has been shown to affect the replication of a wide range of DNA and 
RNA viruses, suggesting that the SRPKs play an important role in the replication cycles of 
many viruses. 
Several different viruses have been shown to interact with or be dependent upon the activity 
of SRPK1, demonstrating the importance of SRPK1 in the life cycles of these infectious 
agents.  Additionally proteins from HSV-1 and Adenovirus have been shown to affect the 
phosphorylation status of the SR proteins.  This chapter examines the effect of the interaction 
between SRPK1 and the E1^E4 protein from multiple HPV types on SRPK1 kinase activity.  
The kinase activity of SRPK1 has been examined with in vitro kinase assays, using the 
prototypical SR protein ASF/SF2 as a substrate.   
 
3.2 Results 
3.2.1 Expression of GST-ASF/SF2 
In order to investigate how the interaction between SRPK1 and HPV E4 proteins affects the 
kinase activity of SRPK1 in vitro, the prototypical SR protein Alternative Splicing 
Factor/Splicing Factor 2 (ASF/SF2) was expressed recombinantly as a GST fusion protein.  
The coding sequence of ASF/SF2 was excised from a plasmid containing the ASF/SF2 cDNA 
(pEGFP-ASF/SF2) by BamHI digestion and ligated into the complementarily digested GST 
vector pGex-2T to form pGex-2T-ASF/SF2. E. coli BL21-CodonPlus
®
 cells were transformed 
with pGex-2T-ASF/SF2 and used to express the GST-ASF/SF2 protein.    
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Figure 3.1  Expression of GST-ASF/SF2.  Coomassie stained gel of increasing 
amounts of purified protein (0.5, 2.5 and 5 µg) and an anti-GST Western blot with 2.5 µg 
protein loaded, showing a doublet of approximately 50 kDa (expected size of GST-
ASF/SF2 is 56 kDa). 
Chapter 3 
111 
The product migrated as a doublet of approximately 50 kDa (expected molecular mass of 56 
kDa); this doublet was recognised by an anti-GST antibody (Figure 3.1) and an anti-ASF/SF2 
antibody (data not shown).   
3.2.2 GST-ASF/SF2 is a substrate for His-SRPK1 
Initial experiments were carried out to show that the GST-ASF/SF2 could be phosphorylated 
by the recombinantly expressed His-tagged SRPK1 in vitro.  In vitro kinase assays were 
carried out in the presence and absence of 
32
P labelled ATP.  GST-ASF/SF2 was added to the 
in vitro kinase assay with or without His-SRPK1 and GST was also included with His-SRPK1 
as a control.  The resolved gel containing 
32
P labelled ATP was exposed to X-ray film (Figure 
3.2A), and the gel without 
32
P was Western blotted with a phospho-specific antibody against 
the phosphorylated RS domain of SR proteins, 1H4 (Figure 3.2B).  Both methods identified a 
band corresponding to phosphorylated GST-ASF/SF2 only in the presence of the SRPK1 
kinase, indicating that the recombinantly expressed GST-ASF/SF2 was a substrate in vitro for 
His-SRPK1.  GST was not a substrate for His-SRPK1.   
Once GST-ASF/SF2 had been established as a substrate for His-SRPK1 in vitro, the kinase 
assay conditions were optimised.  In the first instance the optimum incubation time was 
determined.  Experiments were carried out for increasing lengths of time, ranging from 0.5 to 
60 min, with all other conditions remaining constant (Figure 3.3).  The phosphorylation levels 
were determined by phosphorimager analysis of the radiolabelled gel.  Consistently 50% of 
the total phosphorylation of GST-ASF/SF2 occurred after 10 min.   Subsequent in vitro kinase 
assays were therefore carried out for either 10 or 30 min. 
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Figure 3.2  Phosphorylation of GST-ASF/SF2 by His-SRPK1.  An in vitro kinase 
assay with 8 µg GST-ASF/SF2 in the presence or absence of 1 µg His-SRPK1. (A) 
Radiolabelled 
32
P autoradiograph with band corresponding to phosphorylated GST-
ASF/SF2 only in the presence of His-SRPK1. (B) Using the antibody 1H4 specific for 
the phosphorylated RS domain of SR proteins in a Western blot, a band corresponding to 
GST-ASF/SF2 was detected only in the presence of His-SRPK1.   
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Figure 3.3  SRPK1 kinase assay time course.  The kinase assays were carried out for 
increasing amounts of time and the level of labelled ATP incorporated into GST-
ASF/SF2 (5 µg) was measured by phosphorimager analysis, 1 µg of His-SRPK1 was 
used.  The data shown is representative of three data sets. 
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In order to ensure that the amount of His-SRPK1 was not limiting the level of 
phosphorylation of GST-ASF/SF2 in the assay, an in vitro kinase assay was carried in which 
the amount of GST-ASF/SF2 added was titrated from 17.5 to 0.007 μg (Figure 3.4).  The 
level of phosphorylation was very similar with 17.5 and 14 μg of the substrate but decreased 
to 50% with 10.5 μg indicating that His-SRPK1 is in excess in this assay.  Thus, between 10 
and 12 μg of GST-ASF/SF2 will be used in successive kinase assays, when 2 µg of His-
SRPK1 is used.   
 
3.3 HPV1 E1^E4 inhibits SRPK1 phosphorylation of ASF/SF2 
3.3.1 HPV1 E1^E4 interacts with SRPK1 
To confirm that the recombinantly expressed proteins prepared for these studies interact as 
previously reported by this laboratory (Bell et al., 2007), GST-HPV1 E1^E4 bound to 
glutathione agarose beads was mixed with a bacterial lysate containing His-SRPK1.  
Following a brief incubation at 4°C for 1 h and washing of the beads, the proteins bound to 
the beads were resolved by SDS-PAGE and Western blotted with an anti-His antibody.  GST-
ASF/SF2 was used as a positive control and GST used to control for non-specific interactions.  
Figure 3.5 shows that GST-HPV1 E1^E4 coprecipitates His-SRPK1 to a similar level as the 
cellular substrate GST-ASF/SF2 and no interaction is seen with the GST protein.   
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Figure 3.4  Titration of GST-ASF/SF2 into an in vitro kinase assay.  An in vitro 
kinase assay with decreasing amounts of GST-ASF/SF2 (17.5, 14, 10.5, 7, 3.5, 0.7, 0.35, 
0.07. 0.035 and 0.007 µg) and 2 µg His-SRPK1.  The level of 
32
P-ATP incorporated into 
the gel was measured by phosphorimager analysis and used to calculate the percentage of 
phosphorylation normalised to the maximum amount of GST-ASF/SF2.  The graph 
shown contains the mean from two independent experiments. 
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Figure 3.5  GST-HPV1 E1^E4 binds to His-SRPK1.  Approximately 10 µg of GST-
HPV1 E1^E4, GST-ASF/SF2 and GST were bound to glutathione agarose beads and 
mixed with bacterial lysate containing His-SRPK1.  Western blotting for the His-tag 
revealed that GST-HPV1 E1^E4 and GST-ASF/SF2 coprecipitated equivalent amounts 
of His-SRPK1.  GST proteins shown by Coomassie stain. 
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3.3.2 Inhibition of SRPK1 phosphorylation of ASF/SF2 
Comparable levels of SRPK1 were coprecipitated by HPV1 E1^E4 and ASF/SF2.  Therefore, 
to determine if the interaction with the E1^E4 protein has any effect on SRPK1 kinase 
activity, GST-HPV1 E1^E4 or GST were added in increasing amounts into an in vitro kinase 
assay in the presence of GST-ASF/SF2 and His-SRPK1.  The level of phosphate incorporated 
into the ASF/SF2 protein was measured by using trichloroacetic acid (TCA) protein 
precipitation and scintillation counting of the precipitate, as described in Chapter 2 (Section 
2.3.6).  With increasing amounts of GST-HPV1 E1^E4 added to the in vitro kinase assay the 
level of phosphate incorporated into GST-ASF/SF2 decreased (Figure 3.6).  No variation of 
phosphate incorporation occurred in the presence of the GST protein.  At the maximum 
amount of GST-HPV1 E1^E4 added the phosphate incorporated into ASF/SF2 is reduced by 
65% compared to an equivalent amount of GST (p = 0.0002).  This data indicated that the 
GST-tagged HPV1 E1^E4 is a potent inhibitor of GST-ASF/SF2 phosphorylation by His-
SRPK1.  
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Figure 3.6 GST-HPV1 E1^E4 inhibits GST-ASF/SF2 phosphorylation by His-
SRPK1.  GST (0.3, 0.6, 1.2, 2.5, 5 or 10 µg) or GST-HPV1 E1^E4 (0.15, 0.3, 0.6, 1.2, 
2.5 or 5 µg) was added in increasing amounts to an in vitro kinase assay containing 1 µg 
GST-ASF/SF2 and 1 µg His-SRPK1.  (A) 
32
P autoradiograph and Coomassie stained gel.  
Lane (a) contains only GST-ASF/SF2 and His-SRPK1; lane (b) contains only GST-
ASF/SF2.  (B) Bar graph showing the percentage of phosphorylation normalised to assay 
minus GST or GST HPV1 E1^E4 (lane (a)).  The data shown were collected from three 
independent experimental replicates.  
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3.3.3 Inhibition is dependent on the interaction between SRPK1 and 
HPV1 E1^E4 
To confirm that the inhibition of SRPK1 kinase activity by HPV1 E1^E4 is dependent on an 
interaction between the two proteins, the inhibitory actions of two HPV1 deletion E1^E4 
mutants were tested.  The mutant protein Δ44-48 which has been shown to be a non-binder of 
SRPK1 and the deletion mutant Δ49-53 which retains SRPK1 binding activity (Bell et al., 
2007).  These mutants, expressed as GST-fusion proteins were included in an in vitro kinase 
assay with GST-ASF/SF2 and His-SRPK1 (Figure 3.7).  The non-binding deletion mutant 
Δ44-48 did not inhibit phosphorylation of GST-ASF/SF2 (p=0.18), whereas the binding 
mutant, Δ49-53, significantly (p=0.048) reduced the phosphorylation of ASF/SF2 when 
compared to phosphorylation in the presence of GST alone.   
3.3.4 Determination of the mode of inhibition of HPV1 E1^E4 
A selective inhibitor, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]isonicotinamide 
(SRPIN340) (Fukuhara et al., 2006) (Figure 3.8A) has been shown to inhibit two members of 
the SRPK family (SRPK1 and SRPK2).  To confirm that the recombinantly expressed His-
SRPK1 was able to respond to this inhibitor, SRPIN340 was added to an in vitro kinase assay 
with GST-ASF/SF2 and His-SRPK1.  As shown in Figure 3.8B, SRPIN340 is an effective 
inhibitor of His-SRPK1 mediated phosphorylation of the ASF/SF2 fusion protein, inhibiting 
the phosphorylation of this substrate by up to 70% when added at a concentration of 50 μM 
(Figure 3.8C).   
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Figure 3.7 HPV1 E1^E4 mediated inhibition of SRPK1 activity is dependent on an 
interaction with E1^E4.   GST-HPV1 E1^E4 deletion mutants, Δ44-48 (non-binding 
mutant, 3 µg) and Δ49-53 (a binding mutant, 5 µg) were added in an in vitro kinase assay 
containing 5 µg GST-ASF/SF2 and 1 µg His-SRPK1.  GST-HPV1 E1^E4 (2.5, 5 and 10 
µg) and GST (10 µg) were added as positive and negative controls respectively.  (A) 
32
P 
autoradiograph and Coomassie stained gel.  (B) The data in the graph is the mean taken 
from two independent experiments.  
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Figure 3.8 Inhibition of SRPK1 phosphorylation of ASF/SF2 by SRPIN340.  (A) 
Structure of selective inhibitor SRPIN340.  (B) 
32
P autoradiograph and Coomassie 
stained gel showing the addition of 10 or 50 µM SRPIN340 to an in vitro kinase assay 
containing 2 µg GST-ASF/SF2 and 1 µg His-SRPK1.  (C) Graph showing the 
phosphorimager count from gel B.  The data shown is representative of two independent 
experiments.   
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SRPIN340 inhibits SRPK1 activity by binding to the active site and is referred to as a 
competitive inhibitor (Fukuhara et al., 2006).  To determine if the mode of inhibition by 
HPV1 E1^E4 is competitive like SRPIN340, or if it is a non-competitive or uncompetitive 
inhibitor, an in vitro kinase assay was carried out in which the amount of GST-ASF/SF2 was 
titrated in the presence of constant amounts of His-SRPK1 and GST-HPV1 E1^E4, or GST as 
a control.  The level of phosphate incorporated into the ASF/SF2 protein was measured by 
TCA protein precipitation (Section 2.3.6).  The level of phosphate incorporation into 
ASF/SF2 in the presence of GST-HPV1 E1^E4 was consistently lower than with the GST 
control, with a reduction of 56% at the highest amount of GST-ASF/SF2 (p=0.001).  To 
determine the mode of inhibition, a Lineweaver-Burk plot was produced (Figure 3.9C), where 
the Km and Vmax of the reaction can be determined from the x and y intercepts respectively.  
In the presence of a competitive inhibitor such as SRPIN340 the Vmax of the reaction does not 
vary with increasing amounts of inhibitor.  With a non-competitive inhibitor, which binds to 
an alternative site on the enzyme, the Km does not vary and for an uncompetitive inhibitor the 
Km/Vmax does not vary in the presence of increasing amounts of substrate (Mathews et al., 
2000).  However, with increasing amounts of the substrate GST-ASF/SF2 in the presence of 
GST-HPV1 E1^E4, the Km, Vmax and Km/Vmax are all changed in comparison to the assay 
containing the GST control protein, and this response can be indicative of mixed inhibition.  
The Lineweaver-Burk plot assumes simple enzyme kinetics, with E+S  ES  E+P, 
however the kinase activity of SRPK1 is processive (Aubol et al., 2003), with the reaction 
kinetics varying between the initial phosphorylation and the following multisite 
phosphorylation (Aubol and Adams, 2011, Ngo et al., 2008).  The measure of total phosphate 
incorporated into ASF/SF2 does not account for the changing reaction rate and therefore does 
not allow for accurate rate determination.   
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Figure 3.9 Determination of the mode of inhibition by HPV1 E1^E4 using 
Michaelis-Menten kinetics.  (A) 
32
P autoradiograph and Coomassie stained gel showing 
the titration of 0.6, 1.2, 2.4, 5, 10 or 20 µg GST-ASF/SF2 into an in vitro kinase assay 
containing 1 µg of His-SRPK1, in the presence of 5 µg GST-HPV1 E1^E4 or 7 µg GST.  
(B) The level of phosphate incorporated into the ASF/SF2 with increasing amounts of 
GST-ASF/SF2 is shown.  The data in the graph shown is the mean (± standard deviation) 
from five experiments.  (C) Lineweaver-Burk plot of the data in graph B, with linear 
regression trendlines. 
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This means that to accurately determine the mode of inhibition of SRPK1 by HPV1 E1^E4 
using Michaelis-Menten kinetics, the use of the Lineweaver-Burk plot was inadequate.   
3.3.5 HPV1 E1^E4 inhibits binding of SRPK1 to ASF/SF2 
Initial attempts to establish the mode of inhibition of HPV1 E1^E4 on SRPK1 by 
determination of Michaelis-Menten kinetics were unsuccessful.  This was possibly due to the 
limitations of the approach used as mentioned previously.  Another method to investigate the 
binding of proteins is using surface plasmon resonance (SPR) to measure protein-protein 
interactions, as used by Biacore
®
 technology.  Biacore
®
 can be used to accurately determine 
the specificity of interactions, the affinity of interactions and the kinetics of binding (ka and 
kd).  The approach was therefore to use Biacore
® 
technology to determine whether SRPK1 
bound the viral E1^E4 protein with the same affinity as its cellular substrate ASF/SF2 and to 
determine the kinetics of this interaction.  Initially, purified His-SRPK1 was bound to a 
nitrilotriacetic acid (NTA) chip, using the His-tag.  Whilst the His-SRPK1 bound successfully 
to the chip (as determined by an increase in response units), neither GST-ASF/SF2 nor GST-
HPV1 E1^E4 would bind to the bound SRPK1 (Figure 3.10A).  To determine whether this 
was due to steric interactions interfering with the binding, His-SRPK1 was bound to nickel 
agarose beads and used to coprecipitate GST-ASF/SF2 or GST-HPV1 E1^E4.  No binding of 
the GST-tagged proteins to SRPK1 was detectable by Western blotting (data not shown); 
suggesting that binding of the His-tag to a support induced steric hindrance to prevent SRPK1 
binding to its substrate or to the viral inhibitor. 
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Figure 3.10 Biacore
®
 interaction study using NTA and GST-antibody chips.  (A) 
Two micrograms of His-SRPK1 was bound to a nitrilotriacetic acid (NTA) chip on 
chambers 2, 3 and 4.  One microgram of GST-ASF/SF2 was passed through chambers 1 
and 2 at 5 μl/min and 1 μg of GST-HPV1 E1^E4 was passed through chambers 1, 2 and 
3 at 5 μl/min.  (B)  A goat anti-GST antibody was bound to a CM5 chip by amine 
coupling, then 3.5 μg of GST were bound to chambers 1 and 4, 1.2 μg of GST-ASF/SF2 
bound to chamber 2 and 1.4 μg of GST-HPV1 E1^E4 bound to chamber 3.  His-SRPK1 
was passed through chambers 3 and 4 at 5 μl/min, then chambers 1-4 in the presence of 
MgCl2 and ATP at 5 μl/min for 5 min then 15 min. 
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A second approach therefore was to determine if the substrate GST-ASF/SF2 could retain 
binding to SRPK1 when bound to a solid support and whether the interaction could be 
blocked by addition of E1^E4 or small molecule inhibitors.  Thus, GST or GST-ASF/SF2 
were bound to glutathione agarose beads and mixed with His-SRPK1 in the presence of the 
various inhibitors; HPV1 E1^E4 that had been cleaved from the GST-tag using thrombin 
(Section 2.1.5.4) (Figure 3.11A), or the small molecule inhibitors SRPIN340 or staurosporine, 
an ATP analogue (a schematic of binding is shown in Figure 3.11B).  After repeated 
washings, the proteins bound to GST and GST-ASF/SF2 were resolved by SDS PAGE and 
Western blotted with an anti-polyHis antibody (Figure 3.11C).  As expected, the addition of 
the inhibitors, SRPIN340 and staurosporine, which are known to bind in the active site 
reduced binding of His-SRPK1 to the substrate GST-ASF/SF2.  Addition of the cleaved 
HPV1 E1^E4 protein also reduced the binding of the kinase to GST-ASF/SF2, and to a 
similar extent as the two competitive inhibitors SRPIN340 and staurosporine.    
This data shows that the bound substrate ASF/SF2 was recognised by SRPK1 in solution and 
that binding of the kinase is inhibited by E1^E4. Therefore a CM5 Biacore
®
 chip was 
generated with an anti-GST antibody immobilised on its surface.  However, whilst the GST 
proteins were all able to bind to the anti-GST chip, His-SRPK1 did not bind to any of the 
immobilised proteins (Figure 3.10B).   
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Figure 3.11 HPV1 E1^E4 inhibits the binding of His-SRPK1 to GST-ASF/SF2.  
(A) Coomassie gel and anti-HPV1 E1^E4 Western blot showing efficient thrombin 
cleavage of the GST-tag from GST-HPV1 E1^E4 and elution of the purified protein from 
a benzamidine column.  (B) Schematic showing the coprecipitation of His-SRPK1 by 
GST-ASF/SF2 and the addition of inhibitors.  (C) GST-ASF/SF2 or GST was bound to 
glutathione agarose beads and incubated with His-SRPK1 alone or in the presence of 
HPV1 E1^E4, SRPIN340 or Staurosporine.  Following resolution by SDS PAGE the gels 
were Western blotted with anti-His and anti-GST antibodies.  This data is representative 
of two experimental replicates. 
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The next approach was to couple the GST proteins and His-SRPK1 directly to the CM5 
Biacore
®
 chip via amine coupling.  The coupling of the proteins was performed at a pH lower 
than the pI of the proteins, and this was determined experimentally by changing the pH until 
„sticking‟ occurred between the protein and the chip (section 2.3.8.3).  The GST-ASF/SF2 
and His-SRPK1 were coupled to separate chambers of the chip at pH 5.0 and pH 4.0 
respectively (Figure 3.12A).  The His-SRPK1 was also coupled in the presence of ATP and 
MgCl2 at pH 5.0 (Figure 3.12B), as this can help retain the ability of the kinase to bind to its 
substrate (Nordin et al., 2005).  When GST-ASF/SF2 was flowed into the chamber containing 
immobilised His-SRPK1, binding occurred.  However when GST-ASF/SF2 was added as a 
control to the chamber containing immobilised GST-ASF/SF2, binding also occurred to a 
similar level (Figure 3.12C).  Injection of His-SRPK1 into the chambers also did not bind to 
the immobilised GST-ASF/SF2 or to the immobilised His-SRPK1.  A small increase in 
response units (< 370 units) was seen when GST-HPV1 E1^E4 was added to the immobilised 
SRPK1, however normally a change of over 1000 response units is expected when binding 
occurs.  Also, the small change in response units with GST-HPV1 E1^E4 was not a 
reproducible observation between chips as shown in figure 3.12D.   
An explanation for the lack of binding may be due to the His-SRPK1 being bound in an 
inaccessible configuration.  Therefore to test this, an anti-SRPK1 antibody was used to 
determine whether the His-SRPK1 immobilised on the chip was accessible.  No binding of 
the antibody was observed, even though His-SRPK1 bound to the chip with 12,000 response 
units, leading to the conclusion that the SRPK1 was bound in an inaccessible configuration 
and the “binding” that was observed, was due to non-specific interactions with the chip. 
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Figure 3.12 Biacore
®
 interaction study using amine coupled proteins on a CM5 
chip.  (A) GST-ASF/SF2 was flowed over chamber 1 at pH 7.9, 5.5 and 5.0; His-SRPK1 
was flowed over chamber 2 at pH 5.0, 4.5 and 4.0.  (B)  His-SRPK1 was passed through 
chamber 3 in the presence of 2 mM MgCl2 and 1 mM ATP at pH 5.0 and 5.5.  (C)  His-
SRPK1 was bound at pH 4.0 and GST-ASF/SF2 bound at pH 5.0.  One microgram of 
GST-ASF/SF2 was passed through the chambers, followed by 1 μg His-SRPK1, then 1 
μg, 2 μg and 5 μg of GST-HPV1 E1^E4.  (D) His-SRPK1 was bound at pH 5.0 in the 
presence of 2 mM MgCl2 and 1 mM ATP.  Five micrograms of GST-ASF/SF2 was 
passed through chamber 1, followed by 5 μg of GST-HPV1 E1^E4.  Twenty micrograms 
of GST-HPV1 E1^E4 was passed through chamber 2. 
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The failure of a range of strategies to use surface plasmon resonance analysis to determine 
kinetic information of the interaction between SRPK1 and the viral inhibitor HPV1 E1^E4 
probably reflects a combination of complex kinetics of SRPK1 mediated phosphorylation and 
possibly a mix in the mode of inhibition exhibited.  Therefore, due to time constraints the aim 
of obtaining information on the mode of binding was not pursued further.    
 
3.4 HPV16 and HPV18 E1^E4 do not inhibit SRPK1 kinase activity 
In addition to the cutaneous mu HPV1 virus, the E1^E4 proteins of the mucosatropic alpha 
HPV types HPV16 and HPV18 have also been shown to interact with SRPK1 (Bell et al., 
2007).  The interaction between His-SRPK1 and GST-tagged HPV16 and HPV18 E1^E4 was 
confirmed by “pull down” of the His-tagged SRPK1 from bacterial lysate.  Western blotting 
with an anti-His or anti-SRPK1 antibody (Figure 3.13) showed that both GST proteins were 
able to interact with His-SRPK1.  As noted previously (Bell et al., 2007), the GST-tagged 
HPV16 and HPV18 proteins were less effective at precipitation of His-SRPK1 than the type 1 
protein.  
To determine whether HPV16 and 18 E1^E4 proteins affect kinase activity, GST-tagged 
HPV16 and HPV18 E1^E4 proteins were added to an in vitro kinase assay containing GST-
ASF/SF2 and His-SRPK1 (Figure 3.14).  Whilst in the reactions with GST-HPV1 E1^E4, 
phosphorylation of ASF/SF2 decreased with increasing amounts of fusion protein, the level of 
phosphorylation in the presence of increasing amounts of the HPV16 or HPV18 E1^E4 
proteins remained constant, suggesting that binding to SRPK1 does not inhibit its activity.  
Although phosphorylation increased slightly with HPV16 and HPV18 E1^E4 compared to the 
addition of GST alone, the difference was not significant (p=0.36 for HPV16 and p=0.69 for 
HPV18).   
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Figure 3.13 His-SRPK1 interacts with HPV type 16 and 18 E1^E4.  Approximately 
10 µg of GST and GST-tagged HPV1, 16 and 18 E1^E4 and ASF/SF2 proteins bound to 
glutathione agarose beads were mixed with bacterial lysate expressing His-SRPK1.  
Western blotting of the washed precipitates with anti-His or anti-SRPK1 antibodies 
showed that GST-HPV1, 16 and 18 E1^E4 proteins interacted with His-SRPK1 (GST-
E1^E4 proteins marked with * in Coomassie).  The data is representative of two 
independent experiments. 
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Figure 3.14 GST-HPV16 and GST-HPV18 E1^E4 proteins do not inhibit His-
SRPK1 phosphorylation of GST-ASF/SF2.  GST-tagged HPV1, 16 and 18 E1^E4 
proteins were added in increasing amounts (2.5, 5 and 10 µg) to an in vitro kinase assay 
containing 3 µg GST-ASF/SF2 and 1 µg His-SRPK1.  In comparison to the GST control, 
GST-HPV16 and 18 E1^E4 did not reduce the level of phosphorylation of GST-
ASF/SF2.  The data in the graph is the mean (± standard deviation) from four 
experimental replicates.   
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3.5 HPV5 E1^E4 
The binding of SRPK1 to E1^E4 proteins of anogenital viruses HPV16 and HPV18 (α group) 
and of the cutaneous benign virus HPV1 (μ group), suggests that SRPK1 might be a 
conserved partner to E1^E4 proteins.  To test whether SRPK1 interacts with E1^E4 from β-
viruses the E1^E4 coding sequence of HPV5 was derived from the total HPV5 genome by 
PCR (see Chapter 2, Table 4).  The cDNA of E1^E4 was ligated into the EcoRI restriction 
enzyme site of pGex-2T and following transformation into E. coli BL21 CodonPlus
®
 cells, 
the fusion protein GST-HPV5 E1^E4 was produced.  Following optimisation of expression 
conditions (Figure 3.15), a protein was produced of the expected size of 53 kDa and this was 
recognised by an anti-GST antibody.  DNA sequencing of the E1^E4 cDNA showed that the 
E1^E4 sequence was most similar to HPV5b with only two amino acid changes to the 
published sequence (see Appendix 1A).  For the purpose of this thesis, the HPV5b E1^E4 
protein will be referred to as HPV5 E1^E4.   
To determine whether HPV5 E1^E4 interacts with SRPK1, GST-HPV5 E1^E4 was bound to 
glutathione agarose beads, and mixed with His-SRPK1 for 10 min at 4°C.  Western blotting 
of the washed precipitate with an anti-SRPK1 antibody (Figure 3.16) showed that GST-HPV5 
E1^E4 did interact with the His-SRPK1.  Binding to SRPK1 was observed in multiple 
experiments and consistently the HPV5 E1^E4 protein bound less SRPK1 than GST-HPV1 
E1^E4, up to 50% less. 
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Figure 3.15 Expression of GST-HPV5 E1^E4.  For optimisation of expression, E.coli  
BL21 CodonPlus
®
 cells transformed with pGex-2T-HPV5 E1^E4 were grown at  37°C 
and 30°C for up to 20 h.  The glutathione purified lysates were resolved by SDS PAGE 
and Coomassie stained or Western blotted using an anti-GST antibody. 
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Figure 3.16 GST-HPV5 E1^E4 interacts with His-SRPK1.  Approximately 10 µg of 
GST-HPV5 E1^E4 was bound to glutathione agarose beads, along with 10 µg of GST-
HPV1 E1^E4 and GST, and mixed with 1 µg His-SRPK1 for 10 min.  (A) Western blot 
of washed precipitates blotted with anti-SRPK1 antibody.  (B) Densitometry plot of 
coprecipitated His-SRPK1 in western blot A, data is the average of three repeats.   
Chapter 3 
136 
3.5.1 HPV5 E1^E4 is a substrate for SRPK1 but does not affect kinase 
activity  
To determine whether HPV5 E1^E4 affects SRPK1 kinase activity, GST-HPV5 E1^E4 
protein was added to an in vitro kinase assay in increasing amounts with GST-ASF/SF2 as a 
substrate.  Figure 3.17A shows that in comparison to the assays containing the GST protein 
the level of phosphorylation of GST-ASF/SF2 does not change significantly with increasing 
amounts of the GST-HPV5 E1^E4 protein.  The observed small increase is not significant, 
(p=0.095).  This data indicates that GST-HPV5 E1^E4 is not a potent inhibitor or activator of 
SRPK1 kinase activity. 
HPV5 E1^E4 is however a potential substrate for SRPK1 as there are 2 RS repeats within the 
E1^E4 coding sequence (Appendix 1B).  When GST-HPV5 E1^E4 is added only in the 
presence of His-SRPK1 a phospho-species of approximately 40 kDa is present (Figure 
3.17B).  This phospho-species is also present in the inhibitor assays in reactions containing 
the GST-HPV5 E1^E4 protein but not in the reactions containing the HPV1 fusion protein or 
GST control (Figure 3.17A).  This species is smaller than the full-length GST-HPV5 E1^E4 
of 53 kDa, but could represent phosphorylated E1^E4 that has arisen from proteolytic 
breakdown of the full-length species and is more susceptible to phosphorylation or indicates 
that that phospho-species exhibits increased migration upon SDS-PAGE.  Interestingly, a 
similar increase in migration of the phospho-species was observed following in vitro SRPK1 
phosphorylation of the GST-HPV1 E1^E4 protein (Bell et al., 2007).  
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Figure 3.17 HPV5 E1^E4 is a substrate but not an inhibitor for SRPK1.  (A) GST-
HPV5 E1^E4 (1.25, 2.5, 5 and 10 µg) was added to an in vitro kinase assay containing 2 
µg GST-ASF/SF2 and 1 µg His-SRPK1, GST-HPV1 E1^E4 (1.25, 2.5, 5 and 10 µg) and 
GST (10 µg) were added as controls.  (B) GST-HPV5 E1^E4 (2.5 µg) in the presence 
and absence of 1 µg His-SRPK1. The band marked with the * is a phospho-species 
which is present only in the presence of GST-HPV5 E1^E4 and His-SRPK1, and also 
increases in intensity with increasing amounts of GST-HPV5 E1^E4.  (C) Bar graph 
showing the mean (± standard deviation) percentage phosphorylation of GST-ASF/SF2 
normalised to GST from three independent experiments. 
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3.6 Discussion 
This study has shown for the first time that the interaction between HPV1 E1^E4 and SRPK1 
causes the inhibition of phosphorylation of ASF/SF2 by SRPK1 in vitro.  The maximum level 
of inhibition observed was 65%, the lack of total inhibition may be due to HPV1 E1^E4 
sometimes binding to SRPK1 in a manner which does not inhibit SRPK1 activity.  HPV1 
E1^E4 must bind to SRPK1 for inhibition to occur, as a non-binding deletion mutant of HPV1 
E1^E4 is unable to inhibit SRPK1 activity.  The inhibition of SRPK1 activity was not 
however a conserved function of the other E1^E4 proteins of HPV5, HPV16 and HPV18 that 
bind to SRPK1.  HPV1 and HPV5 are specific for cutaneous epithelia, whereas HPV16 and 
HPV18 are mucosaspecific, in cutaneous infections the late stages of the life cycle are 
induced as soon as the cell leaves the basal layer, whereas in mucosal infections the 
vegetative stages occur in the upper layers, due to the activity of E6 and E7.  In the cutaneous 
infections the modulation of SRPK1 activity by E1^E4 may be required to alter cellular 
factors which are no longer present in the upper layers when the mucosal viruses are 
undergoing viral amplification.  Alternatively the E1^E4 proteins of HPV16 and HPV18 may 
require additional cellular factors or post-translational modifications to modulate SRPK1 
activity.  Interestingly in the in vitro kinase assays, HPV5, HPV16 and HPV18 increase the 
activity of SRPK1; although this is not significant it may indicate that in vivo these proteins 
influence SRPK1 function by an alternative method. 
The mechanism of inhibition of SRPK1 kinase activity by HPV1 E1^E4 was investigated 
using both kinetic and binding studies, however due to the processitivity of the kinase 
reaction and possible steric hindrances this was not successful.  The sterically specific nature 
of the interaction between SRPK1 and other proteins suggests that the two domains of SRPK1 
must be able to freely move and change conformation during the binding process.  It may be 
possible to determine whether HPV1 E1^E4 is a competitive or non-competitive inhibitor by 
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varying the amount of ATP added to the in vitro kinase assay.  This experiment would allow 
for a kinetic determination that was not affected by the processitivity of the reaction and has 
been utilised by Fukuhara et al., (2006) to demonstrate that SRPIN340 is a competitive 
inhibitor of SRPKs. 
Whilst the mechanism of inhibition was not resolved here the interaction between HPV1 
E1^E4 and SRPK1 was sufficient to prevent ASF/SF2 binding and therefore HPV1 E1^E4 
could be binding to a region of SRPK1 such as the docking groove (Figure 1.12).  HPV1 
E1^E4 contains a bipartate arginine-rich motif and deletion of residues 44-48 (
44
GRPRR
48
) 
abrogates the binding of HPV1 E1^E4 to SRPK1 (Bell et al., 2007).  This arginine-rich motif 
is similar to the ASF/SF2 docking motif and the consensus motif R-X-R/K-X-X-X-R 
identified by Ngo et al., (2005).  Huynh et al., (2009) have shown that if the RS domain of 
ASF/SF2 does not initially bind to the docking groove, the RRMH domain cannot bind to 
SRPK1, demonstrating that ASF/SF2 requires multiple interactions with SRPK1 to be in the 
correct configuration for phosphorylation.  The strict requirements for binding and 
phosphorylation may account for some of the difficulties encountered when investigating the 
interaction using Biacore
TM
. 
The HPV1 E1^E4 protein has been shown to be a substrate for SRPK1 in vitro by Bell et al.,  
(2007), however in the experiments performed in this thesis, this phosphorylation was not 
observed.  The amounts of SRPK1 and HPV1 E1^E4 used in the assays reported here were 
much lower than those used by Bell et al., (2007) due to ASF/SF2 being a superior substrate 
for SRPK1 than HPV1 E1^E4.  In addition to HPV1 E1^E4 being a substrate for SRPK1, the 
E1^E4 protein of HPV5 has been shown to be a substrate for SRPK1 in vitro in this study; 
this phosphorylation may be required to modulate the activity of these proteins.  SRPK1 and 
SRPK2 have been shown to phosphorylate the core protein of hepatitis B virus (HBV) (Daub 
et al., 2002) and this phosphorylation is required for multiple steps in the DNA synthesis of 
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HBV (Lewellyn and Loeb, 2011).  Phosphorylation of three serines in the C-terminal domain 
of the core protein is required for efficient minus-strand DNA elongation, primer 
translocation, circularisation and plus-strand DNA elongation (Lewellyn and Loeb, 2011).  In 
contrast, SRPK1 and SRPK2 have been shown to suppress viral replication of HBV by 
interfering with pre-genomic RNA packaging without affecting the formation of the viral core 
particles, this suppressive effect was not dependent upon the kinase activity of SRPK1/2 (Y. 
Zheng et al., 2005), demonstrating that SRPKs have multiple roles in HBV replication and 
this may be true for HPV too.  Identification of the site of phosphorylation within the E1^E4 
proteins might be helpful in understanding the consequence of SRPK1 mediated 
phosphorylation.  Perhaps phosphorylation facilitates the interaction between E4 and cellular 
and/or viral partners and thus modulates their behaviour, for example the interaction between 
HPV16 E1^E4 and E2, modulates the functions of E2 (C. Davy et al., 2009). 
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CHAPTER 4 INTERACTION OF SRPK1 WITH CELLULAR 
AND VIRAL SR PROTEINS 
4.1 Introduction 
The SR proteins are a family of related proteins and although all members of the family 
contain one or two conserved RRMs and a C-terminal RS domain there are differences 
between family members in their functions and localisation (Chapter 1, Table 2).  The SR 
proteins ASF/SF2, SRp20 and 9G8 have been shown to shuttle rapidly and continuously 
between the cytoplasm and nucleus, whereas SRp75 can shuttle with slower kinetics and 
SC35 does not shuttle (Cazalla et al., 2002, Sapra et al., 2009).   
SRp20 is the smallest SR protein and contains a single RRM, as a shuttling SR protein, 
SRp20 has been shown to be involved in mRNA export and has been shown to promote 
mRNA translation (Hautbergue et al., 2008, Swartz et al., 2007).  In HPV16 and BPV 
infection, SRp20 has been shown to interact with an A/C-rich element located upstream of the 
late 3‟ splice site, and regulate the selection of late splice sites, thus regulating the expression 
of late proteins (Jia et al., 2009).  Interestingly in BPV, the A/C-rich element (SE4) only binds 
SRp20, whereas in HPV16, the A/C-rich ESE binds multiple SR proteins including SRp20, 
ASF/SF2 and SRp75 (Jia et al., 2009).  SC35 is a non-shuttling SR protein which contains a 
single RRM and SC35 has been shown to be involved in transcriptional elongation in a gene-
specific manner, allowing the coupling of transcription and splicing (Lin et al., 2008).  9G8 is 
a shuttling SR protein, with a single RRM, however 9G8 also contains a zinc knuckle.  9G8 
has been shown to be involved in mRNA export and the promotion of mRNA translation 
(Hautbergue et al., 2008, Swartz et al., 2007).  SRp75 is the largest SR protein, with two 
Chapter 4 
142 
RRMs and a long RS domain.  Hyperphosphorylation of SRp75 by CLKs has been shown to 
modulate the alternative splicing of Adenovirus E1A (Yomoda et al., 2008). 
The prototypical SR protein, ASF/SF2, has two RRMs, with the RRMH domain interacting 
with SRPK1 during phosphorylation to stabilise the complex (Ngo et al., 2008).  Whether the 
RRM of SRp20 and SC35 interacts with SRPK1 is undetermined, but SRPK1 may bind to 
these proteins in a different configuration and therefore may be more or less susceptible to 
inhibition of binding. 
There are many proteins, including multiple snRNP components and splicing regulators and 
coactivators which contain RS/SR dipeptides and can interact with the SR proteins via their 
RS domains and/or be phosphorylated by SRPK1.  Included in this class of proteins are the 
E2 proteins of the beta HPV types associated with EV.  They contain a relatively long hinge 
region, of around 200 amino acids, between the conserved transactivation and DNA binding 
domains.  Within the hinge region of these proteins are multiple RS/SR dipeptides and HPV5 
and HPV8 E2 have been shown to interact with several SR proteins and to colocalise with 
SC35 in nuclear speckles, suggesting that HPV5 E2 may have a role in pre-mRNA splicing 
(Lai et al., 1999, Sekhar et al., 2009).  The accumulation of HPV5 and HPV8 E2 in nuclear 
speckles is dependent upon the hinge region of the proteins, but the hinge alone is not 
sufficient for this localisation (Lai et al., 1999, Sekhar et al., 2009).  The hinge region of 
HPV5 E2 is extensively phosphorylated in vivo by SRPK1 and the overexpression of SRPK1 
leads to accumulation of HPV5 E2 in the cytoplasm similar to the relocalisation observed 
with ASF/SF2 (Lai et al., 2000).  The hinge region of HPV5 E2 can interact with the SR 
transport protein TRN-SR2 and this interaction is dependent upon phosphorylation of the RS 
dipeptides (Lai et al., 2000). 
The binding of SRPK1 to the SR proteins with a single RRM may differ to those with two, 
therefore the inhibition caused by HPV1 E1^E4 may be substrate specific.  Additionally as 
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certain SR proteins have been shown to have specific functions during viral infections, HPV1 
may be purposely targeting one or more of these proteins.  This chapter examines the 
substrate specificity of HPV1 E1^E4 inhibition of SRPK1 kinase activity, using cellular and 
viral SR proteins as substrates in in vitro kinase assays.   
 
4.2 Results 
4.2.1 Investigation of HPV E1^E4 action on SRPK1 phosphorylation of 
cellular SR proteins other than ASF/SF2 
4.2.1.1 In vitro SRPK1 phosphorylation of cellular SR proteins  
The effect on kinase activity of the interaction between SRPK1 and E1^E4 have been 
examined with respect to the prototypical SR protein, ASF/SF2.  However, the effects 
observed could be substrate specific and therefore it is necessary to examine the influence of 
E1^E4 on SRPK1 phosphorylation of other SR proteins.  To investigate this, the following SR 
proteins were chosen to express as GST-fusion proteins; SC35, 9G8, SRp75 and SRp20.   
The intention was to express the SR proteins as GST fusion proteins, therefore the IMAGE 
clones were obtained from Source BioScience LifeSciences and following amplification and 
restriction digestion the cDNAs were ligated into complementarily digested pGex-2T (see 
Chapter 2, Table 4 for IMAGE clone details and primers).  The GST-tagged SR proteins were 
expressed in E.coli BL21 CodonPlus
®
 cells and following optimisation of expression 
conditions they were resolved by SDS PAGE (Figure 4.1).   
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Figure 4.1 Expression of GST-tagged SR proteins.  Coomassie stained gel showing 
the purified GST-tagged SR proteins: SC35, 9G8, SRp20 and SRp75 in increasing 
amounts. UD, sample taken before dialysis.  BSA, aliquot of bovine serum albumin 5 μg, 
allowing for relative amounts of the SR proteins to be calculated.  Western blots show 
that GST-tagged SC35, SRp20 and SRp75 were recognised by an anti-GST antibody.  
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All of the GST-SR fusion proteins migrated with masses smaller than the predicted sizes.  
GST-SC35, GST-9G8 and GST-SRp20 all produced products with masses of between 40 and 
45 kDa, which were smaller than the expected sizes of 53 kDa, 55 kDa and 47 kDa 
respectively.  The product from the expression of GST-SRp75 was of a mass of 50 kDa 
(expected 85 kDa), but this product was recognised by an anti-SRp75 (SFRS4) antibody (data 
not shown).  Cleavage of some of the RS domain at the C-terminus may have occurred, as the 
GST-tag is at the N-terminus and the anti-SRp75 antibody recognises an epitope at the start of 
the RS domain. 
To ensure that the GST-tagged SR proteins were therefore functional each one was added to 
an in vitro kinase assay in the presence and absence of His-SRPK1.  In the autoradiograph 
shown in Figure 4.2 each of the GST-tagged SR proteins were phosphorylated by His-SRPK1 
in vitro. 
4.2.1.2 Effect of HPV1, 5, 16 and 18 E1^E4 on SRPK1 phosphorylation of cellular SR 
proteins 
To test whether the inhibition of SRPK1 kinase activity in vitro by HPV1 E1^E4 is substrate 
specific, GST-HPV1 E1^E4 was added into an in vitro kinase assay with the GST-tagged SR 
proteins and His-SRPK1.  As Figure 4.3 shows, GST-HPV1 E1^E4 inhibits His-SRPK1 
phosphorylation of all the GST-tagged SR proteins.  In comparison to phosphorylation of the 
SR proteins in the presence of GST, the level of inhibition by HPV1 E1^E4 was significant in 
all cases; GST-ASF/SF2 p = 0.006; GST-SRp75 p = 0.0002; GST-SRp20 p = 0.02 and GST-
9G8 p = 0.002.  It can be concluded that HPV1 E1^E4 inhibits SRPK1 phosphorylation of 
multiple substrates.  However the potency of inhibition varied between substrates, ranging 
from 58% inhibition with GST-SRp20 to 86% inhibition with GST-SRp75.  
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Figure 4.2 Phosphorylation of GST-SR proteins by His-SRPK1.  GST-tagged 
SRp75 (2 µg), SRp20 (2 µg), 9G8 (4 µg) and SC35 (4 µg) were added to an in vitro 
kinase assay in the presence and absence of (1 µg) His-SRPK1.  
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Figure 4.3 Inhibition of SRPK1 kinase activity by HPV1 E1^E4.  Five micrograms 
of GST (lanes 1-2), GST-ASF/SF2 (lanes 3-5), GST-SRp75 (lanes 6-8), GST-SRp20 
(lanes 9-11) and GST-9G8 (lanes 12-14) were added to an in vitro kinase assay with 1 µg 
His-SRPK1.  Five micrograms of GST-HPV1 E1^E4 (lanes 2, 5, 8, 11 and 14) was added 
as an inhibitor and 5 µg of GST (lanes 1, 4, 7, 10 and 13) added as a control.  The data in 
the graph shown is the mean ± standard deviation of three experimental replicates. P 
values: * <0.05, ** < 0.01, *** < 0.0005.  
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SRPK1 phosphorylation of several different SR protein substrates was inhibited by HPV1 
E1^E4, indicating that there is no substrate specificity with regards to the inhibitory function 
of HPV1 E1^E4.  However, whilst HPV16 and HPV18 E1^E4 do not inhibit SRPK1 
phosphorylation of the shuttling SR protein ASF/SF2, it is possible that their binding to 
SRPK1 may inhibit the phosphorylation of other substrates.  Therefore the effect of HPV16 
and HPV18 E1^E4 proteins on SRPK1 phosphorylation of SC35 was investigated; SC35 was 
used in this assay as it is a good substrate in vitro for His-SRPK1 and as SC35 only contains a 
single RRM, the binding to SRPK1 may be different to that with ASF/SF2.  GST-tagged 
HPV16 and HPV18 E1^E4 were added in increasing amounts to an in vitro kinase assay with 
GST-SC35 and His-SRPK1.  Figure 4.4 shows that the GST-tagged E1^E4 proteins of 
HPV16 (lanes 5 to 7) and HPV18 (lanes 8 to 10) do not inhibit His-SRPK1 phosphorylation 
of GST-SC35.  There was a small increase in the level of phosphorylation when compared to 
the reaction containing the GST control but this was not significant (p = 0.41 for HPV16; p = 
0.50 for HPV18). 
To confirm that the binding of GST-HPV1 E1^E4 to His-SRPK1 is required for the inhibition 
of phosphorylation of SC35, the deletion mutants of HPV1 E1^E4, Δ44-48 (an SRPK1 non-
binding mutant) and Δ49-53 (an SRPK1 binding mutant) were added to the in vitro kinase 
assay with GST-SC35.  As shown in Figure 4.4, the wild type HPV1 E1^E4 inhibited the 
phosphorylation of GST-SC35 (p = 0.05) (lanes 2 to 4), whereas the deletion mutant of HPV1 
E1^E4, Δ44-48 which does not bind to SRPK1 did not (lane 12).  As expected, addition of the 
deletion mutant Δ49-53 which retains SRPK1-binding function, significantly reduced the 
level of phosphorylation of GST-SC35 (p = 0.005) (lane 11). 
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Figure 4.4 HPV16 and HPV18 E1^E4 do not inhibit SRPK1 phosphorylation of 
SC35.  GST-tagged HPV16 and HPV18 E1^E4 along with HPV1 E1^E4 were added in 
increasing amounts (2.5, 5 and 10 µg) to an in vitro kinase assay with 1 µg His-SRPK1 
and 5 µg GST-SC35, 10 µg of GST-tagged deletion mutants of HPV1 E1^E4 Δ44-48 and 
Δ49-53 were added along with 10 µg GST.  The data in the bar graph is the mean ± 
standard deviation of three experimental replicates.  P values: * > 0.1, ** < 0.05, *** < 
0.01 
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GST-HPV5 E1^E4 was added to an in vitro kinase assay with GST-SRp20 and GST-SC35 as 
substrates and no detectable inhibition of SRPK1 kinase activity was observed (data not 
shown).  GST-HPV5 E1^E4 produces a phospho-species (Chapter 3, section 3.5.1) which 
migrates at around 40 kDa, this phospho-species migrates at around the same size as the 
phosphorylated products produced by GST-SRp20 and GST-SC35 making analysis difficult, 
therefore no further experiments were performed using these substrates with HPV5 E1^E4. 
4.2.2 Effect of E1^E4 on SRPK1 phosphorylation of viral SR proteins 
The E2 proteins of the beta papillomaviruses have a large number of RS or SR dipeptide 
repeats in the hinge region (Figure 4.5A), HPV5 E2 has 27 repeats and HPV8 E2 has 24 
(Figure 4.5B), making these viral proteins substrates for SRPK1 (Lai et al., 2000, W. S. Wang 
et al., 2009c).  The interaction between HPV E1^E4 proteins and SRPK1 could modulate the 
phosphorylation of other HPV proteins by impinging on SRPK1 activity in differentiating 
cells.  
To determine whether these E2 proteins were substrates for His-SRPK1 in vitro, GST-fusions 
of HPV5 and HPV8 E2 proteins were produced.  In addition, the hinge regions (E2H) of both 
HPV types were also made into GST-fusion proteins (Chapter 2, Table 4).  Since HPV1 E2 
has 4 dipeptide repeats within the hinge region, the fusion proteins for HPV1 E2 and E2H 
were also produced (Figure 4.5B).  Following ligation of the E2 and E2H cDNAs into pGex-
2T, transformation into E. coli BL21 CodonPlus
®
 cells and optimisation of expression 
conditions, the GST-fusion proteins were produced and resolved by SDS PAGE (Figure 
4.5C).  The HPV1 E2 and E2H constructs produced proteins of the expected sizes of 72 kDa 
and 42 kDa respectively.  The expressed fusion proteins of HPV5 and HPV8 full length E2 
were of smaller mass (55 kDa and 65 kDa) than the expected sizes of 86 kDa and 84 kDa 
respectively.   
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Figure 4.5 Expression of GST-tagged HPV1, HPV5 and HPV8 E2 and E2 Hinge.  
(A) Schematic of the HPV E2 protein of β viruses.  (B) Amino acid sequence of HPV5 
E2 hinge region, amino acids 198 to 436; HPV8 E2 hinge region, 198 to 420 and HPV1 
E2 hinge region, 198 to 323.  SR and RS dipeptides are shown in red. (C) Coomassie 
gels showing resolved GST-tagged E2 and E2H proteins of HPV1, HPV5 and HPV8 in 
increasing amounts and a sample taken before dialysis (UD). 
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The fusion proteins produced by the E2H constructs were of around the correct sizes of 54 
kDa and 53 kDa.  Protein species considerably smaller than the expected proteins were 
observed with all of the GST-E2 and E2H constructs, this may be due to proteolytic cleavage 
of the proteins or loss of the GST-tag during the purification steps. 
To demonstrate that the E2 proteins and E2 hinge regions were substrates for His-SRPK1, the 
GST-tagged E2 and E2H proteins were added to an in vitro kinase assay with His-SRPK1.  
Figure 4.6 shows that GST-tagged HPV5 and HPV8 E2H were substrates for His-SRPK1 in 
vitro, GST-HPV1 E2H was phosphorylated by SRPK1, but only to a small extent, so could 
only be seen after a long exposure.  These levels of phosphorylation are as predicted by the 
variation in the number of RS repeats in the proteins (Figure 4.5B).  The GST-tagged full 
length E2 proteins of HPV1 and HPV5 were phosphorylated by SRPK1 to a similar extent as 
the corresponding E2H proteins.  GST-HPV8 E2 however does not appear to be 
phosphorylated very efficiently by SRPK1 in vitro when compared to the E2H protein; this 
was possibly due to the folding of the protein being incorrect.  
To test whether HPV1 E1^E4 inhibits SRPK1 kinase activity with viral substrates, GST-
HPV1 E1^E4 was added along with the E2 and E2H GST-fusion proteins (Figure 4.7).  The 
addition of GST-HPV1 E1^E4 reduced the level of phosphorylation of all of the GST-tagged 
E2 and E2H proteins compared to GST.  The reduction in phosphorylation was significant 
with HPV1 and HPV5 E2H (p = 0.007 and 0.006 respectively) but was not significant with 
HPV8 E2H (p = 0.14).  The viral substrates, like the cellular SR protein substrates, show 
variation in the potency of HPV1 E1^E4 as an inhibitor of SRPK1, with inhibition varying 
from 19% to 51%.   
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Figure 4.6 In vitro kinase assay with viral E2 and E2H proteins.  (A) 
32
P 
autoradiograph and Coomassie stained gel from in vitro kinase assay with 3 µg of GST-
tagged HPV1, HPV5 and HPV8 E2 and E2H proteins, and 1 µg of GST-HPV1 E1^E4.  
A longer exposure autoradiograph allows the phosphorylation of the HPV1 proteins to be 
seen.  (B) Graph showing the normalised data for the E2H proteins, ** = p < 0.01, graph 
contains the mean ± standard deviation from three experimental replicates. 
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To determine whether HPV5 E1^E4 altered SRPK1 mediated phosphorylation of HPV5 E2, 
GST-HPV5 E1^E4 was added in increasing amounts to an in vitro kinase assay in the 
presence of GST-tagged HPV5 E2 and E2H.  GST-HPV5 E1^E4 did not inhibit SRPK1 
phosphorylation of the GST-tagged proteins of HPV5 full length E2 or the E2 hinge region 
(data not shown).  The level of phosphorylation of the full length E2 protein did increase with 
increasing amounts of HPV5 E1^E4 in comparison to GST, this may be due to an interaction 
between the E2 and E1^E4 tagged proteins, which may alter the conformation of the E2 
protein allowing phosphorylation to occur more efficiently.  This effect was not observed 
upon the phosphorylation of the E2 hinge region, however the phosphorylated forms of GST-
HPV5 E1^E4 and E2H migrate at around the same molecular mass, making analysis of the 
effect of HPV5 E1^E4 on the phosphorylation of HPV5 E2H difficult.  
 
4.3 Discussion 
The interaction between HPV1 E1^E4 and SRPK1 caused the inhibition of SRPK1 
phosphorylation of a number of different SR protein substrates; however the potency of 
inhibition did vary.  As shown for ASF/SF2 the inhibition of SRPK1 activity towards these 
other SR substrates required the binding of HPV1 E1^E4 to SRPK1, as a non-binding mutant 
did not cause any inhibition, suggesting that the mechanism of inhibition was similar and the 
variation in potency is perhaps due to differences in SRPK1 substrate binding.  The 
phosphorylation of SRp75 and 9G8 by SRPK1 was more susceptible to inhibition than the 
phosphorylation of SRp20.  This data suggests that the larger SR proteins with more than one 
RRM, or in the case of 9G8 additional function domains may be more prone to E1^E4 
mediated inhibition than those proteins with a single RRM.   
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The variation in the potency of inhibition by HPV1 E1^E4 on different cellular substrates, 
may allow for the differential regulation of the diverse SR protein functions. 
As with ASF/SF2, HPV16 and HPV18 E1^E4 did not cause any significant change in the 
levels of phosphorylation of SC35, suggesting that the interaction between SRPK1 and 
HPV16 and HPV18 E1^E4 occurs via a different region of SRPK1 and does not interfere with 
substrate binding. 
The hinge regions of the E2 proteins of the beta papillomaviruses HPV5 and HPV8, were 
good substrates for SRPK1 in vitro and this concurs with the findings of others (Lai et al., 
1999, Sekhar et al., 2009).  HPV5 E1^E4 did not inhibit SRPK1 phosphorylation of HPV5 
E2; however the level of E2 phosphorylation observed did increase slightly and this may be 
due to the E2 and E1^E4 proteins interacting directly and causing a change in the 
conformation of E2, or the interaction between E1^E4 and SRPK1 may enable SRPK1 to bind 
E2 more efficiently.  The E2 protein of the beta papillomaviruses has been shown to be 
extensively phosphorylated in vivo, with PKA phosphorylation of an RXXS motif in the hinge 
region being required for the association between E2 and mitotic chromosomes (Sekhar et al., 
2009).  Additionally phosphorylation of the RS dipeptides in the hinge region has been shown 
to be required for the localisation of the E2 proteins to nuclear speckles (Lai et al., 1999, 
Sekhar et al., 2009).  Therefore SRPK1 phosphorylation of E2 may control both the 
localisation of E2 and some of the functions of E2 in the life cycle of the virus, such as the 
promotion the efficient packaging of viral genomes into virions (K. N. Zhao et al., 2000). 
Additionally, the hinge region of HPV1 E2 was a substrate for SRPK1 and HPV1 E1^E4 
inhibited SRPK1 phosphorylation of this viral SR protein.  Whether SRPK1 can 
phosphorylate the hinge region of HPV1 E2 in vivo is unknown and the significance of the 
inhibition of SRPK1 phosphorylation of E2 by HPV1 E1^E4 on the life cycle of HPV1 is yet 
to be determined.  In HPV16 the E1^E4 protein has been shown to stabilise the E2 protein 
Chapter 4 
156 
and control its subcellular localisation, thus regulating some of E2s functions (Davy 2009).  
The regulation of SRPK1 phosphorylation of HPV1 E2 by HPV1 E1^E4 may be a method of 
controlling the stability and functions of E2. 
In summary, HPV1 E1^E4 can inhibit SRPK1 kinase activity with all tested substrates, 
(although the inhibition of HPV8 E2 hinge was not significant) but the variation in inhibition 
between the different substrates demonstrates that the potency of E1^E4 mediated SRPK1 
inhibition is substrate specific. 
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CHAPTER 5 BIOLOGICAL FUNCTIONS OF THE 
INTERACTION BETWEEN HPV1 E1^E4 AND SRPK1 
5.1 Introduction 
HPV1 E1^E4 is found in numerous inclusions in a natural infection and these inclusions have 
been shown to be associated with several cellular proteins including the ND10 body defining 
protein PML, and the cellular kinase SRPK1 (Bell et al., 2007, Breitburd et al., 1987, Roberts 
et al., 2003).  SRPK1 is relocalised to E4 inclusions in the granular layer of warts but not in 
the spinous layer, even though E4 inclusions are present in these layers (Bell et al., 2007).  
Indicating that SRPK1 sequestration to inclusions is required in the later stages of the HPV1 
life cycle, where the capsid proteins are being expressed (Bell et al., 2007, Peh et al., 2002).  
Overexpression of HPV1 E1^E4 proteins in established epithelial cell lines gives rise to the 
formation of similar “in vivo-like” inclusions (Roberts et al., 2003, Rogel-Gaillard et al., 
1992).  Coexpression of HPV1 E1^E4 and SRPK1 causes the recruitment of SRPK1 to the 
cytoplasmic E4 inclusions, indicating that redistribution of SRPK1 is E4 dependent (Bell et 
al., 2007). 
The phosphorylation state of the RS domain of the SR proteins is involved in mediating the 
subcellular localisation of the SR proteins as well as the interactions of the SR proteins with 
other proteins and RNA.  SR proteins are predominantly concentrated in nuclear speckles 
which are sites of storage for transcription factors and also sites of active transcription.  
Overexpression of SRPK1, SRPK2 and CLK/STY has been shown to lead to the disassembly 
of nuclear speckles and cytoplasmic accumulation of the SR proteins (Colwill et al., 1996, 
Gui et al., 1994a, H. Y. Wang et al., 1998).  The disassembly of nuclear speckles requires the 
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kinase to be active and leads to the hyperphosphorylation of the SR proteins (Koizumi et al., 
1999, H. Y. Wang et al., 1998). 
Pre-mRNA splicing is an essential step for gene expression in higher eukaryotes and is 
controlled by multiple factors.  The minigene system allows the identification of cis-acting 
regulatory elements and trans-acting factors which bind to these elements and establish 
splicing efficiency and regulate alternative splicing.  The expression of a minigene by 
transient transfection allows for the easy analysis of splicing regulation (Cooper, 2005).  Use 
of a minigene coding for an alternatively spliced exon of mouse SRp20 has shown that SRp20 
regulates the alternative splicing of its own mRNA (Jumaa and Nielsen, 1997).  
Overexpression of SRp20 leads to the inclusion of the alternatively spliced exon, which 
produces a truncated protein, lacking the RS domain that is inactive for many SR protein 
functions.  In contrast, expression of ASF/SF2, promotes the skipping of the exon and 
therefore the production of the functional full length SRp20 protein (Jumaa and Nielsen, 
1997).  Interestingly the expression of the SR proteins SRp40 and 9G8 has no effect on the 
alternative exon inclusion, whereas SC35 leads to a novel splicing of the SRp20 minigene, 
demonstrating the range of effects the different SR proteins have on a single splice site 
(Jumaa and Nielsen, 2000).  The autoregulation through splicing demonstrated by SRp20 has 
been observed with several other SR proteins including ASF/SF2 and SC35, with alternative 
ASF/SF2 transcripts being contained in the nucleus and SC35 producing unstable mRNAs (S. 
Sun et al., 2010, Sureau et al., 2001).  The hyperphosphorylation of SR proteins by CLK2, has 
been shown to promote the skipping of the alternative exon in SRp20, to increase the amount 
of active protein produced (Stoss et al., 1999). 
The minigene system can be used to analyse the cellular factors utilised by viruses to 
alternatively splice viral genes.  The Adenovirus E1A gene has multiple splice isoforms and 
using an E1A minigene, the overexpression of ASF/SF2 has been shown to activate the 
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proximal 5‟ ss, prevent abnormal exon skipping and promote exon inclusion, leading to the 
production of the largest isoform of E1A (Caceres et al., 1994).  Overexpression of the CLK 
kinases has been shown to promote the usage of the distal 5‟ ss and the production of the 
smaller isoforms (Yomoda et al., 2008).  The same study showed that the overexpression of 
SRPK1 and other SR protein kinases had no effect on splice site selection in the E1A 
minigene (Yomoda et al., 2008). 
In this chapter the effect of the interaction between HPV1 E1^E4 and SRPK1 on the kinase 
activity has been examined in vivo.  In addition the effect of relocalisation of SRPK1 to E4 
inclusion bodies will be examined with regards to cellular distribution of the SR proteins.  
Finally the effect of the interaction between SRPK1 and HPV1 E1^E4 on splice site selection 
will also be examined using the minigene system. 
5.2 Results 
5.2.1 In vivo inhibition of SRPK1 by HPV1 E1^E4 
The inhibition studies carried out with His-SRPK1 and GST-HPV1 E1^E4 showed that HPV1 
E1^E4 is a potent inhibitor of SRPK1 in vitro.  However the effects of the interaction between 
SRPK1 and HPV E1^E4 in cells is unknown.  In order to determine whether HPV1 E1^E4 
can inhibit SRPK1 in vivo, Flag-tagged SRPK1 was transfected into H1299 cells along with 
plasmids expressing HPV1 E1^E4 and HPV1 E1^E4 Δ44-48 (a non-binding mutant).  Flag-
tagged MCM7 (minichromosome maintenance complex component 7), which has been shown 
to interact with HPV1 E1^E4 (Roberts et al., 2008), was also added to control for any non-
specific effects.  Following transfection the cells were harvested and immunoprecipitated with 
an anti Flag antibody or an anti-HPV1 E4 antibody.  The immunoprecipitated proteins were 
then added to an in vitro kinase assay containing GST-ASF/SF2 and 
32
P labelled γ-ATP.  
Following resolution by SDS PAGE, the gel was exposed to X-ray film (Figure 5.1A) and 
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quantified by phosphorimager analysis (Figure 5.1B).  The HPV1 E4 immunoprecipitation 
was performed to ensure that the HPV1 E1^E4 deletion mutant Δ44-48 did not bind to 
SRPK1 (Figure 5.1C).  Protein expression was analysed in the cell lysates by Western blot 
using anti-Flag and anti-HPV1 E4 antibodies (Figure 5.1D).   
In the presence of the HPV1 E1^E4 protein, the immunoprecipitated Flag-SRPK1 (Flag IP) 
showed a significant reduction in phosphorylation of the substrate GST-ASF/SF2 in the in 
vitro kinase assay compared to the Flag-SRPK1 immunoprecipitated from cells co-transfected 
with Flag-SRPK1 and the HPV1 E1^E4 deletion mutant Δ44-48 which was unable to bind to 
SRPK1 (Figure 5.1A).  The phosphorylation of GST-ASF/SF2 observed with 
immunoprecipitated Flag-MCM7 was due to non-specific sticking of kinases to the Sepharose 
beads and was considered the background level of phosphorylation.  The proteins 
immunoprecipitated with HPV1 E1^E4 (HPV1 E4 IP) were able to phosphorylate GST-
ASF/SF2 to a small extent (Figure 5.1C), this may be due to HPV1 E1^E4 sometimes binding 
to SRPK1 in a manner which does not cause inhibition of kinase activity. 
The kinase assay showed that HPV1 E1^E4 can inhibit SRPK1 in vivo, with the level of 
inhibition of HPV1 E1^E4 wild type compared to the non-binding mutant Δ44-48 at 36% this 
inhibition is significant (p = 0.030).  The level of inhibition in vivo however is not as great as 
the inhibition observed in vitro of 65% (Chapter 3, Figure 3.6).  This was most likely due to 
the presence of SRPK1 that was not in complex with HPV1 E1^E4 or was bound in a 
conformation which does not cause inhibition.   
This data indicates that HPV1 E1^E4 alters SRPK1 kinase activity in vivo and HPV1 E1^E4 
may therefore affect SRPK1 functions.   
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Figure 5.1 In vivo inhibition of SRPK1 by HPV1 E1^E4.  Flag-tagged SRPK1 and 
MCM7 were co-transfected into cells with WT and Δ44-48 HPV1 E1^E4.  The proteins 
were subject to IP with anti-Flag and anti-HPV1 E4 antibodies and added to an in vitro 
kinase assay with GST-ASF/SF2.  (A) 
32
P autoradiograph and Coomassie stained gel 
from in vitro kinase assay with Flag IP proteins.  (B) Graph showing the normalised data 
for the Flag IP, * = p < 0.05, graph contains the mean ± standard deviation from five 
experimental replicates.  (C) 
32
P autoradiograph and Coomassie stained gel from in vitro 
kinase assay with proteins from HPV1 E4 IP.  (D) Western blot with 1/20th of the input 
lysate blotted with rabbit anti-Flag and mouse anti-HPV1 E4 (4.37). 
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5.3 SRPK1 colocalises with HPV1 and HPV5 E1^E4 in cells 
To understand the effect of HPV E4 proteins on SRPK1 functions the localisation of SRPK1 
in the presence of HPV1 E1^E4 and HPV5 E1^E4 was examined.  HPV1 E1^E4 is found in 
numerous nuclear and cytoplasmic inclusions in natural infections and when expressed in 
established epithelial cell lines (Breitburd et al., 1987, Roberts et al., 2003, Rogel-Gaillard et 
al., 1992).  The distribution of E4 in naturally-occurring HPV5 infections has not been 
reported. 
In immortalised human keratinocytes, Flag-SRPK1 co-localized to HPV1 E1^E4 inclusions 
(Bell et al., 2007), although the distribution of endogenous SRPK1 was not examined in this 
study.  To confirm and extend these findings immortalised keratinocytes (SVJD), HPV 
containing cervical cancer keratinocytes (HeLa) and the non small cell lung carcinoma cells 
H1299 were each transfected with a plasmid expressing HPV1 E1^E4, fixed 48 h following 
transfection and stained for endogenous SRPK1 and HPV1 E4 (Figure 5.2).  In cells 
transfected with the empty plasmid SRPK1 has a mainly cytoplasmic staining pattern, 
however there is some nuclear staining, and this is consistent with the literature (Figure 5.2A) 
(J. H. Ding et al., 2006).  For all three cell lines, in cells expressing HPV1 E1^E4 a proportion 
of endogenous SRPK1 was present in E4 inclusions in the cytoplasm and in the nucleus 
(Figure 5.2B – H1299 cells, Figure 5.2C – HeLa cells and data not shown). 
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Figure 5.2 Localisation of SRPK1 with HPV1 E1^E4 in H1299 and HeLa 
cells.  (A) H1299 cells were transfected with an empty plasmid.  (B) H1299 cells were 
transfected with a plasmid expressing HPV1 E1^E4, alternative images under the same 
conditions shown.  (C) HeLa cells were transfected with a plasmid expressing HPV1 
E1^E4.  The cells were fixed with a 0.1% Triton® X-100 pre treatment, then 4% 
paraformaldehyde followed by acetone permeabilisation.  Cells were stained with mouse 
anti-SRPK1 (green) and mouse anti-HPV1 E4 (4.37) (red), nuclei were indentified with 
DAPI (blue).  Arrowheads indicate HPV1 E4 inclusions.  Scale bar indicates 10 µm. 
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Figure 5.3 Localisation of Flag-SRPK1 with HPV1 E1^E4 in H1299 cells.  
H1299 cells were transfected with Flag-SRPK1 and a plasmid expressing HPV1 E1^E4.  
Cells were stained with rabbit anti-Flag (red) and mouse anti-HPV1 E4 (4.37) (green), 
nuclei were indentified with DAPI (blue).  (A) Epifluorescent microscopy, top image: 
cells transfected with Flag-SRPK1 and empty plasmid, bottom image: cells transfected 
with Flag-SRPK1 and pcDNA HPV1 E1^E4.  (B) Confocal microscopy showing two 
alternative images under the same conditions.  White arrowheads indicate HPV1 E4 
inclusions, blue arrowheads indicate colocalisation not related to inclusions.  Scale bar 
indicates 10 µm. 
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Colocalisation between SRPK1 and HPV1 E1^E4 is also seen with exogenous Flag-tagged 
SRPK1 as previously reported (Bell et al., 2007).  Flag-SRPK1 shows the same staining 
pattern as endogenous SRPK1, with mainly cytoplasmic staining; however as with 
endogenous SRPK1 a proportion of cells have intense nuclear staining (Figure 5.3A).  The 
Flag-SRPK1 is sequestered to the HPV1 E4 inclusions and this is confirmed with confocal 
microscopy (Figure 5.3B).  The Flag-SRPK1 is also colocalised with HPV1 E1^E4 not in 
inclusions, demonstrating that the colocalisation between SRPK1 and HPV1 E1^E4 is not 
dependent upon the E4 protein being in the inclusions, shown with blue arrowheads in Figure 
5.3B. 
Since HPV5 E1^E4 has been shown to be a substrate in vitro (Chapter 3, section 3.5.1) for 
SRPK1 it was important to determine if HPV5 E1^E4 altered the localisation of SRPK1 in 
cells.  Therefore to determine whether HPV5 E1^E4 could cause a re-localisation of SRPK1 
in vivo, a HA-tagged construct containing the HPV5 E1^E4 sequence was constructed using a 
HA cassette, (Chapter 2, section 2.2.7) and the pGex-2T HPV5 E1^E4 plasmid.  The HA-
tagged HPV5 E1^E4 was transfected into HeLa, H1299 and SVJD cells and fixed 48 h 
following transfection.  Cells were pre-washed with 0.1% Triton
®
 X-100 and then fixed with 
4% paraformaldehyde followed by acetone permeabilisation.  The HA-HPV5 E1^E4 was 
detected with an antibody against the HA tag.  HPV5 E1^E4 was found present in the 
cytoplasm and nucleus, as a diffuse staining but also present as numerous distinct cytoplasmic 
aggregates, as shown in Figure 5.4 (A and B) in HeLa cells.  In around 5% of the transfected 
population of cells, intense nuclear and cytoplasmic staining of HPV5 E1^E4 was observed 
(Figure 5.4C).  The localisation of the HA-HPV5 E1^E4 was the same in the three cell lines 
used.  In cells expressing HA-HPV5 E1^E4, a proportion of the endogenous SRPK1 formed 
aggregates and co-stained with the HA-HPV5 E1^E4 in some of these aggregates and around 
the nuclear membrane (Figure 5.5).  
Chapter 5 
166 
 
Figure 5.4 Localisation of HA-HPV5 E1^E4 in HeLa cells.  HeLa cells were 
transfected with HA-HPV5 E1^E4 and showed three different staining patterns.  (A) 
Diffuse cytoplasmic and nuclear staining with cytoplasmic aggregates.  (B) Diffuse 
cytoplasmic staining with distinct cytoplasmic aggregates.  (C) Intense cytoplasmic and 
nuclear staining.  Cells were stained with mouse anti-HA (green) and nuclei were 
indentified with DAPI (blue).  Scale bar indicates 10 µm. 
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Figure 5.5 Localisation of HA-HPV5 E1^E4 and SRPK1 in HeLa, H1299 and 
SVJD cells.    (A) HeLa (two alternative images under the same conditions), (B) H1299 
and (C) SVJD cells were transfected with HA-HPV5 E1^E4.  Cells were stained with 
mouse anti-SRPK1 (green) and rabbit anti-HA (red), nuclei were identified with DAPI 
(blue).  White arrowheads indicate some areas of co-staining, blue arrowheads indicate 
nuclear SRPK1 aggregates which do not co-stain with HPV5 E1^E4.  Scale bar indicates 
10 µm.  
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Figure 5.6 Localisation of Flag-SRPK1 with HA-HPV5 E1^E4 in HeLa cells.  
(A and B) HeLa cells were transfected with Flag-SRPK1 and HA-HPV5 E1^E4, two 
alternative images under the same conditions.  Cells were stained with rabbit anti-Flag 
(red) and mouse anti-HA (green), nuclei were indentified with DAPI (blue) and analysed 
by confocal microscopy.  Box indicates area enlarged below.  Scale bar indicates 10 µm. 
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To extend the finding that HA-HPV5 E1^E4 caused a change in the staining pattern of 
endogenous SRPK1, co-transfection of HA-HPV5 E1^E4 with Flag-SRPK1 expression 
plasmids into cells was performed.  As with the endogenous SRPK1, HA-HPV5 E1^E4 
altered the localisation of the Flag-SRPK1 into aggregates, confocal analysis of these cells 
showed that SRPK1 was colocalised to the cytoplasmic E1^E4 aggregates (Figure 5.6A).  
Interestingly, in a subset of E1^E4 transfected cells, SRPK1 formed nuclear aggregates which 
were not colocalised with E1^E4 (Figure 5.6B).   
This data suggests that HPV5 E1^E4 induces a relocalisation of SRPK1 in the cytoplasm and 
nucleus and that a proportion of SRPK1 is colocalised with the HPV5 protein, similar to that 
seen with HPV1 E1^E4. 
 
5.4 HA tagged SR proteins 
To aid with the visualisation of SR proteins in vivo and to investigate the localisation and 
functions of the SR proteins in overexpression and splicing studies, HA-tagged constructs of 
the SR proteins ASF/SF2, SC35 and SRp20 were generated (Chapter 2, 2.2.7).  The 
expression and distribution of these tagged proteins was analysed following transfection into a 
panel of established cells lines including COS-1 epithelial cells, HeLa cervical cancer cells 
and H1299 lung carcinoma cells.  After 48 h post transfection cellular lysates (COS-1 cells) 
were solubilised in RIPA buffer, resolved by SDS-PAGE and Western blotted using an anti-
HA antibody.  Bands corresponding to the expected sizes of 28.9 kDa for HA-ASF/SF2, 20.4 
kDa for HA-SRp20 and 26.9 kDa for HA-SC35 were detected (Figure 5.7A).  The HA-tagged 
SR proteins are resolved as doublets as they can be both hypo- and hyper-phosphorylated in 
vivo.    
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Figure 5.7 Expression and localisation of HA-tagged SR proteins.  (A) Cos 
cells were transfected with HA-tagged constructs, lysed in RIPA buffer and the gel 
western blotted with a mouse anti-HA antibody.  (B) H1299 and HeLa cells were 
transfected with HA-ASF/SF2 or HA-SC35 and stained with rabbit anti-HA (red) and 
mouse anti-SC35 (green), nuclei were stained with DAPI (blue).  Scale bar indicates 10 
µm. 
Chapter 5 
171 
The HA-tagged SR proteins were transfected into H1299 and HeLa cells on slides and after 
48 h washed with 0.1% Triton
®
 X-100 and then fixed with 4% paraformaldehyde followed by 
acetone permeabilisation.  The transfection showed that the HA-tagged ASF/SF2, SRp20 and 
SC35 had a mainly nuclear localisation and could often be visualised in nuclear speckles.  Co-
staining with endogenous SC35 showed colocalisation between the endogenous SC35 
speckles and a proportion of the HA-tagged ASF/SF2 and SC35 proteins (Figure 5.7B).  The 
antibody used to identify SC35 speckles is for a phosphorylated form of the protein and 
showed that the majority of the HA-SC35 is not phosphorylated in the cells.  The expression 
of the HA-SRp20 plasmid was poor in the cell lines used, with very low levels of staining 
seen in the transfected cells; therefore no further analysis was performed using this construct. 
 
5.5 Overexpression of SRPK1 causes the relocalisation of SR proteins 
The phosphorylation of SR proteins is required for multiple functions during pre-mRNA 
splicing and several groups have reported previously that overexpression of SRPK1 leads to 
the release of SR proteins from nuclear speckles (Gui et al., 1994a, H. Y. Wang et al., 1998).  
To demonstrate that this was observed in the cell lines used for this study, Flag-tagged 
SRPK1 was transfected into H1299 cells and 48 h post transfection the cells were fixed with 
various fixation methods.  The cells were stained using antibodies against the endogenous 
phosphorylated SR proteins (Figure 5.8), endogenous ASF/SF2 (Figure 5.9), and endogenous 
SC35 (Figures 5.10 and 5.11).   
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Figure 5.8 Localisation of phosphorylated SR proteins upon Flag-SRPK1 
expression.  (A) H1299 cells were transfected with Flag empty vector.  (B) H1299 cells 
were transfected with Flag-SRPK1, three different staining patterns for the SR proteins 
were observed under the same conditions.  Cells were stained with mouse anti-phospho 
SR protein (1H4) (green) and rabbit anti-Flag (red), nuclei were stained with DAPI 
(blue).  Scale bar indicates 10 µm. 
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Figure 5.9 Localisation of ASF/SF2 upon expression of Flag-SRPK1.  (A) 
H1299 cells were transfected in top image with Flag empty vector or in bottom image 
with Flag-SRPK1 and fixed using methanol. (B) H1299 cells were transfected in top 
image with Flag empty vector or in bottom image with Flag-SRPK1 and fixed using  
paraformaldehyde followed by 0.1% Triton
®
.  Cells were stained with mouse anti-
ASF/SF2 (green) and rabbit anti-Flag (red), nuclei were stained with DAPI (blue).  Scale 
bar indicates 10 µm. 
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Figure 5.10 Localisation of SC35 upon expression of Flag-SRPK1.  (A) H1299 
cells transfected with Flag empty vector.  (B) H1299 cells transfected with Flag-SRPK1, 
two alternative images under the same conditions. Cells were stained with mouse anti-
SC35 (green) and rabbit anti-Flag (red), nuclei were stained with DAPI (blue).  Scale bar 
indicates 10 µm. 
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Figure 5.11 Localisation of SC35 upon expression of Flag-SRPK1.  (A) H1299 
cells transfected with Flag empty vector.  (B) H1299 cells transfected with Flag-SRPK1, 
three alternative images under the same conditions.  Cells were stained with mouse anti-
SC35 (green) and rabbit anti-Flag (red), nuclei were stained with DAPI (blue).  Cells 
were analysed by confocal microscopy, scale bar indicates 10 µm. 
 
 
Chapter 5 
176 
5.5.1 Phosphorylated SR proteins 
The antibody against the phosphorylated SR proteins (1H4) (Figure 5.8) showed a mainly 
nuclear distribution of the SR proteins, with distinct speckles in the nucleus, corresponding to 
splicing speckles, when fixed using cold methanol for 10 min.  Upon expression of Flag-
tagged SRPK1, when the SRPK1 is expressed in the nucleus, the SR protein speckles become 
more diffuse and the staining becomes more cytoplasmic.  The change in localisation occurs 
because the phosphorylation state of the SR proteins changes and the proteins are released 
from the splicing speckles (Koizumi et al., 1999).  When the SRPK1 is cytoplasmic, no 
visible effect is observed upon 1H4 staining.  
5.5.2 ASF/SF2 
The prototypical SR protein ASF/SF2 had different localisations under different fixation 
conditions.  With 10 min of cold methanol, ASF/SF2 was present in both the nucleus and the 
cytoplasm, with distinct speckles visible in the nucleus (Figure 5.9A).  Upon expression of the 
Flag-SRPK1 vector, nuclear ASF/SF2 staining is markedly decreased and staining increases 
in the cytoplasm.  Under different fixation conditions of 20 min of paraformaldehyde 
followed by 15 min of 0.1% Triton
®
 X-100, the ASF/SF2 has diffuse nuclear staining with 
speckles of more intense staining (Figure 5.9B).  The effect of SRPK1 overexpression on 
ASF/SF2 localisation was less pronounced under these staining conditions, with the speckles 
becoming less intense against the diffuse nuclear staining, some cytoplasmic staining was 
observed, however this was difficult to capture in an image. 
5.5.3 SC35 
The SR protein SC35 is considered to be a non-shuttling SR protein and is confined to the 
nucleus, SC35 is generally used as a marker of splicing speckles (Fu and Maniatis, 1990).  As 
the overexpression of SRPK1 leads to the loss of nuclear speckles and cytoplasmic 
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accumulation of the phosphorylated SR proteins and ASF/SF2, cells transfected with Flag-
SRPK1 were stained for endogenous phosphorylated SC35.  The cells were fixed with 4% 
paraformaldehyde followed by acetone permeabilisation, giving the characteristic nuclear 
speckled pattern of SC35 (Figure 5.10).  The presence of nuclear SRPK1 led to loss to the 
nuclear speckles in around 70% of cells and in around 25% of cells a complete loss of nuclear 
SC35 staining.  When the SRPK1 was not located in the nucleus, the distribution of SC35 was 
not altered.  Confocal analysis showed that there was a small amount of colocalisation 
between the SRPK1 and SC35 in the cytoplasm and around the nuclear membrane (Figure 
5.11). 
The loss of SC35 speckles which occurred when Flag-SRPK1 was expressed was specific to 
SRPK, as the expression of other plasmids including GFP and Flag-MCM7, which can be 
present in the nucleus, did not cause any change in SC35 localisation (Figure 5.12). 
5.5.4 HA-tagged SR proteins  
The HA-tagged SR proteins did not alter in their cellular localisation upon transfection with 
Flag-SRPK1 (Figure 5.13), confocal microscopy showed colocalisation between the HA-
tagged SR proteins and Flag-SRPK1, especially with HA-ASF/SF2 (Figure 5.13B). 
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Figure 5.12 Localisation of SC35 upon expression of GFP and Flag-MCM7.  
(A) H1299 cells were transfected with GFP-C1 and cells were stained with mouse anti-
SC35 (red), two alternative images under the same conditions.  (B) H1299 cells were 
transfected with Flag-MCM7.  Cells were stained with mouse anti-SC35 (red) and rabbit 
anti-Flag (green), nuclei were stained with DAPI (blue).  Scale bar indicates 10 µm. 
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Figure 5.13 Localisation of HA-tagged SR proteins with expression of Flag-
SRPK1.  H1299 cells were transfected with Flag-SRPK1 and (A) HA-SC35 (two 
alternative images under the same conditions) or (B) HA-ASF/SF2.  Cells were stained 
with mouse anti-Flag (M2) (green) and rabbit anti-HA (red), nuclei were stained with 
DAPI (blue).  Cells were analysed by confocal microscopy, scale bar indicates 10 µm. 
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5.6 Inhibition of SRPK1 kinase activity does not inhibit SRPK1-mediated 
relocalisation 
5.6.1 HPV1 E1^E4 
As HPV1 E1^E4 has been shown to inhibit the kinase activity of SRPK1 in vitro and in vivo, 
and SRPK1 has been implicated in defining SR protein localisation, the effect of HPV1 
E1^E4 on SRPK1-mediated distribution of SR proteins was analysed.  Initially the effect of 
HPV1 E1^E4 on the endogenous SR proteins was examined.  HPV1 E1^E4 was transfected 
into H1299 and HeLa cells and 24 h post transfection the cells were washed with 0.1% 
Triton
®
 X-100 and then fixed with 4% paraformaldehyde followed by acetone 
permeabilisation.  The cells were stained for endogenous SC35 (Figure 5.14A), ASF/SF2 
(Figure 5.14B) and phosphorylated SR proteins (1H4) (Figure 5.14C).  When HPV1 E1^E4 
formed nuclear inclusions, a small proportion of the SR proteins costained with these HPV1 
E4 inclusion bodies.  In vitro HPV1 E1^E4 does not interact with any SR proteins (data not 
shown) so the recruitment of SR proteins to E4 inclusions may occur via the formation of a 
complex with other proteins.  Apart from the recruitment to E4 inclusions, the distribution of 
the SR proteins is not altered in the presence of HPV1 E1^E4, with the inhibition of 
endogenous SRPK1 kinase activity by HPV1 E1^E4 having no effect on SR protein 
localisation.   
The overexpression of SRPK1 caused a relocalisation of SR proteins, therefore HPV1 E1^E4 
was cotransfected into H1299 and HeLa cells with Flag-SRPK1 to investigate whether the 
inhibition of SRPK1 activity could disrupt this relocalisation (Figure 5.15).  Twenty-four 
hours post transfection the cells were fixed with 4% paraformaldehyde, permeabilised with 
0.1% Triton
®
 X-100 and then the cells were stained with antibodies against Flag and 
endogenous SC35.  As HPV1 E1^E4 relocalised SRPK1 to inclusions and a triplicate stain 
was difficult to perform due to the antibody subtypes, a cell was considered to be HPV1 
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E1^E4 positive if SRPK1 was observed to be sequestered to inclusion bodies.  In the presence 
of HPV1 E1^E4 the expression of nuclear Flag-SRPK1 still caused the loss of SC35 nuclear 
speckles in 60% of cells and caused a complete loss of nuclear SC35 staining in 30% of the 
cellular population. The sequestration of SRPK1 to E4 inclusion bodies in the nucleus caused 
a reduction in the loss of SC35 speckles (Figure 5.15C), whereas sequestration of SRPK1 to 
E4 inclusion bodies in the cytoplasm had no effect on SC35 speckle loss (Figure 5.15A and 
B).  When SRPK1 was not located in the nucleus, no effect was observed on SC35 staining 
(Figure 5.15D).  HPV1 E1^E4 does not inhibit the redistribution of SC35 upon SRPK1 
overexpression in the nucleus, except when the nuclear SRPK1 is sequestered to E4 inclusion 
bodies. 
5.6.2 SRPIN340 
The small molecule inhibitor SRPIN340 has been shown to specifically inhibit SRPK1 and 
SRPK2 (Fukuhara et al., 2006).  To determine whether the kinase activity of SRPK1 was 
required to cause the relocalisation of SC35 upon SRPK1 overexpression, 10 µM SRPIN340 
was added to cells for 20 h following transfection of Flag-SRPK1.  The cells were fixed with 
4% paraformaldehyde, permeabilised with 0.1% Triton
®
 X-100 and then were stained with 
antibodies against Flag and endogenous SC35 (Figure 5.16).  Cells had an equivalent amount 
of DMSO (0.1% v/v) added, to check any effects observed were not due to solvent effects.  
Addition of SRPIN340 had no negative effect on the redistribution of SC35 from speckles 
upon SRPK1 overexpression.  With SRPIN340, cells with nuclear SRPK1 had a loss of SC35 
speckles in 27% of the cells and a complete loss of nuclear SC35 in 67% of the cells.  A 
higher proportion of the cell population had a loss of nuclear SC35 staining when compared 
to a Flag-SRPK1 transfection in the absence of DMSO.  However between the SRPIN340 and 
DMSO treated cells there was no change in the loss of nuclear SC35 staining, suggesting that 
the DMSO not SRPIN340, promoted the loss of SC35 speckles. 
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Figure 5.14 Localisation of SR proteins with HPV1 E1^E4 in H1299 cells.  
H1299 cells were transfected with HPV1 E1^E4.  Cells were stained with mouse 4.37 
(red) and (A) mouse anti-SC35 (green) two alternative inmages under the same 
conditions, (B) mouse anti-ASF/SF2 (green) or (C) mouse anti-phospho SR protein 
(1H4) (green); nuclei were stained with DAPI (blue).  Arrowheads indicate nuclear E4 
inclusions and scale bar indicates 10 µm. 
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Figure 5.15 Localisation of SC35 with Flag-SRPK1 and HPV1 E1^E4.  H1299 
cells were transfected with Flag-SRPK1 and HPV1 E1^E4.  Cells were stained with 
rabbit anti-Flag (red) and mouse anti SC35 (green), nuclei were stained with DAPI 
(blue).  (A and B) Nuclear SRPK1 staining with cytoplasmic HPV1 E4 inclusions.  (C) 
Nuclear SRPK1 with nuclear HPV1 E4 inclusions.  (D) Cytoplasmic SRPK1 and 
cytoplasmic HPV1 E4 inclusions.  Arrowheads indicate HPV1 E4 inclusions.  Scale bar 
indicates 10 µm. 
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Figure 5.16 Localisation of SC35 with Flag-SRPK1 expression and SRPIN340 
treatment.  H1299 cells were transfected with Flag-SRPK1 and treated with 10 µM 
SRPIN340, four alternative images under the same conditions.  Cells were stained with 
rabbit anti-Flag (red) and mouse anti SC35 (green), nuclei were stained with DAPI 
(blue).  Scale bar indicates 10 µm. 
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Inhibition of SRPK1 kinase activity, either by cotransfection with HPV1 E1^E4 or by 
treatment with SRPIN340 had no effect on the relocalisation of SR proteins caused by the 
overexpression of SRPK, except when the SRPK1 was recruited to nuclear E4 inclusions.   
5.7 The effect of HPV1 E1^E4 on SRPK1 function in alternative splicing 
The phosphorylation state of the RS domain of SR proteins is altered during pre-mRNA 
splicing, with the initial recruitment of SR proteins to splice sites requiring the RS domain to 
be hyperphosphorylated  (Gui et al., 1994a).  The precise role of SRPK1 in splicing is yet to 
be determined, therefore the interaction between SRPK1 and HPV1 E1^E4 may act to 
modulate splice site selection and allow for preferential viral genome splicing. 
5.7.1 The minigene system 
The minigene system allows the identification and in vivo analysis of cis-acting regulatory 
elements and trans-acting factors which establish splicing efficiency and regulate alternative 
splicing.  Minigenes contain an exon and flanking introns in an expression plasmid and allow 
the easy analysis of factors which affect the alternative splicing of that splice junction.  
Minigene constructs were obtained for X16 (mouse SRp20) (Figure 5.17A), which allowed a 
mammalian splice junction to be investigated and the adenovirus E1A gene (Figure 5.17B), 
which allowed a viral splice site to be investigated.  The X16 minigene contained exon 4 of 
X16 flanked by part of exons 3 and 5 and the corresponding introns.  Two alternatively 
spliced variants are produced; these are termed either „exon 4 included‟ or „exon 4 skipped‟ 
and can easily be distinguished between when resolved by native PAGE (Figure 5.17A).  The 
E1A minigene produced five alternatively spliced variants, termed 9S, 10S, 11S, 12S and 
13S, from the three 5‟ splice sites and two 3‟ acceptor sites as shown in figure 5.17B.   
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Figure 5.17 X16 and E1A minigene constructs.  (A) The alternative splicing of the 
X16 minigene.  Ethidium bromide stained native PAGE showing the two different splice 
variants.  (B)  The alternative splicing of the E1A minigene.  Ethidium bromide stained native 
PAGE showing the five alternative splice variants. 
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5.7.2 The effect of SR proteins and SRPK1 on splice site selection 
The SR proteins SRp20 and ASF/SF2 are known to differentially regulate the X16 minigene, 
with SRp20 promoting exon 4 inclusion and ASF/SF2 promoting exon 4 skipping (Jumaa and 
Nielsen, 1997).  To aid with quantification α-32P dCTP was added to the PCR reaction, this 
allowed the resolved native PAGE gel to be analysed using the phosphorimager.  When the 
X16 minigene was transfected into 293 cells along with GFP, GFP-ASF/SF2, HA-SRp20 and 
Flag-SRPK1, the GFP-containing cells produced a mixture of the two splice variants, with 
56% of the spliced RNA containing exon 4.  The GFP-ASF/SF2 expressing cells, produced 
mainly the exon 4 skipped variant (93%), and those expressing HA-SRp20 expressed mainly 
the exon 4 inclusion variant (84%) (Figure 5.18).  These results confirm that ASF/SF2 and 
SRp20 differently regulate the X16 minigene (p = 0.00002).  The expression of Flag-SRPK1 
had no significant effect on the splice site selection of the X16 minigene (p = 0.67-0.87), 
however the anti-Flag Western blot showed that the Flag-SRPK1 transfection was not very 
efficient. 
The SR protein ASF/SF2 is known to activate proximal 5‟ splice sites, prevent abnormal exon 
skipping and promote exon inclusion with the E1A minigene (Caceres et al., 1994).  When the 
E1A minigene was transfected into 293 cells along with GFP, GFP-ASF/SF2, HA-SRp20 and 
Flag-SRPK1, the cells expressing GFP produced a mixture of the five splice variants, the 
main forms produced are the 13S (33%) and 9S (28%) (Figure 5.19).  Expression of GFP-
ASF/SF2 increased the amount of 13S produced to 55% of the total RNA compared to the 
GFP transfected cells (p = 0.003); however all of the other splice variants were present.  
Expression of HA-SRp20 had no significant effect on the splice variants produced when 
compared to the GFP expressing cells (p = 0.79 for 13S).  The expression of Flag-SRPK1 had 
no significant effect on the splice variants produced (p = 0.77-0.93 for 13S).   
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Figure 5.18 X16 minigene with ASF/SF2, SRp20 and SRPK1.  GFP, GFP-ASF/SF2 
and HA-SRp20 in the presence and absence of Flag-SRPK1 were co-transfected with the X16 
minigene into 293 cells.  (A) 
32
P autoradiograph and ethidium bromide stained native PAGE 
gel showing the alternative splice variants.  (B) Graph showing the percentage of exon 4 
included RNA produced.  The data show the mean ± standard deviation of five repeats.  *** = 
p < 0.0001.  (C) Western blot showing transfection levels of GFP, GFP-ASF/SF2, HA-SRp20 
and Flag-SRPK1. 
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Figure 5.19 E1A minigene with ASF/SF2, SRp20 and SRPK1.  GFP, GFP-ASF/SF2 
and HA-SRp20 in the presence and absence of Flag-SRPK1 were co-transfected with the 
E1A minigene into 293 cells.  (A) 
32
P autoradiograph and ethidium bromide stained 
native PAGE gel showing the alternative splice variants.  (B) Graph showing the 
percentage of spliced RNA on the gel which was 13S.  * = p < 0.005.  (C) Graph 
showing the percentage of spliced RNA on the gel which was 9S. Graphs show the mean 
± standard deviation of five repeats.  (D) Western blot showing transfection levels of 
GFP, GFP-ASF/SF2, HA-SRp20 and Flag-SRPK1. 
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5.7.3 The effect of HPV1 E1^E4 on splice site selection 
The previous experiments showed that different SR proteins affect the choice of splice site 
with two different minigenes and that the overexpression of SRPK1 had no effect on the 
splice variants produced.  However, interference with activity of endogenous SRPK1 might 
affect the splicing reactions within the minigene system.  Therefore, to investigate whether 
HPV1 E1^E4 had any effect on splice site selection, HPV1 E1^E4 was transfected into 293 
cells with Flag empty vector or Flag-SRPK1 and GFP, GFP-ASF/SF2 or HA-SRp20 and the 
X16 minigene (Figure 5.20).  The expression of HPV1 E1^E4, with and without Flag-SRPK1 
had no significant effect on the splice site selection with the X16 minigene, even in the 
presence of either of the two SR proteins (p = 0.31-91).  In some experimental repeats the 
presence of HPV1 E1^E4 decreased the production of the exon 4 included variant in the 
presence of HA-SRp20 and Flag-SRPK1; however this result was not consistent between 
repeats.  This data suggests that if HPV1 E1^E4 is controlling host splicing, this is on a cell-
by-cell basis and is not the major functional consequence of the interaction of HPV1 E1^E4 
and SRPK1.  However as the X16 minigene is a mouse gene, the regulation of X16 splicing 
may not be performed by exactly the same mechanisms as for a human gene, therefore for any 
conclusions about the effect of HPV1 E1^E4 on host splicing requires additional experiments 
using human genes to be performed.  The expression of HPV1 E1^E4 had no effect on splice 
site selection with the Adenovirus E1A minigene either (data not shown), this suggests that 
HPV1 E1^E4 is not controlling viral gene splicing.  However the splicing of HPV genes may 
be regulated by different mechanisms to the Adenovirus E1A gene, therefore further 
investigation is required to determine the effect of HPV1 E1^E4 on viral splice site selection. 
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Figure 5.20 X16 minigene with HPV1 E1^E4. HPV1 E1^E4 with Flag empty vector 
or Flag-SRPK1 and GFP, GFP-ASF/SF2 or HA-SRp20 were co-transfected with the X16 
minigene into 293 cells.  (A) 
32
P autoradiograph and ethidium bromide stained native 
PAGE gel showing the alternative splice variants.  (B) Graph showing the percentage of 
the spliced RNA on the gel which was exon 4 included.  Graph shows the mean ± 
standard deviation of four repeats.  (C) Western blot showing transfection levels of GFP, 
GFP-ASF/SF2, HA-SRp20, Flag-SRPK1 and HPV1 E1^E4. 
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5.8  Discussion 
The findings of co-expression of HPV1 E1^E4 and SRPK1 in cells has shown that HPV1 
E1^E4 inhibits SRPK1 activity in vivo.  The level of inhibition within the in vivo experiment 
however is much reduced than that observed in vitro (36% inhibition compared to 65%).  This 
may be because not all of the SRPK1 is in complex with HPV1 E1^E4, as observed using 
confocal microscopy of immunostained cells (Figure 5.3).  Interestingly, SRPK1 that was 
coprecipitated with the HPV1 E1^E4 antibody was able to phosphorylate ASF/SF2 to a small 
extent, suggesting that SRPK1 may be able to bind to HPV1 E1^E4 in a manner which does 
not always cause the loss of kinase activity.   
It has been shown previously that HPV1 E1^E4 causes the relocalisation of exogenous 
SRPK1 to E4 inclusion bodies (Bell et al., 2007), and this relocalisation is observed with 
endogenous SRPK1 as well (Figure 5.2).  The SRPK1 was also colocalised with HPV1 
E1^E4 which was not in inclusions, demonstrating that the relocalisation of SRPK1 is not 
dependent upon the formation of E4 inclusions.  In warts, although numerous E4 inclusions 
are present in cells in the lower suprabasal layers there is no evidence of SRPK1 
sequestration; however the level of SRPK1 expression is low in these cells.  Hence, 
sequestration may be dependent on specific E4 posttranslational modifications that occur only 
in the more superficial cells. 
The distribution of HPV5 E1^E4 has not been reported previously and here it is shown that 
HPV5 E1^E4 was located in the cytoplasm and nucleus, with several characteristic staining 
patterns (Figure 5.4).  The different staining patterns of HPV5 E1^E4 may be cell cycle 
regulated.  HPV5 E1^E4 formed distinct cytoplasmic aggregates, which may be similar to the 
E4 inclusions formed in infections with other cutaneous HPVs including HPV1 and HPV2 
(Doorbar and Gallimore, 1987).  SRPK1 was observed to be colocalised to these aggregates, 
demonstrating that HPV5 E1^E4 can cause the relocalisation of SRPK1.  Additionally, the 
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presence of HPV5 E1^E4 caused SRPK1 to form aggregates which were not colocalised with 
HPV5 E1^E4.  The nature of these SRPK1 aggregates are unknown, however SRPK1 has 
been shown to localise to stress granules under chemical stress (Raithatha and Roberts, 
unpublished data), therefore the SRPK1 aggregates formed with HPV5 E1^E4 may be stress 
granules. 
The overexpression of SRPK1 has been shown to lead to the disassembly of nuclear speckles 
and the cytoplasmic accumulation of the SR proteins (Gui et al., 1994a).  Studies using a 
kinase dead SRPK1, have confirmed that the kinase activity of SRPK1 is required to cause 
this relocalisation (H. Y. Wang et al., 1998).  The loss of nuclear speckles and nuclear 
staining of multiple SR proteins was observed with the overexpression of SRPK1 and this was 
most obvious when SRPK1 was in the nucleus and concurs with the findings of others that 
indicate SRPK1 must be present in the nucleus to cause the loss of nuclear speckles.  The 
sequestration of SRPK1 to cytoplasmic E4 inclusions however, did not prevent the 
translocation of SRPK1 into the nucleus.  In contrast, in cells where SRPK1 is sequestered to 
nuclear E4 inclusions the extent of disassembly of nuclear speckles in these cells was often 
reduced; therefore the sequestration of SRPK1 to E4 nuclear inclusions may inhibit this form 
of the kinase from phosphorylating SR proteins within speckles as occurs in cells expressing a 
kinase dead SRPK1.  Surprisingly inhibition of SRPK1 with SRPIN340 also did not impede 
the disassembly of nuclear speckles with SRPK1 overexpression; this was unexpected but 
may be due to the conditions used in the experiment, as the SRPIN340 was added 4 h into the 
transfection.  The relocalisation caused by SRPK1 overexpression may occur before this time 
and not be rescued by the inhibition of SRPK1 activity. 
This study confirmed that SRp20 and ASF/SF2 differentially regulate the X16 minigene; 
however the overexpression of SRPK1 had no effect on the splice isoform produced.  This is 
in contrast to the observations of Stoss et al., (1999), who showed that CLK2 can promote the 
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exclusion of the alternative exon 4; and demonstrates the specificity of the kinases in vivo.  In 
accordance with Yomoda et al., (2008), SRPK1 overexpression had no effect on the splice 
isoforms produced with the E1A minigene, again demonstrating the functions of the different 
kinases in splicing regulation.  The SR proteins ASF/SF2 and SRp20 produced different 
splice isoforms with the E1A minigene, however unlike Caceres et al., (1994); all isoforms 
were still present with the expression of ASF/SF2, whereas their study demonstrated a 
complete switch to the largest 13S isoform.  The discrepancies between the studies may be 
due to differences in experimental conditions e.g. transfection efficiency.  The data presented 
in this chapter confirms that different SR proteins perform different roles in splice site 
selection, with some splice sites only having ESEs which are recognised by specific SR 
proteins.   
Somewhat surprisingly, the addition of HPV1 E1^E4 to the minigene systems had no overall 
effect on the splicing isoforms produced.  However in the presence of SRp20, different results 
were observed in individual repeats with the X16 minigene, with some showing a decrease in 
the amount of exon 4 included isoform in the presence of HPV1 E1^E4.  The reasons for this 
are unclear, but since overexpression of SRPK1 did not have any effect upon splicing in the 
X16 minigene system it could be that only a specific population of endogenous SRPK1 is 
involved and HPV1 E1^E4 may only target this form in a subpopulation of cells.  It might 
also be possible that any effect of HPV1 E1^E4 upon SRPK is dependent on posttranslational 
modification of the viral protein e.g. N-terminal processing (Knight et al., 2004) and 
additional forms are required alongside the full-length protein.  It is also possible that HPV1 
E1^E4 is unable to target and inhibit the form of SRPK1 that is involved in splicing reactions 
but perhaps inhibits other functions of SRPK1. 
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CHAPTER 6 ROLE OF SRPK1 IN EPITHELIAL 
DIFFERENTIATION  
6.1 Introduction 
Multiple viruses have been shown to modulate SR proteins during infection, one such virus is 
HIV, which has been shown to induce the degradation, dephosphorylation and relocalisation 
of SR proteins.  Interestingly overexpression of SRPK1 or SRPK2 in the presence of HIV, 
can avoid the virus mediated degradation of the SR proteins (Fukuhara et al., 2006), 
demonstrating that HIV is modulating SRPK activity.  The phosphorylation of SR proteins by 
SRPKs has been shown to stabilise the proteins and accordingly inhibition of the SRPKs with 
the small molecule inhibitor SRPIN340, promotes their degradation (Fukuhara et al., 2006).  
Stabilisation of several SR proteins, including SRp75, by the overexpression of SRPK2, 
increases HIV production; however inhibition of the SRPKs with SRPIN340 has little effect 
on suppressing HIV replication (Fukuhara et al., 2006).  In contrast the inhibition of SRPKs 
with SRPIN340 has been shown to inhibit the propagation of other viruses, including Sindbis 
virus, severe acute respiratory syndrome coronavirus (SARS), cytomegalovirus (CMV) and 
hepatitis C virus (HCV), which are all acutely replicating viruses (Fukuhara et al., 2006, 
Karakama et al., 2010).  The production of HCV 1b and 2a replicons were suppressed with 
treatment with SRPIN340, but not with a control compound which does not inhibit SRPKs 
(Karakama et al., 2010).  The effect of this inhibition upon SRPKs was directed at the 
intracellular core protein of HCV whose expression was downregulated by treatment with 
SRPIN340, and following the knockdown of SRPK1 and SRPK2 with siRNA (Karakama et 
al., 2010).  These findings demonstrate that SRPKs are required for the efficient replication of 
HCV and that the targeting of SRPKs is a potential anti-viral treatment option for HCV.  
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The organotypic raft system allows cultured keratinocytes to stratify and differentiate in a 
manner similar to normal epithelium such that the structure accurately mimics the in vivo 
physiology of the epidermis.  The organotypic raft system most commonly used today is 
based on the technique developed by Asselineau and Prunieras (1984).  Briefly, primary 
keratinocytes are seeded onto a collagen plug in which mouse fibroblasts are embedded.  
Once confluence is attained the structure is then lifted to the air-liquid interface using a metal 
grid support and the cultures maintained for up to 2 weeks to allow full differentiation to 
occur.  Studies of the HPV life cycle have been seriously hampered by the lack of tissue 
culture systems in which to grow the virus, but the adaption of the organotypic raft system to 
HPV containing cells has been an invaluable technique.  Alongside the use of rafts has been 
the development of keratinocyte based models that support maintenance and replication of 
viral episomes from high-risk HPV types (Frattini et al., 1996).  Transfection of viral 
episomes into primary keratinocytes isolated from cervical, foreskin or tonsillar sites enables 
the establishment of stable cells lines that maintain the episomes.  Upon differentiation in 
organotypic rafts the complete virus life cycle is recapitulated.  Thus primary HFKs 
containing viral genomes grown as organotypic raft cultures allow late, differentiation-
dependent virus functions to be studied, for example see (Knight et al., 2011).   
Little is known of the function of SRPK1 in epidermal differentiation and there is growing 
evidence that the family of SRPK kinases have functions other than those connected to 
splicing and RNA metabolism (Giannakouros et al., 2011).  Likewise the role these kinases 
play in the virus life cycle is also unknown, although it is known that the virus modulates SR 
protein expression and there is evidence that some of these SR proteins are required for HPV 
RNA splicing (Jia et al., 2009, Somberg and Schwartz, 2010).  Identifying the role of SRPK1 
in epidermal differentiation and in the life cycle may be a successful route to understand the 
function of E1^E4 association with SRPK1 and also to understand why some HPVs such as 
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HPV1 inhibit SRPK1.  As SRPK1 has been shown to be required for the replication of several 
viruses (Fukuhara et al., 2006) understanding SRPK1 function in the HPV life cycle might 
identify a new antiviral therapeutic target for viral intervention.  To these ends, this chapter 
examines the distribution of SRPK1 in organotypic raft cultures of normal primary human 
keratinocytes and in rafts of HPV18 genomes containing keratinocytes (Wilson et al., 2007).  
Additionally the effect of inhibition of SRPK by using the small molecular inhibitor 
SRPIN340 on early and late virus functions will also be examined 
 
6.2 Distribution of SRPK1 upon epithelial differentiation 
In primary epidermal tissue, SRPK1 has been shown to be present in the basal and suprabasal 
cells, with expression levels increasing as the cells become more differentiated (Bell et al., 
2007).  SRPK1 staining is however mostly absent from the fully differentiated cornified layer.  
This pattern of SRPK1 distribution suggests that epithelial terminal differentiation might be 
dependent on the regulation of SRPK1 function.  To investigate this further, the organotypic 
raft system of primary human keratinocytes was used (Chapter 2, 2.6.5).  When primary 
human foreskin keratinocytes (HFKs) were allowed to differentiate in the raft system and 
were fixed and sectioned, the different epithelial layers from basal through parabasal, spinous 
and granular to the cornified layer were clearly present when stained with haematoxylin and 
eosin (H and E) (Figure 6.1A).  The haematoxylin stains nuclei and acidic structures blue and 
the eosin stains the cytoplasm and basic structures shades of pink.    
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Figure 6.1 Expression of SRPK1 in organotypic rafts of primary human 
foreskin keratinocyte.  (A) H and E stained section of untransfected HFKs; the layers of 
stratified epithelium are indicated.  (B) HFKs stained with anti-SRPK1 monoclonal 
antibody (green) and nuclei stained with DAPI (blue).  (C) Expanded boxed area of B, 
showing SRPK1 staining in upper stratified layers.  Immunofluorescence staining was 
analysed by confocal microscopy, scale bar indicates 10 µm. 
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The raft sections were subjected to antigen retrieval using a low-temperature EDTA method 
(Watson et al., 2002) and then stained with an anti-SRPK1 monoclonal antibody (Figure 
6.1B).  Similar to the primary tissue, SRPK1 was present at low levels in the basal and 
parabasal layers.  The expression of SRPK1 was upregulated in correlation with the 
morphological differentiation of the cells, with SRPK1 expression being highest in the 
granular layer (Figure 6.1C).  SRPK1 staining had a grainy cytoplasmic appearance and 
unlike in monolayer culture, SRPK1 was not present in the nuclei of the differentiated cells.   
6.2.1 Effect of HPV18 on SRPK1 distribution 
When HPV18 containing HFKs are grown in the raft system, there a several differences in the 
morphology of the epithelia produced.  These include the retention of nuclei in the upper 
stratified layers and thickening of the parabasal and spinous layers (Figure 6.2A).  To 
determine if the distribution of SRPK1 is altered in cells containing HPV18 genomes, the 
HPV18 DNA-containing rafts were stained with the SRPK1 monoclonal antibody and SRPK1 
distribution was compared to the pattern in non-HPV containing cells (Figure 6.2B).  The 
distribution of SRPK1 expression was comparable to the differentiation dependent expression 
in the absence of HPV18.  However, in cells in the upper spinous and granular layers, where 
SRPK1 expression is highest, SRPK1 formed prominent aggregates in the cytoplasm and 
these were often observed to be distributed around the nuclear membrane (Figure 6.2C).  Akin 
to the untransfected cells, there was no accumulation of SRPK1 in the nuclei.  Whilst SRPK1 
aggregates are present in untransfected cells, in the HPV18 containing cells, the aggregates 
are more often larger and more numerous suggesting that the presence of HPV18 was 
modulating SRPK1 subcellular distribution.  
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Figure 6.2 SRPK1 expression in HPV18 genome containing organotypic rafts.  
(A) H and E stained organotypic raft of HFKs containing the HPV18 genome, layers of 
stratified epithelium are indicated.  (B) HPV18 containing HFKs stained with anti-
SRPK1 monoclonal antibody (green) and nuclei stained with DAPI (blue).  (C) Expanded 
boxed area of B, showing SRPK1 staining in upper stratified layers.  Red arrowheads 
indicate SRPK1 aggregates, blue arrowheads indicate SRPK1 aggregates at nuclear 
membrane.  Immunofluorescence staining was analysed by confocal microscopy, scale 
bar indicates 10 µm. 
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Figure 6.3 Localisation of SRPK1 and E1^E4 in HPV18 genome containing 
rafts.  (A) HPV18 genome containing HFKs stained with mouse anti-SRPK1 (green) and 
rabbit anti-HPV18 E1^E4 (R424, red), nuclei are stained with DAPI (blue).  (B) 
Expanded boxed areas of panels a) to c), showing SRPK1 and HPV18 E1^E4 staining.  
Arrowheads indicate SRPK1 aggregates.  Immunofluorescence staining was analysed by 
confocal microscopy, scale bar indicates 10 µm.  
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Since SRPK1 accumulates to E4 inclusions within HPV1 warts and HPV18 E1^E4 interacts 
with SRPK1 in vitro (Chapter 3, 3.4) (Bell et al., 2007), it is possible that HPV18 E4 is 
modulating the distribution of SRPK1.  Therefore to determine whether E4 is present in the 
SRPK1 aggregates HPV18 containing rafts were co-stained for SRPK1 and HPV18 E1^E4 
(Figure 6.3A).  The SRPK1 aggregates were present both in cells that were positive for E1^E4 
and those which were negative (Figure 6.3B).  This data suggests that HPV18 E1^E4 does not 
cause the aggregation of SRPK1 in the upper layers of the epithelium.   
 
6.3 The effect of SRPK inhibition on HPV18 genome containing HFKs 
6.3.1 In monolayer cell culture 
The presence of HPV18 genomes has been shown to induce changes in the subcellular 
localisation of SRPK1, suggesting that SRPK1 function may be utilised by HPV18 for some 
part of the virus life cycle, or perhaps the function of this kinase is inhibited during the 
infectious cycle.  To determine the importance of SRPKs in the HPV18 life cycle the small 
molecule inhibitor SRPIN340 can be used to inhibit SRPK kinase activity in vivo (Fukuhara 
et al., 2006).  Initially, SRPIN340 was added to HPV18 containing HFKs growing in 
monolayer, in increasing concentrations to determine whether there was any toxic effect of 
SRPIN340 on cell growth and to determine if the inhibitor modulated viral episome 
replication (Figure 6.4).  The SRPIN340 was dissolved in DMSO, so an equivalent amount of 
DMSO was added to controls for each SRPIN340 concentration to account for any solvent 
effects.  To determine whether SRPIN340 had any toxic effects on the cells, a toxicity assay 
was performed (Chapter 2, 2.6.3) (Figure 6.4A).  Cells were treated with different 
concentrations of SRPIN340 (1, 5, 10, 25 and 40 μM) and viable cells counted after 48 hours.   
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Figure 6.4 The effect of SRPIN340 on HPV18 containing HFKs.  SRPIN340 of 
increasing concentrations was added to HFKs for 48 h, with equal amounts of DMSO 
added to control cells.  (A) Cells were harvested and viable cells counted after trypan 
blue staining.  Graph shows average ± standard deviation for 2 experimental repeats (10 
counting chambers for each).  (B) Autoradiograph of Southern blot of HPV DNA 
maintenance replication in SRPIN340 treated HPV18 containing HFKs.  Blot probed 
with HPV18 DNA. 
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This showed that there was no significant change in cell viability with increasing SRPIN340 
concentration, even at the highest concentration of 40 µM (p = 0.63) when compared to the 
DMSO control.  Total DNA was extracted from the cells and analysed by Southern blot to 
monitor HPV18 genome maintenance (Chapter 2, 2.6.4) (Figure 6.4B).  There was stable 
episome replication at all concentrations of SRPIN340 examined, suggesting that SRPK 
function was not required for the maintenance of HPV18 genomes in primary HFKs.   
6.3.2 In organotypic rafts 
The inhibition of SRPK activity had no effect on the maintenance of HPV18 genomes in 
monolayer culture, but since SRPK1 is most abundant in the upper layers of the epithelium 
where the virus is undergoing its vegetative cycle SRPK1 function may have more relevance 
to the later stages of the virus life cycle.  To examine the effect of SRPIN340 on the 
stratification of the HPV genome containing cells SRPIN340 was added to cells growing in 
organotypic raft culture for the final seven days out of thirteen.  The SRPIN340 was added in 
two concentrations to untransfected HFKs and cells containing HPV18 genomes.  DMSO 
solvent controls were also included.  After 13 days, rafts were formalin fixed and paraffin-
embedded and sections analysed using H and E staining (Figure 6.5).  Following SRPIN340 
treatment, untransfected HFK stratified into multi-layered structure with a similar 
morphological appearance to untreated, or rafts treated with DMSO alone.  However, rafts 
incubated with SRPIN340 showed slightly reduced thickness of the spinous and parabasal 
layers (Figure 6.5A).  In the HPV18 genome containing HFKs, a dose dependent response 
was observed with SRPIN340 treatment.  At 10 µM SRPIN340, the raft produced a stratified 
structure, however the different stratified layers were less defined than when compared to 
DMSO treated rafts.  Additionally there was some disorder in the granular layer, as the cells 
were less granulated and more koilocytotic (Figure 6.5B).   
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Figure 6.5 The effect of SRPIN340 on organotypic rafts.  (A) Untransfected 
HFKs were treated with 25 µM SRPIN340 or an equal amount of DMSO.  (B) HFKs 
transfected with HPV18 genomes were treated with 10 µM SRPIN340 or an equal 
amount of DMSO.  (C) HFKs transfected with HPV18 genomes were treated with 25 µM 
SRPIN340 or an equal amount of DMSO.  Arrowheads indicate koilocytes.  Scale bar 
indicates 10 µm.        
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At the higher dose of SRPIN340 (25 µM), the thickness of the spinous and parabasal layers 
were reduced, and the disorder of the granular layer more marked at this concentration of 
SRPIN340.  There was also a high degree of nuclei retention in the cornified layer 
(parakeratosis) and an increase in the amount of cells which are koilocytotic (Figure 6.5C).  
Koilocytic cells are epithelial cells which contain an acentric, hypercromatic, moderately 
enlarged nucleus which is displaced by a large perinuclear vacuole, koilocytic cells are a 
marker for the productive phase of HPV (Krawczyk et al., 2008).      
The organotypic rafts were also treated with SRPIN340 for the complete thirteen days of 
growth of the rafts.  Using these conditions of treatment gross changes in morphology were 
observed for rafts treated with SRPK inhibitor but also the DMSO vehicle control when 
compared to non-treated.  There was a large amount of invasion of the underlying collagen 
layer, however as this was present in the DMSO treated cells as well as SRPIN340, this effect 
is likely to be due to the DMSO (data not shown).  When SRPIN340 was added to the rafts 
for the last 2 days of growth, the rafts were thinner compared to the DMSO treated, with a 
small amount of disorder in the granular and spinous layers (data not shown). 
The morphology of the organotypic rafts treated with SRPIN340 suggests that SRPKs are 
involved in some differentiation dependent functions of HPV18, as inhibition of SRPK 
function, resulted in thinner rafts with atypical stratification. 
6.4 Discussion 
The distribution and expression of SRPK1 in primary epidermal tissue and in primary HFKs 
grown in organotypic raft culture is similar.  In the basal and parabasal layers the expression 
of SRPK1 is low; however as the cells differentiate the expression of SRPK1 increases up 
into the granular layer.  In the fully differentiated cornified layer, SRPK1 staining is absent.  
The SRPK1 is only present in the cytoplasm of the differentiated cells, however in cultured 
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cells grown in monolayer, some cells have nuclear SRPK1 (Figure 5.2A).  The nuclear 
transport mechanism for SRPK1 is unknown, however SRPK1 has been observed to be 
translocated to the nucleus at the end of the G2 phase of cell cycle (J. H. Ding et al., 2006).  
The differentiated cells are no longer undergoing cell cycle; therefore there may be no longer 
be a need for nuclear SRPK1 in these cells.  The SRPK1 staining has a grainy but fairly 
uniform appearance in the differentiated untransfected cells, but the presence of HPV18 
genomes causes SRPK1 to form aggregates which are commonly located around the nuclear 
membrane.  The formation of the SRPK1 aggregates is not dependent upon HPV18 E1^E4, as 
the aggregates are present in both cells positive and negative for HPV18 E1^E4 staining.  The 
cause and the function of the SRPK1 aggregates is currently unknown, but they may be 
similar to the SRPK1-containing aggregates caused by transfection with HPV5 E1^E4 (Figure 
5.5).  HPV1 causes the relocalisation of SRPK1 to E4 inclusions; so the aggregation of 
SRPK1 into inclusions or aggregates may be a conserved strategy by which HPV modulates 
the functions of SRPK1.  Staining of the rafts with an antibody against poly(A)-binding 
protein (PABP) a known constituent of stress granules, showed no colocalisation of stress 
granules with the SRPK1 aggregates (data not shown). 
SRPIN340 has been shown to be non-toxic in heptato carcinoma cells (Huh7) and human 
embryonic kidney cells (Flp-In293) grown in cell culture up to 30 µM (Fukuhara et al., 2006, 
Karakama et al., 2010).  This study shows that SRPIN340 is non-toxic to HPV18 genome 
containing primary HFKs up to 40 μM.  The treatment of the HPV18 genome containing 
HFKs with SRPIN340, demonstrates that SRPKs are not required for the stable maintenance 
of episomal genomes in these cells.  This suggests that SRPK regulation of SR proteins is not 
required for the efficient viral genome splicing, the other kinases able to phosphorylate SR 
proteins, such as the CLKs may perform this regulation.  The treatment of organotypic rafts 
with SRPIN340 produces morphological changes in the stratification of the rafts.  There is an 
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increased amount of koilocytosis and parakeratosis when SRPIN340 is added to the cells 
during differentiation.  Since these morphological changes were not strongly evident in the 
DMSO controls then this suggests that SRPKs are modulating HPV18 replication in some as 
yet undefined manner.  SRPIN340 caused the predominance of koilocytes, which are 
epithelial cells containing an acentric, hypercromatic, moderately enlarged nucleus that is 
displaced by a large perinuclear vacuole.  The mechanism of koilocyte formation is largely 
unknown; however studies have linked the proteins E5 and E6 with their formation 
(Krawczyk et al., 2008).  These cells are associated with virion production in the granular 
layers of the epithelium and are used as a marker of the productive phase of HPV.  
Additionally, treatment with SRPIN340 caused a high degree of parakeratosis, with nuclei 
retention in the cornified layer of the raft.  Parakeratosis is beneficial to the virus, as the viral 
capsid is produced in the nucleus.  The morphological changes observed with SRPIN340 
treatment suggest that the inhibition of SRPK activity promotes the late vegative stages of the 
virus life cycle. 
Time constraints did not allow for further analysis of the effect of SRPIN340 on the different 
viral functions that occur in suprabasal cells including vegetative events of viral genome 
amplification, capsid expression and virion production and infectivity. 
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CHAPTER 7 DISCUSSION 
7.1 Overview of findings 
The work in this thesis has sought to address the hypothesis that the interaction between 
E1^E4 and SRPK1 alters SRPK1 activity and that this association influences the functions of 
SRPK1 in the HPV life cycle.  This study has uncovered the novel finding that the E1^E4 
protein of HPV1 is a potent inhibitor of SRPK1 kinase activity in vitro and in vivo and that 
this inhibition is dependent upon E1^E4 binding to SRPK1.  Other E1^E4 proteins also bind 
SRPK1 in vitro, including those of HPV16 and HPV18 (Bell et al., 2007), and as shown in 
this thesis the beta virus HPV5, however none of these influence SRPK1 activity in vitro.  
HPV1 E1^E4 inhibits phosphorylation of a range of SR protein substrates including the 
prototypical SR protein ASF/SF2, SRp20, SC35, SRp75 and 9G8 but with some evidence of 
differences in potency of inhibition by the E1^E4 protein.  The serine-arginine rich beta HPV 
E2 proteins (5 and 8) are known to behave as SRPK1 substrates and in this study the E2 
protein of HPV1 was also found to be phosphorylated by SRPK1 in vitro and HPV1 E1^E4 
inhibited SRPK phosphorylation of this protein.  Both SRPK1 binding partners HPV1 E1^E4 
and HPV5 E1^E4 are substrates for the cellular kinase (Bell et al., 2007)(and this thesis) and 
overexpression of these E1^E4 proteins in cells sequesters SRPK1 to inclusions and 
aggregates, suggesting that altered SRPK1 localisation may modulate SRPK1 functions.  
However, upon overexpression of HPV1 E1^E4 only moderate effects on SR protein cellular 
localisation and on cellular and viral RNA splicing in minigene systems were observed.  By 
making use of an HPV18-keratinocyte cell model (Wilson et al., 2007) grown as organotypic 
rafts it was found that SRPK1 localisation in the more differentiated cell layers is modified in 
comparison to cells negative for the virus.  Moreover, addition of the small molecule inhibitor 
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of SRPK, SRPIN340 to these raft cultures enhanced the morphological features of HPV 
replication in a dose-dependent manner and suggests that HPV modulates SRPK activity to 
facilitate the virus life cycle.  
7.2 Inhibition of SRPK1 by HPV1 E1^E4 
The direct interaction between HPV1 E1^E4 and SRPK1 inhibited the kinase activity of 
SRPK1 both in vitro and in vivo.  The biological significance of the inhibition of SRPK1 
function is still unknown, however examination of the splicing regulation of mammalian and 
viral genes using the minigene system showed that the splice site selection was not altered 
significantly in the presence of HPV1 E1^E4.  The splicing of HPV genes was not examined 
in this study and may be regulated by different proteins to the adenovirus gene analysed.   
The role of SRPK1 overexpression in splice site selection has not been demonstrated by this 
study and others (Yomoda et al., 2008).  Phosphorylation of the SR proteins by CLK 
overexpression has been shown to affect splice site selection (Stoss et al., 1999, Yomoda et 
al., 2008) however studies have not demonstrated a role for SRPK1.  To determine whether 
SRPK1 does play a role in splice site selection, SRPIN340 or siRNA knockdown of SRPK1 
could be used with the minigene system.  If inhibition of SRPK by SRPIN340 does cause a 
change in splice site selection this could reveal whether E1^E4 targets specific pools of 
SRPK1 in the cell. 
SR proteins have also been shown to have roles in mRNA export and protein translation, none 
of which have been examined in this study and perhaps the inhibition of SRPK1 activity by 
E1^E4 may be affecting one or more of these other functions of SR proteins.  Therefore the 
investigation of the effect of HPV1 E1^E4 on these processes is required to determine the 
biological effects of this inhibition.  This study has focussed on the effect of SRPK1 on SR 
proteins involved in RNA metabolism, however evidence is accumulating that SRPKs have 
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effects on other cellular activities including chromatin reorganisation, regulation of cyclins 
and metabolic signalling (Giannakouros et al., 2011).   
In comparison to the in vitro findings, the potency of HPV1 E1^E4 as an inhibitor of SRPK1 
is reduced in vivo.  This may be due to posttranslational modifications of E4 such as 
phosphorylation which do not occur in vitro, impeding the ability of E4 to interact with and 
inhibit SRPK1.  In natural HPV1 infections SRPK1 sequestration to cytoplasmic E4 
inclusions is restricted to the more differentiated cells (Bell et al., 2007), cells in which the 
late viral genes are expressed.  It is well known that the HPV1 E4 protein is extensively 
modified in these cells by proteolytic cleavage (Breitburd et al., 1987); in these cells the 
processed forms may contribute the inhibitory function of E4 and these smaller forms may be 
lacking in the established cells lines in which the experiments were performed. 
As the sequestration of SRPK1 to E4 inclusions in a natural HPV1 infection coincides with 
late HPV functions, the inhibition of SRPK1 function may aid in the switch from early to late 
gene expression, as the SR proteins ASF/SF2 and SRp20 have been implicated in this 
regulation (Jia et al., 2009, Somberg and Schwartz, 2010).   
There are other human members of the SRPK family which are found in epithelial cells 
(SRPK1a and SRPK2), and have been shown to have specific functions and interactions.  
SRPK2 has been shown to phosphorylate acinus and control the transcription of cyclin A1 
(Jang et al., 2008), while SRPK1a has been shown to specifically interact with scaffold 
attachment factor B (Nikolakaki et al., 2001).  The interaction of E1^E4 with these proteins 
should be examined to determine whether the inhibition caused by HPV1 E1^E4 is specific to 
SRPK1 and also whether any of the other E1^E4 proteins can inhibit these kinases.  This 
would allow for more insight into the biological functions of the SRPK-E1^E4 interaction. 
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7.3 Relocalisation of SRPK1 
Like the HPV1 E1^E4 protein, overexpression of the E1^E4 protein of HPV5 induces a 
relocalisation of SRPK1 to E4 containing cytoplasmic aggregates.  In addition HPV18 causes 
aggregation of SRPK1 in the upper layers of differentiating epithelial cells demonstrating that 
the modulation of SRPK1 localisation may be a conserved feature among HPV types, 
although not always E4 dependent.  The modulation of SRPK localisation may inhibit SRPK1 
functions or may provide the virus with a source of the kinase which can be preferentially 
used for viral replication, either by phosphorylating viral proteins or cellular targets.  It is 
therefore interesting that the HPV1 E2 protein is phosphorylated within the hinge region by 
SRPK1, as are E2 proteins of the beta viruses (Lai et al., 1999, Sekhar et al., 2009) (see 
section below). 
The SRPK1 aggregates caused by the expression of HPV5 E1^E4 were localised close to 
periphery of the nucleus, suggesting that a complex with a membrane protein may be formed.  
One potential membrane bound protein which is a known substrate of SRPK1 is the lamin B 
receptor (LBR), which is involved in the disassembly and reassembly of the nuclear envelope 
(Takano et al., 2002).  Disturbances of nuclear integrity might be relevant to easing the escape 
of newly made virions from the cells of the upper layers of warts.  Abrogation of the 
interaction between LBR and heterochromatin by the human polyomavirus JC virus leads to a 
loss in nuclear envelope integrity and a promotion of virus escape (Okada et al., 2005). 
The overexpression of SRPK1 has been shown to cause the disassembly of nuclear speckles 
(Colwill et al., 1996, Gui et al., 1994a, H. Y. Wang et al., 1998); the sequestration of SRPK1 
to cytoplasmic HPV1 E4 inclusions did not inhibit the nuclear translocation of SRPK1 or the 
disassembly of the speckles.  Sequestration to nuclear E4 inclusions however did reduce the 
level of disassembly observed, suggesting that HPV1 E1^E4 may only be targeting specific 
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pools of SRPK1 to modulate its activity.  Interestingly these nuclear inclusions are also 
associated with ND10 body associated proteins (Roberts). 
7.4 Role of SRPK1 in the late virus life cycle 
Splicing of the early transcripts has been shown to require ASF/SF2 and SRp20 (Jia et al., 
2009, Somberg and Schwartz, 2010).  Within organotypic raft cultures of HPV18 genome 
containing keratinocytes however, the level of SRPK1 is low and only increases in the upper 
levels concomitant with late HPV functions.  Perhaps therefore SRPK1 does not act upon the 
SR proteins in these early phases of the HPV18 life cycle.  The SR proteins can be 
phosphorylated by the CLK family of kinases (Colwill et al., 1996); therefore it is likely that 
these kinases control these SR protein functions.  The distribution of these kinases in the rafts 
should be examined.  Further evidence that SRPK1 is not an important regulator of early HPV 
events came from the inhibitor studies which showed that SRPK functions are not required for 
the efficient maintenance of HPV18 episomes. 
When the role of SRPKs was examined in the late virus life cycle, the inhibition of SRPK1 
activity changed the growth morphology of organotypic rafts containing HPV18 genomes.  
The rafts had an increase in the amount of koilocytotic cells that are indicative of virus 
production and suggests that SRPK1 inhibition might be associated with enhanced virion 
production.  The increased appearance of koilocytes correlated with an increase of 
parakeratosis, indicating that the nuclei were not being degraded.  Preservation of nuclear 
integrity is a significant phase within the HPV lifecycle promoting the vegetative phase.  As 
already mentioned the SRPK1 substrate LBR is involved in nuclear envelope disassembly.  
The phosphorylation of the LBR by CDK1 has been shown to induce the disassembly of the 
nuclear envelope and prevents the premature reassembly of the envelope during normal cell 
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cycle (Tseng and Chen, 2011).  SRPK1 may therefore control the disassembly of the nuclear 
envelope in the upper layers of the epithelium, after the cells have exited cell cycle. 
Further study is required to extend these interesting findings using SRPIN340.  Whether there 
is an increase in virion production can be verified by immunostaining the raft with antibodies 
to the capsid proteins.  Virus can be isolated from the rafts and infectivity assays performed to 
compare virus production between untreated and SRPIN340 treated structures.  The effect of 
the inhibitor on viral genome amplification could be examined by using fluorescence insitu 
hybridisation.  It would also be important to verify SRPK1 inhibition in treated rafts by 
isolating the protein and testing activity in in vitro kinase assays.  If SRPKs are modulating 
the switch from early to late gene expression then they present a viable therapeutic target as 
upregulated production of the capsid proteins and downregulation of the E6 
immunomodulatory protein could cause immune system activation. 
7.5 Substrates of SRPK1 
The E2 protein of HPV5 and HPV8 contains multiple RS repeats in the hinge region, but the 
HPV1 E2 is also a substrate for SRPK1 in vitro.  The RS repeats of the beta papillomaviruses 
have been shown to modulate their subcellular localisation (Lai et al., 1999, Sekhar et al., 
2009), however the effect of RS repeat phosphorylation on E2 functions are unknown.  The 
HPV5 E2 protein has been shown to recruit the splicing machinery to pre-mRNAs 
transactivated by E2 itself (Lai et al., 1999) and the phosphorylation of the E2 hinge by 
SRPK1 may act to regulate this function.  The phosphorylation of HPV1 E2 by SRPK1 in 
vitro is novel and the regulation of this phosphorylation by HPV1 E1^E4 may act to stabilise 
the E2 protein and also may modulate some of the E2 proteins functions in the later stages of 
the virus life cycle.  It has been reported that the HPV16 E1^E4 protein can stabilise and 
modulate the subcellular localisation of the E2 protein (Davy 2009).  Additionally the E1^E4 
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proteins of HPV1 and HPV5 are substrates for SRPK1 in vitro (Bell et al., 2007); the 
phosphorylation of these proteins may act to stabilise them and/or change their functions.   
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APPENDIX  
Appendix 1A  pGex-2T-HPV5 E1^E4 against HPV5b complete genome  
(Accession D90252.1) 
Base changes shown in bold and underlined 
HPV5 E1^E4   AGCTCCACGCCTCCAGGGTCGCCAGGAAGACAAGCAGACACAGACACCACCGCCAAGACC  
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3328  AGCTCCACGCCTCCAGGGTCGCCAGGAAGACAAGCAGACACAGACACCACCGCCAAGACC  3387 
 
HPV5 E1^E4   CCCACCACCTCCACAACCGCCGTTGACTCCACGTCCAGACAGCTCACCACATCAAAACAG  
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3388  CCCACCACCTCCACAACCGCCGTTGACTCCACGTCCAGACAGCTCACCACATCAAAACAG  3447 
 
HPV5 E1^E4   CCACAACAAACCGAAACCAGAGGAAGAAGGTACGGACGGAGGCCCTCCAGCAAGTCAAGG 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3448  CCACAACAAACCGAAACCAGAGGAAGAAGGTACGGACGGAGGCCCTCCAGCAAGTCAAGG  3507 
 
HPV5 E1^E4   AGATCGCAAACGCAGCAAAGGCGATCAAGGTCCCGACACCGGTCCCGGTCTCGGTCCCGG 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3508  AGATCGCAAACGCAGCAAAGGCGATCAAGGTCCCGACACCGGTCCCGGTCTCGGTCCCGG  3567 
 
HPV5 E1^E4   TCGCGCTCCAAGTCCCAAACCCACACCACTCGGTCCACCACCAGGTCCCGGTCCACGTCG 
             |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
HPV5b  3568  TCGCGCTCCAAGTCCCAAACCCACACCACTTGGTCCACCACCAGGTCCCGGTCCACGTCG  3627 
 
HPV5 E1^E4   GTCGGCAAGACTCGGGCCCTTACAAGCAGATCGCGATCCAGGGGAAGGTCCCCAAGTACC 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3628  GTCGGCAAGACTCGGGCCCTTACAAGCAGATCGCGATCCAGGGGAAGGTCCCCAAGTACC  3687 
 
HPV5 E1^E4   TGCAGAAGGGGAGGTGGAAGGTCACCCAGGCGGCGATCAAGGTCACCCTCCACCTACTCC 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3688  TGCAGAAGGGGAGGTGGAAGGTCACCCAGGCGGCGATCAAGGTCACCCTCCACCTACTCC  3747 
 
HPV5 E1^E4   TCCTGCACCACACAACGGTCACAGCGGGCACGGGCCAAAAGTCCAACAACCAGAGGGGCC 
             |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||| 
HPV5b  3748  TCCTGCACCACACAACGGTCACAGCGGGCACGGGCCGAAAGTCCAACAACCAGAGGGGCC  3807 
 
HPV5 E1^E4   CGAGGGTCGAGAGGGTCACGAGGAGGGAGCCGTGGGGGGAGATTGCGGCGACGAGGAAGG 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3808  CGAGGGTCGAGAGGGTCACGAGGAGGGAGCCGTGGGGGGAGATTGCGGCGACGAGGAAGG  3867 
 
HPV5 E1^E4   TCATCCTCCTCCTCCTCCTCCCCCTCCCACAAACGGTCACGAGGGGGGTCTGCTAAGCTC 
             |||   |||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
HPV5b  3868  TCA---TCCTCCTCCTCCTCCCCCGCCCACAAACGGTCACGAGGGGGGTCTGCTAAGCTC  3924 
 
HPV5 E1^E4   CGTGGCGTCTCTCCTGGTGAAGTGGGAGGGTCACTTCGATCAGTTAGTTCAAAGCATACA 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3925  CGTGGCGTCTCTCCTGGTGAAGTGGGAGGGTCACTTCGATCAGTTAGTTCAAAGCATACA  3984 
 
HPV5 E1^E4   GGAAGACTTGGAAGATTACTGGAAGAAGCTCGCGACCCCCCAGTAA 
             ||| |||||||||||||||||||||||||||||||||||||||||| 
HPV5b  3985  GGACGACTTGGAAGATTACTGGAAGAAGCTCGCGACCCCCCAGTAA  4030 
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Appendix 1B GST-HPV5 E4 against HPV5b E4 protein sequence 
Amino acid changes shown in bold and underlined, RS dipeptides shown in grey 
 
GST-HPV5 E4  APRLQGRQEDKQTQTPPPRPPPPPQPPLTPRPDSSPHQNSHNKPKPEEEGTDGGPPASQG 
           APRLQGRQEDKQTQTPPPRPPPPPQPPLTPRPDSSPHQNSHNKPKPEEEGTDGGPPASQG 
HPV5b E4    APRLQGRQEDKQTQTPPPRPPPPPQPPLTPRPDSSPHQNSHNKPKPEEEGTDGGPPASQG 
 
GST-HPV5 E4  DRKRSKGDQGPDTGPGLGPGRAPSPKPTPLGPPPGPGPRRSARLGPLQADRDPGEGPQVP 
            DRKRSKGDQGPDTGPGLGPGRAPSPKPTPLGPPPGPGPRRSARLGPLQADRDPGEGPQVP 
HPV5b E4  DRKRSKGDQGPDTGPGLGPGRAPSPKPTPLGPPPGPGPRRSARLGPLQADRDPGEGPQVP 
 
GST-HPV5 E4 AEGEVEGHPGGDQGHPPPTPPAPHNGHSGHGPKVQQPEGPEGREGHEEGAVGGDCGDEEG 
            AEGEVEGHPGGDQGHPPPTPPAPHNGHSGHGPKVQQPEGPEGREGHEEGAVGGDCGDEEG 
HPV5b E4   AEGEVEGHPGGDQGHPPPTPPAPHNGHSGHGPKVQQPEGPEGREGHEEGAVGGDCGDEEG 
 
GST-HPV5 E4 HPPPPPPPPTNGHEGGLLSSVASLLVKWEGHFDQLVQSIQEDLEDYWKKLATPQ 
            H PPPPPPPTNGHEGGLLSSVASLLVKWEGHFDQLVQSIQ+DLEDYWKKLATPQ 
HPV5b E4   H-PPPPPPPTNGHEGGLLSSVASLLVKWEGHFDQLVQSIQDDLEDYWKKLATPQ 
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